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A series of low molecular weight thermoreversible cystine hydrogelators were
synthesised via solid-phase chemistry. Novel hydrogels were found to gelate at
concentrations of <2 mM using microwave super-heating. Benzoyl cystine amide
derivative hydrogel, which could form at a concentration of 0.5 mM, equivalent to
0.022% w/w of gelator with respect to water (an incredible 111,000 molecules of
water gelated per single molecule of gelator), was applied to cell culture of cervical
cancer (HeLa) cells, which were found to distribute within the gel. Hydrogels were
produced on a microarray format using a novel strategy involving deposition of
hydrogel solutions by inkjet printing. The incorporation of fluorescent dye
(Rhodamine B) into hydrogels provided a novel means for studying hydrogel
morphology.
Reversible boronate chemistry was implemented for the capture and release of
proteins and peptides onto a solid-support as part of a modified peptide enrichment
strategy. The strategy was proven following synthesis of hydroxamic acid and
catechol modified peptides and a study of their interaction with solid-supported
phenylboronic acid. NHS active ester affinity tags and cross-linkers were synthesised
and applied to a 3D proteomics cross-linking analysis pipe-line. The introduction of a
PEG unit led to a cross-linker with increased hydrophilicity and improved
observation of both inter and intra-protein cross-links by mass spectrometry.
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It can be said that a gel or jelly is easier to recognise than it is to describe. The first
definition by Graham1 in 1861 was based on the qualitative macroscopic
observations that could be made at the time and was "rigidity of the crystalline
structure shuts out external impressions, the softness of the gelatinous colloid
partakes of fluidity." 80 years ago Lloyd" stated that:
"Only one rule seems to hold for all gels, and that is that they must be built
up from two components, one of which is a liquid at the temperature under
consideration, and the other of which, the gelling substance proper, is a solid.
The gel itself has the mechanical properties of a solid, i.e., it can maintain its
form under the stress of its own weight, and under mechanical stress, it shows
the phenomenon of strain."
This definition is as true today as it was in 1926 and its tone has been prophetic.
Over 100 years after the first definition by Graham, Flory provided an update in
order to correlate the microscopic and macroscopic properties of a gel:
"One may infer from this universal characteristic of those systems regarded
as gels that they must possess a continuous structure of some sort, the range
of continuity of the structure being of macroscopic dimensions If it be
granted that the presence of a continuous structure is the feature common to
all gels, then it becomes important to differentiate the several kinds of
structures occurring in various gels."3
Flory then went on to give the four types of gel, classified according to their
structural basis; well-ordered lamellar structures, covalent polymeric networks,
polymer networks formed through physical aggregation and particulate, disordered
structures.
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A basic definition of a gel can be given as a material having the structural coherence
of a solid but swollen as a result of having a composition with a predominantly liquid
content. Gels can be either inorganic or organic in nature. The liquid component in
the gel can be water, whereby the gels are referred to as hydrogels, or an organic
solvent, producing a resulting gel that can be called an organogel.
There has always been an enormous amount of interest in gels because their physical
and morphological properties are applied in many areas including in foods, as
templated materials,4 drug delivery agents,5'6 cosmetics,7'8 lubricants,9 enzyme
immobilization matrices10 and separation media.11 In recent years there has been an
explosion in interest in organogels12 while there are increasing demands for
biocompatible gels for the study and manipulation of human cells.13
Just as there is an enormous scope for applications of hydrogel, the range of
chemistries and compounds that are capable of gelating solvent is huge. Most of the
gels that are known and familiar to scientists consist of natural polymeric compounds
such as gelatine, pectin and agarose. Inorganic gels prepared by swelling silica in
organic solvents are very familiar to all modern day organic chemists and swollen
organic polymers such as styrene-divinylbenzene have found widespread use in solid
phase organic chemistry. Four main classes of gelators can thus be considered: 1)
synthetic polymers, 2) natural polymers 3) inorganic materials, and 4) low-molecular
weight organic compounds.
1.1.1 Synthetic polymeric hydrogels
The majority of reported gels are three-dimensional networks swollen by solvent and
consisting of hydrophilic homopolymers or copolymers.1 ' 5 In most cases the three-
dimensional network is stabilised by polymer chains being either covalently or
ionically crosslinked.16 Wichterle and Lim developed the first polymeric hydrogel
network in 1954, a copolymer of 2-hydroxyethyl methacrylate (HEMA) and ethylene
dimethacrylate (EDMA) prepared by free radical polymerisation.17 Work continued
3
and in the 1960's the enormous commercial potential of versatile synthetic polymeric
hydrogels was recognised.
HEMA EDMA
Figure 1.1 Copolymer monomers. Copolymerisation of two monomers 2-hydroxyethyl methacrylate
(HEMA) and ethylene dimethacrylate (EDMA) produced the first polymeric hydrogel network.
Gelation occurs in a multiple step process. Firstly the three-dimensional network
must be formed and secondly the network must act as a microporous structure that is
capable of absorbing water. This results in swelling of the polymer chains to create a
hydrogel, with increasing amounts of water becoming incorporated into the gel until
a saturation limit. The polymer therefore exhibits solid-like properties because of this
network, whereas the liquid-like properties are a result of water being the major
constituent (>80%).
The term hydrogelator is typically applied to a synthetic polymer if the final mass
contains at least 20% water by weight.18 A classification system that is particularly
useful when considering biomedical applications is to classify polymer hydrogels as
neutral hydrogels, ionic hydrogels and swollen interpenetrating networks (IPNs).19
Polymeric hydrogels are also classified according to monomeric composition, which
is based on the method of preparation: homopolymeric hydrogels, copolymeric
hydrogels and interpenetrating hydrogels. Depending on the ionic charges present on
the monomer, the resulting hydrogels can be either neutral, anionic, cationic or
ampholytic.
As the name suggests, homopolymers form a polymer network derived from only
one monomer and their hydrogels are generally crosslinked. One important category
of crosslinked homopolymeric hydrogels are the poly(hydroxyalkyl methacrylates),
including poly(3-hydroxypropyl methacrylate) (PHPMA), poly(glyceryl
methacrylate) (PGMA) and poly(2-hydroxyethyl methacrylate) (PHEMA).
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PHEMA PHPMA PGMA
Figure 1.2 Poly(hydroxylalkyl methacrylates). Three examples of homopolymeric hydrogels.
Poly(hydroxyalkyl methacrylates) are important polymers used as materials for drug
delivery and contact lenses, with PHEMA hydrogels being amongst the most widely
20 21used and studied of all synthetic hydrogel materials. '
Many commercial applications exist for gels as thickeners and expanders. Such gels
include poly(N-vinyl-2-pyrrolidinone (PNVP), poly(acrylamide) (PAM),
poly(ethylene glycol) (PEG) and poly(vinyl alcohol) (PVA).22
PNVP PAM PEG PVA
Figure 1.3 Uncrosslinked homopolymers.
PNVP and PVA have proven to be useful in biomedical applications because of
increased solubility in water and an acceptable degree of solubility in many other
solvents, both polar and non-polar.23,24 PEG and PAM have found uses in
25
agricultural applications.
A copolymeric hydrogel is formed when two or more different monomer species are
used to form the three-dimensional network. One of the components must be
hydrophilic for a hydrogel to result but the advantage of using a copolymer is that the
other component can be used to improve gel strength. Depending on the purpose of
the hydrogel, a copolymeric system can be employed to introduce extra functionality
5
and usually copolymers are produced to give improved properties. The most
successful copolymeric hydrogels include: NVP-co-HEMA, HEMA-co-MMA and
HEMA-co-AA.26
One study looked at the effect of hydrogel charge density on osteoblast cell
attachment.19 Neutral hydrogels were prepared by polymerization of poly(ethylene
glycol) dimethacrylate (PEGDMA) and 2-hydroxyethylmethacrylate (HEMA).
Negatively charged hydrogels were produced by addition of sodium 2-sulfoethyl
methacrylate (SEMA) and positively charged hydrogels via the addition of [2-
(methacryloyloxy)ethyl] trimethyl ammonium chloride (MAETAC).
HEMA PEGDMA SEMA MAETAC
Figure 1.4 Neutral, cationic and anionic monomers used to make copolymeric hydrogels.'9
A fourth, very important class of polymeric hydrogel materials are the so-called
Interpenetrating Polymer Network (IPN) hydrogels. This class is defined as two
independent crosslinked synthetic and/or natural polymer components contained in a
network.27 An IPN is typically formed by polymerisation of a second polymer inside
a first polymer. This is usually achieved by swelling the first polymer with the
second monomer in solution before initiation. An IPN can consist of one crosslinked
component and a non-crosslinked polymer, whereby the resulting material is referred
to as a semi-IPN.28 A gelatin-bonded dextran based IPN hydrogel was used as a
three-dimensional scaffold to encapsulate smooth muscle cells and for the 2-D
culture (cell culture on a hydrogel surface) of endothelial cells.29
1.1.2 Low molecular weight organogelators
A low molecular weight gelator is roughly defined as a molecule with a molecular
mass <3000 that is capable of reversibly aggregating/gelating a range of organic
solvents at low concentrations (less than 5% w/w). Whilst the first commercial
6
polymeric hydrogels were being produced, low molecular weight organogelators
were treated as a mere curiosity.
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Figure 1.5 Low molecular weight organogelators.
Most low molecular weight organogelators have been discovered serendipitously,
31
with some researchers commenting on the initial annoyance of having formed a gel.
7
Interest in low molecular weight organogelators however has been developing since
the 1990s. In fact low molecular weight hydrogelators appear to offer several
advantages over polymeric hydrogels. For biological applications, one of the
persistent problems that needs to be overcome for example is to find biodegradable
polymers that can be used for controlled drug release.32 Small molecule
hydrogelators could be able to overcome this hurdle as many of them are derived
from biocompatible components that the body could degrade. Perhaps more
importantly, the huge diversity of functionality in the synthesis of gelators means that
it becomes possible to incorporate a drug directly into the gelling component,
eliminating the need for a prior drug capturing step.
One intrinsic characteristic of virtually all low molecular weight organogelators is
thermo-reversibility. Hence the preparation of an organogel usually involves
warming a gelator in solvent until the solid has fully dissolved and then cooling the
solution to below the gel transition temperature (Tgs). The gel transition temperature
is the point where a solution becomes a gel, which means that it is the temperature
where flow is no longer discernible over long periods a process analogous to
crystallisation. Gelation is governed by the concentration of an organogelator in a
specific solvent and the time taken for gelation to occur. Low molecular weight
gelators have been shown to gelate a wide variety of organic solvents (such as
alcohols, paraffins, aromatic and chlorinated molecules) as well as polysiloxanes,
nematic and smectic liquid-crystalline materials, electrolytes and polymerisable
liquids amongst others.12
1.1.2.1 Gelation Theory - Low molecular weight organo-gelation
Historically, the particular aggregation state of gels formed by low mass organic
compounds was defined based on fairly qualitative macroscopic observations of the
flow properties of materials. However advances in analytical technology have
enabled the study of materials at a microscopic level. This has resulted in a much
greater understanding of the chemistry of supramolecular aggregates, which includes
organogels, by revealing the organisation and architecture of such materials. A
8
greater understanding of the nature of a gel and the mechanism of gel formation has
shaped the definition of an organogel. Various theories concerning how gel
formation occurs have been proposed but there are two main theories.
(I) considers gelation as a form of incomplete crystallisation where the gel
consists of 'microcrystalline forms surrounded by solvent'.34'35
(II) proposes that gels are formed by non crystalline aggregates that trap solvent
via surface tension within the micro-regions between them.3,36'37
This latter theory suggests that gelator molecules aggregate thermo-reversibly to
form fibres or strands (up to micrometers in length). These fibres then form
interlocking 3D networks that are capable of containing solvent molecules (Figure
1.6). The fibres or strands are held together by numerous low energy interactions and
there is a range of attractive packing interactions that depend on the structure of the
gelator. These interactions include London dispersion forces, hydrogen bonding and
n-Jt stacking interactions between aromatic groups. The points where fibres cross-
38link are called 'junction zones' or 'nodes' and they result in the generation of
cavities that can contain the liquid component of the gel. This prevents the flow of
liquid and results in an apparent thickening of the solvent. The numbers of these
nodes ((pseudo)crystalline microdomains) influence both the thickness and the
elasticity properties of the material and prevent phase separation into
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Figure 1.6 Organogel formation mechanism.39
Reproduced with permission (copyright American Chemical Society, 2010).
This theory is widely accepted and maintains that gels are multicomponent colloidal
systems that are mainly composed of a liquid which retains its physical state at
microscopic level despite having a solid-like appearance.
The structure of a gel can be broken down to a primary, secondary and tertiary level,
analogous to the structural understanding of proteins (Figure 1.7).40'41 Molecular
level interactions that promote anisotropic aggregation in one or two dimensions
determine the primary structure, which is on a nanometer scale with aggregation
dependent upon the direction of the molecules. There must be a balance between the
tendency for molecules to dissolve or to aggregate in order for gelation to occur.
Hydrogen bonding interactions are very influential for organogelator aggregation and
such interactions are reduced in water unless they are combined in a cooperative
manner and protected from solvent.42 In aqueous environments hydrophobic forces
become more influential than hydrogen bonds in dictating gelation, while the
43
hydrogen bonding interactions are more directing. ~ The secondary structure is
defined as the morphology of the aggregates that result from the primary structure,
which can be fibres, ribbons, sheets, micelles or vesicles.44 The types of interactions
that occur along the fibres determine the transition from secondary to tertiary
structure. Gels can be formed by both physically branched fibres that form
10
interconnected networks and entangled fibres. Fibres that are physically long, thin
and flexible are able to trap solvent better than shorter fibres."
5 A 10nm 10um
Figure 1.7 Primary, secondary and tertiary structure of a self-assembled physical gel.
Reproduced with permission (copyright American Chemical Society, 2004).
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The study of the mechanism of gelation has been facilitated by the use of a range of
non-destructive physical techniques ranging from UV-VIS,45 circular
45,46,47 iu nna i-V nt\/id 48>49 jr 45-50 fluorescence techniques45'51 and
48,50
dichroism,
differential scanning calorimetry.'*0"™ Spectroscopic methods take advantage of the
spectral differences between isolated 'monomeric' units and aggregated states.
Electron microscopy techniques (SEM and TEM) are exceptional tools that allow
clear identification and imaging of the 3D fibre like superstructures in xerogels (dry
gels) (Figure 1.8).
5?
Figure 1.8 SEM of a low-molecular weight organogelator."
The techniques of SANS (small angle neutron scattering) and SAXS (small angle X-
ray scattering) have been applied to organogels and can provide information such as
dimension and topology (these techniques use high energy X-ray beams and can
characterise dilute systems such as organogels without the need for drying them first)
11
(Figure 1.9). These scattering experiments provide characteristic profiles for
materials that are related to the morphology of the sample, to its homogeneity and the























Figure 1.9 Organisation of hydrogel fibres. The three levels of organisation present in phenolic
organogels (strand, fibre, fibre bundle), the length of each and the observational method utilised.
Reproduced with permission (copyright Elsevier, 2001).
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Combining these techniques has allowed an understanding of the supramolecular
organisation of self-assembled strands and fibres responsible for gel formation (1 to
1000 nm long) in some cases. However there are many important questions that
remain unanswered relating to the interactions of individual gelator monomers at the
0.1-1 nm scale, such as how do assembly processes (of low molecular weight
gelators into fibres) occur and how can they be controlled?54 Studies have been
carried out trying to solve the mechanism of the nucleation process55'56 and to find
out what structural features of low molecular weight organogelators are important for
gel formation and stabilisation.
57
1.1.2.2 Characterisation ofa gel
A thermoreversible gel can initially be characterised by deducing its gel-to-sol phase
transition temperature (TGS)• Usually gel melting temperature increases with an
increasing concentration of gelator. Tqs is considered to be important because it is
deemed a "measure of stability of a gel". Early empirical methods to measure
gelation temperatures were based on the observation of the temperature at which a
gel begins to flow, typically 'inverse flow'46 and 'ball drop'46'58 methods. The
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'inverse flow' method is performed by forming a gel in a sealed tube and inverting it.
It is then immersed and heated in a water bath and increasing its temperature at a
fixed rate. The gel melting temperature being the value at which the gel falls to the
bottom of the tube or when a continuous flow is observed. The 'ball drop' method is
performed by placing a steel ball on top of a gel formed in a sealed tube. The
gelation temperature being the temperature at which the ball falls to the bottom of the
tube.51
Gels can be characterised Theologically and give direct information on elasticity (the
ability of a deformed material to return to its original geometry, quantitatively related
to a parameter known as the 'storage modulus', G') and viscosity (the tendency of a
material to flow when disturbed, directly linked to a factor G", the loss modulus),
allowing unambiguous evaluation of gel strength.34 The resistance of the material to
deformation is quantified with a 'yield value', defined as the 'minimum stress which
has to be applied before a significant flow can occur'.38 These measurements also
allow evaluation of gel-to-sol transition temperatures (TGs), where colloidal contacts
and/or colloidal structures are broken, at which point flow begins, by subjecting the
gel to small discontinuous oscillating stresses while slowly increasing the
temperature. TGS is recorded when the gel breaks. These measurements of TGs depend
upon the experimental conditions (the greater the stress, the lower the TGS) and
therefore do not represent absolute values.34
1.1.3 Applications of hydrogels
The range of applications for both polymeric and low molecular weight gelators, is
huge. Polymeric hydrogels have the greatest abundance of applications such as in
biomedical coatings,59 homogeneous materials such as contact lenses,60
superadsorbent hydrophilic materials found in disposable nappies and personal
hygiene products,61 sustained drug delivery systems and water storage granules in
agriculture.62 Superadsorbent lipophilic gelators can be used to mop up oil spills.63
Natural hydrogels such as gelatin, agar and gel forming polysaccharides are
commonly used as thickening agents in the food industry.64 Gels exploited for their
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separation ability are used in electrophoresis (e.g. DNA agarose gels) and
chromatography and the types of gels employed have remained relatively unchanged
in composition since they were first introduced.65
1.1.3.1 Biomedical applications
There is a growing interest and demand for gels that can be used with cells. The
study of cells and cellular processes has been greatly facilitated by the design and
development of new tools including great advances in microscopy and the use of
fluorescent dye technology. However cells behave differently when they are removed
from their native environments and transferred to a Petri dish. This can become an
extreme problem in the case of human breast epithelial cells, which proliferate like
tumour cells when cultured as a two-dimensional monolayer, but exhibit normal cell
growth behaviour when cultured in three-dimensional membranes that resemble their
native environment.66 It has been confirmed that embryonic stem cells differentiate
more efficiently into blood-forming stem cells when cultured in three-dimensional
scaffolds compared to cells cultured in two dimensions.67 Therefore new materials
that can support and stabilise cells in a 3D manner are greatly needed. Gels have
many properties that make them compatible with cells.
1.1.3.2 Hydrogels as three-dimensional scaffolds and drug delivery systems
Hydrogels have great potential as scaffolds for cellular and tissue supports due to
their three dimensional nature. Hydrogels also have the advantage of being able to be
moulded into shapes and fill cavities. An agarose based gel scaffold employed in the
regeneration of damaged spinal cord has been reported.6 Agarose is particularly
useful as a scaffold because it is biocompatible, which means that it does not cause
an adverse reaction when implanted in vivo. The porosity and mechanical properties
of the resulting gel can be manipulated such that maximum axonal outgrowth could
be achieved after optimisation. The gel also acted as an embedded drug delivery
system for the sustained release of neurotrophins, proteins that induce the survival,
development and function of neurons.68 Moreover, the gel could be applied directly
into damaged areas of spinal cord and formed in situ, so the gel perfectly fills the
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damaged areas. This allowed maximum contact between the tissues and
neurotrophins being delivered to the area.
1.1.4 Discovering new classes of organogelators
There is tremendous interest in organogels and much research is focussed on finding
and predicting new classes of organogelators by rational design. Several research
groups have used the rationale that there is a relationship between the interactions
occurring in a crystal and interactions of the solid component of a gel. X-ray analysis
of crystals of organogelators reveals information about the interactions responsible
for efficient packing in the solid state. This information can be applied to the design
of even better gels that have various structural motifs introduced that are capable of
stabilising these packing interactions. This approach has proven successful in some
cases,34'69 however it is limited70 by the practical difficulties of obtaining crystal
structures of most organogelators, due to the nature of crystallisation and gelation
processes, which are often competing phenomena. The crystal structure-design
approach is also limited because aggregation in solution often results in amorphous
aggregates that are not revealed by looking at the solid state. The approach assumes
that the only factor that dictates gelation success is the nature of interactions between
"solid organogelator" monomers. The fibres in the gel state are part of a 'wet' system
and therefore can not be compared with solid state aggregates.
Another approach that has been explored far less than the rational design of new
classes of organogelators is the preparation of libraries of compounds. Obviously this
approach is limited by the number of experiments that have to be carried out (both
synthesis and screening) in order to identify the key interactions which promote and




Chapter 2: Cystine Based Organogelators
2.1 Introduction
Cystine derivatives are an interesting and potent class of organogelator. The gelation
of dibenzoyl-L-cystine was first reported in 1892 but it wasn't until 1921 that its
capability of gelating aqueous solutions, at concentrations as low as 2 mM, was
73studied in any depth.
A key to the study of cystine organogels was the reported crystal structure of di (p-
toluoyl)-L-cystine, where linear units appeared to be stacked one upon another
(Figure 2.1).74 Hydrogen bonding interactions between the carboxyl carbonyl (acting
as the hydrogen-bond acceptor) and the amide-NH (the hydrogen-bond donor) on
adjacent molecules were clearly identified. A cystine core is essential for gelation. A
study in 1922 showed that replacing -S-S- with -CHiCHi- destroyed gelation,75
presumably because a R-S-S-R dihedral angle of 90° favours hydrogen-bonding
contacts, which is backed up by X-ray data.
Figure 2.1 X-ray crystal structures of di(/>-toluoyl)-L-cystine. (A) Showing intermolecular
interactions. Red sphere represent oxygen, blue nitrogen and yellow sulphur atoms. The dotted lines
represent hydrogen bonds between amide-NH and carboxyl-CO functionalities. (B) Two strands held
together by cooperative hydrogen bonds between carboxyl-hydrogen atoms and amide-CO groups.
Permission requested (copyright John Wiley and Sons, 2003).74
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X-ray analysis showed that each unit was connected to the one above and below it by
two hydrogen bonds. Aromatic rings were situated one above another, leading to the
conclusion that n-n stacking interactions contribute to fibre stability.
Di(2-naphthoyl)-L-cystine diamide gelates aqueous solutions at 0.25 mM (ca. 0.01%
w/w) in less than 30 s.34 The incredible propensity for gel formation makes it a
particularly remarkable organogelator. The hydrogen bonding interactions that each














Figure 2.2 A',A"-L)i(2-naphthoyl)-I,-cystine diamide.34 Showing the low-energy interactions that
contribute to gelation.
2.2 Aims
The aims of this work were to: (i) Investigate the prospect of using cystine hydrogels
as biodegradable three-dimensional scaffolds for cell culture, (ii) the development of
novel ways of forming and studying cystine gelator gels, (iii) to explore further the
relationships between gelator structure and subsequent gelation properties and (iv)
investigate ways to degrade cystine hydrogels.
2.2.1 Solid-phase synthesis of an organogelator library
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Initially a library of substituted cystine based potential organogelators was targeted.
Cystine based organogelators can be readily synthesised in solution via standard
protocols,34 however in this work a more flexible solid phase strategy was adopted.76
Aminomethyl polystyrene resin 2.1 (1.6 mmol/g) and a Rink linker were used, which
provides amides when cleaved from the resin. This was considered to be important
because cystine amides have been shown to be more potent gelators than the
corresponding acids.34 Fmoc-Cys(Trt)-OH was coupled to the Rink amide PS-resin
2.3 followed by deprotection of the Fmoc group. After a second Fmoc deprotection,
resin 2.4 was divided and each portion was coupled with a different carboxylic acid
derivative capping group 2.5 to provide the compounds 2.6-2.12 shown in Table 2.1.
Disulfide bond formation utilised well documented chemistry,77 the use of iodine
served to cleave the S-trityl protection as well as forming an intra resin disulfide
bond. Compounds were cleaved from the solid-support using TFA/TIS/CFFCF and
analysed by RP-LC-MS which indicated purities greater than 95%.
Compounds 2.13 and 2.14 contained a spacer group between the capping group and
cystine were synthesised by coupling either Fmoc-protected glycine or (3-alanine to
cysteine-supported resin 2.4. After Fmoc deprotection, 2-napthoic acid was coupled
to the free amine of 2.4, followed by formation of an intra resin disulfide bond and
cleavage from the resin.
Compounds 2.15-2.20 were synthesised by coupling either Fmoc-Gly-OH or Fmoc-
Phe-OH to the free amine of resin 2.3. Fmoc deprotection was followed by coupling
of Fmoc-Cys(Trt)-OH, followed by a second Fmoc-deprotection. The resulting resins
were divided and capped with one of each of the following capping groups (benzoic
acid, 2-napthoic acid or 4-fluorobenzoic acid). Intra resin disulfide bond formation
and cleavage from the resin was carried out as before to provide compounds 2.15-
2.20.
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Scheme 2.1 Solid phase synthetic procedure for accessing cystine diamides 2.6-2.20.
(a) 2 eq Fmoc-Rink Amide Linker (4-[(2,4-Dimethoxyphenyl)(Fmoc-amino)methyl)-
Phenoxyacetic Acid), 2 eq HOBt, 2 eq DIC, CFLCL/10% DMF, 2 h; (b) 20%
piperidine/DMF, 2 x 20 min; (c) 2 eq Fmoc-Cys(Trt)-OH, 2 eq HOBt, 2 eq DIC,
CH2C12/10% DMF, 2 h, then 20% piperidine/DMF, 2 x 20 min; (d) 2 eq carboxylic acid, 2 eq
HOBt, 2 eq DIC, CH2C12/10% DMF, 2 h; (e) 10 eq I2, DMF, 1.5 h; (f) TFA/TIS/CH2C12
(95:2:3), 2 h; (g) 2 eq either Fmoc-Gly-OH or Fmoc-(3-Ala-OH, 2 eq HOBt, 2 eq DIC,
CH2C12/10% DMF, 2 h, then 20% piperidine/DMF, 2 x 20 min; (h) 2 eq 2-napthoic acid, 2
eq HOBt, 2 eq DIC, CH2C12/10% DMF, 2 h; (i) 2 eq either Fmoc-Gly-OH or Fmoc-Phe-OH,
2 eq HOBt, 2 eq DIC, CH2C12/10% DMF, 2 h, then 20% piperidine/DMF, 2 x 20 min.
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Cystine diacids 2.21-2.25 (Scheme 2.2) were synthesised to complement the cystine
diamides synthesised in Scheme 2.1. Polystyrene Wang resin was used to provide N-
terminal carboxylic acid groups following cleavage from the resin.
Compound 2.21 was synthesised by creating an ester between the Wang linker
polystyrene resin hydroxyl group and the anhydride of Fmoc-Cys(Trt)-OH, formed
using DIC and DMAP. Following Fmoc deprotection, the resulting free amine was
capped with 2-napthoic acid, the resin was treated with iodine and the disulfide
product cleaved using TFA/TIS/CH2CI2 to provide 2.21.
Compounds 2.22-2.25 were synthesised similarly to compound 2.21 by first coupling
either Fmoc-Gly-OH or Fmoc-Phe-OH to Wang linker polystyrene resin. Following
Fmoc deprotection, Fmoc-Cys(Trt)-OH was coupled to the free amine followed by a
second Fmoc deprotection whereupon the resulting resins were divided and capped
with either benzoic acid or 4-fluorobenzoic acid. Intra resin disulfide bond formation
and cleavage from the resin was carried out as before to provide compounds 2.22-
2.25.
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Scheme 2.2 Solid phase synthetic procedure for accessing cystine diacids 2.21-2.25.
(a) 10 eq Fmoc-Cys(Trt)-OH, 5 eq DIC, 0.1 eq DMAP, 2 h, then 20% piperidine/DMF, 2 x
20 min; (b) 2 eq 2-napthoic acid, 2 eq HOBt, 2 eq DIC, CH2C12/10% DMF, 2 h; (c) 10 eq I2,
DMF, 1.5 h; (d) TFA/TIS/CH2C12 (95:2:3), 2 h; (e) 10 eq either Fmoc-Gly-OH or Fmoc-Phe-
OH. 5 eq DIC, 0.1 eq DMAP, 2 h, then 20% piperidine/DMF, 2 x 20 min; (f) 2 eq carboxylic
acid, 2 eq HOBt, 2 eq DIC, CH2C12/10% DMF, 2 h.
Table 2.1 Library of A^W-diacylcystine derivatives.
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Water-rich gels of benzoyl 2.6 and 2-naphthoyl 2.7 were made using the hot solvent
method according to the literature.34 Gels were formed by dissolving solid compound
in the required volume of hot solvent and allowing the solution to gradually cool
down from about 90 °C to room temperature; a process analogous to crystallisation.
As before the common problem was insolubility, with crystallisation and
precipitation often occurring as the dominant processes over gelation. Gelation of
water could only be achieved by dissolving the solid compound in hot DMSO and
introducing hot water, the DMSO acting to pre-dissolve the solid.
Crude napthoyl derivative 2.7 was screened in 25% DMSO/75% FFO and was found
to gelate the water rich mixture at the amazingly low concentration of 0.5 mM
(0.03% w/w), shown in Figure 2.3. Upon addition of hot water to compound pre-
dissolved in DMSO, the napthoyl derivative 2.7 formed a gel almost instantaneously
and furthermore the resulting gel was completely transparent and homogeneous.
Figure 2.3 0.5 mM VW-Di^-naphthoyp-L-cystine diamide gel 2.7. 25% DMSO/HiO gel.
Various concentrations of DMSO (5-25% v/v) were examined in order to
qualitatively assess the effect of co-solvent upon gelation (see Figure 2.4).
For each concentration of DMSO, a final gelator concentration of 2 mM (0.11%
w/w) was used, with the solid compound dissolved in hot DMSO, heated in a water
bath at 90 °C, followed by the addition of hot water. This corresponded to a ratio of
22,765 molecules of solvent for every molecule of gelator!
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Gel formation was defined by the ability to rigidify the solvent such that it was self-
supporting upon inversion of the vial containing the gel. Jelly was defined as an
inhomogeneous mixture of "gel lumps" and solution, which in most cases had
increased viscosity compared with the solvent without gelator. The gelation process
was heavily influenced by the percentage of DMSO used. Gel formed so rapidly that
in many instances it was not possible to add the volume of water required to reach
the desired concentration. The result was formation of a dense lump of gel and a
separate liquid phase composed almost entirely of unincorporated water.
A
B
Figure 2.4 Different DMS0/H20 ratios gelated by /V,/V'-Di(2-naphthoyI)-L-cystine diamide 2.7.
2 mM concentration (percentage of DMSO is shown). (A) Gel prior to inversion. (B) Inverted gel.
With 25% DMSO/FDO there was evidence of randomly distributed air bubbles
within the gel that had been incorporated with the addition of water, which was
evidence that gel formation had occurred very rapidly. Reducing the percentage of
DMSO from 25% to 20% resulted in a destabilisation of the gel upon inversion with
the gel collapsing under gravity. Reducing the percentage of DMSO further to 15%
resulted in definite phase separation, where half the matter was composed of a dense,
rough gel and approximately half the water had failed to become incorporated in the
gel. This trend continued as the percentage of DMSO was decreased. 25%
DMSO/H2O formed the most uniform gel in the series, which was the least cloudy
with the smoothest consistency. This experiment demonstrated the inherent
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difficulties in making qualitative definitions regarding gel formation. Subtle
differences in the dimensions of the vial used also influenced the outcome of each
experiment.
2.3 Microwave-assisted hydrogelation
Sonication and traditional oil/water bath heating both failed to produce consistent
results, in most instances precipitation was favoured over gelation and in many cases
inhomogeneous/inconsistent gels formed. A method was required to remove the need
for using DMSO in order to solubilise the gelator.
Since microwave heating was introduced to the chemical laboratory there have been
a surge of papers touting the benefits of using microwaves over conventional oil bath
heating. Microwave heating allows heating at temperatures that far exceed the
boiling points of solvents at increased pressure. Microwave heating doesn't involve
temperature hot-spots that occur with conventional heating systems due to the inside-
to-out nature of microwave energy transfer, and it has been proven that temperature
ranges within a microwave reaction vessel are much lower than variations that occur
with oil-bath heating.78
At 250 °C, water has a density and polarity similar to that of acetonitrile at room
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temperature. The dielectric constant of water (V) drops rapidly with temperature
and at 250 °C it has fallen from 78.5 (at 25 °C) to 27.5.80 This means that the
solubility of organic compounds increases as the temperature is increased.
Gelation of napthoyl cystine amide derivative 2.7 in pure water was attempted using
a single-mode microwave. A range of temperatures was used between 100 °C and
200 °C with a series of different concentrations to investigate the effect of
microwave heating. Above 180 °C the measured internal pressure began to reach and
exceed the safety level set on the machine. Figure 2.5 shows the result from 2 mM
napthoyl cystine amide gelator 2.7. After cooling it was observed that at 100 °C there
was un-dissolved compound. At 120 °C and 140 °C the solution became increasingly
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cloudy but still there was a large degree of insolubility and precipitation. Gel formed
at 160 °C and 180 °C but was heterogeneous; a large volume of water had not been
incorporated into the gel phase. The gels were stable to inversion at these
temperatures but were cloudy and inhomogeneous.
Figure 2.5 Microwave-assisted hydrogel formation. 2 mM MA^'-Di(2-naphthoyl)-L-cystine diamide
2.7. Microwave heating for 5 mins at temperatures between 100-180 °C.
The result of 1 mM 2.7 is shown in Figure 2.6. Again it was observed at 100 °C and
120 °C that gelation had not occurred. Upon inversion, a self-supporting gel was
produced at 140 °C but with evidence of a clear gel with a large amount of un¬
dissolved compound. At 160 °C and 180 °C all compound had dissolved with a more
homogeneous gel formed at the higher temperature.
Figure 2.6 Microwave-assisted hydrogel formation. 1 mM A,/V'-Di(2-naphthoyl)-L-cystine diamide
2.7. Microwave heating for 5 mins at temperatures between 100-180 °C.
26
Very similar results were produced when the concentration of napthoyl cystine amide
gelator was reduced to 0.5 mM (Figure 2.7).
100 120 140 160 180 100 120 140 160 180
°c °C °C °C °C °C °C °C °C °C
Figure 2.7 Microwave-assisted hydrogei formation. 0.5 mM A(/V'-Di(2-naphthoyl)-L-cystine
diamide 2.7. Microwave heating for 5 mins at temperatures between 100-180 °C. (A) Before vial
inversion. (B) After vial inversion.
A self-supporting gel was formed at 140 °C, which was equivalent to 111.000
molecules of water per molecule of gelator. However at 140 °C there was still
evidence of incomplete solubility whereas at 160 °C and 180 °C there was no
evidence of solid, which meant that all compound had been dissolved at these
temperatures, although the resulting gel was not clear. 0.5 mM was the lowest
concentration that could form a gel.
The optimum conditions for gelation were heating at 180 °C for 5 minutes followed
by an unassisted cooling procedure to room temperature. Increasing the heating time
had little effect on the solubility of gelator at different temperatures however heating
for times longer than 30 minutes were found to destroy the ability to form a gel with
the compound. Heating at high temperature for a long period altered the gelator such
that it didn't form a gel after cooling, which is a phenomenon that needs to be
investigated further.
The benzoyl cystine amide derivative 2.6 was also analysed using the microwave
heating method. A range of concentrations of 2.6 in water were investigated (see
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Figure 2.8), and it was observed that increasing the concentration resulted in a
gradual increase in turbidity but in all cases a completely homogeneous gel. Gel
formed at the low concentration of 0.5 mM (equivalent to 0.022% w/w). This was far
lower than previously reported concentrations for this gelator,34 which meant that
gelation in pure water (using microwave super-heating and cooling) resulted in a far
stronger gel than the gel dissolved in water and co-solvent using the traditional
method. Below 0.5 mM the gel was too weak to be self-supporting and collapsed.
A B
0.5 1 2 3 4 6 8 10 0.5 1 2 3 4 6 8 10
mM
Figure 2.8 Microwave-assisted hydrogel formation of AW-Di(benzoyl)-L-cystine diamide 2.6.
Microwave heating for 5 mins at 180 °C. Concentrations from 0.5-10 mM. (A) Before vial inversion.
(B) After vial inversion.
2.4 Series ofmodified hydrogels
The gelation by microwave heating method allowed qualitative comparisons to be
made of gels formed after making subtle changes in the structure of gelators.
To investigate the significance of the role of the primary amide groups on the
napthoyl cystine derivative 2.6 the compound was synthesised using Wang resin
(affording carboxylic acid groups after cleavage) to give compound 2.21. The result
(shown in Figure 2.9) was that there was no gel formation when the amide groups
were exchanged.
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Figure 2.9 Attempted hydrogelation of A^A'-Di^-naphthoyb-L-cystine 2.21. Microwave heating
concentrations between 2-10 mM for 5 mins at 180 °C. (A) Before vial inversion. (B) After vial
inversion.
There is interest in gelators that have extra amino acids added to the core cystine or
between the cystine core and the capping groups because these gelators could be
enzymatically cleaved.
Two gelators were synthesised using Rink Amide resin, which afforded primary
amide derivatives after cleavage from the resin, one with glycine 2.15 and one with
phenylalanine 2.16 coupled to Rink Amide resin followed by Fmoc deprotection and
cysteine coupling. The amine group from the cysteine was capped with 2-napthoic
acid.
The results are shown in Figure 2.10. After cooling to room temperature,
phenylalanine derivative 2.16 formed a fine precipitate.
Figure 2.10 Addition of di-glycine 2.15 (GLY) and di-phenylalanine 2.16 (PHE) to di-napthoyl
cystine gelators. 2 mM hydrogel. (A) Before vial inversion. (B) After vial inversion.
In contrast, glycine derivative 2.15 was able to form a waxy gel. This suggested that
adding two secondary amide honds did not significantly reduce gelation ability but
adding two extra phenyl groups to the gelator 2.16 completely destroyed gelation
ability.
Two compounds were synthesised, one with a two carbon spacer between the cystine
and the capping group 2.13 and the other with a three carbon spacer 2.14 (Figure
2.11).
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Figure 2.11 Addition of alkyl spacers to di-napthoyl cystine gelators. 2 mM 2.13 and 2.14 in H20.
(A) Before vial inversion. (B) After vial inversion.
In both cases a fluffy white precipitate was produced. The length of spacer inserted
between the cystine and the terminal capping group clearly influencing gelation
ability and affecting solubility.
For subsequent compounds it was decided to change the napthoyl capping group to
the less bulky benzoyl group and a second series with a 4-fluorobenzoyl capping
group. Series of compounds with these capping groups were synthesised using Rink
Amide resin to afford primary amide groups after cleavage from resin and Wang
resin to afford carboxylic acid groups. Also the two different amino acids (glycine or
phenylalanine) were again coupled. All compounds were subjected to the microwave
gel forming protocol at different concentrations in water.
Derivative 2.22 with benzoyl capping groups and substituted glycine produced a self-
supporting uniform gel in water at concentrations between 4-10 mM (Figure 2.12).
At 2 mM the resulting gel was too weak to withstand vial inversion and there was a
partial collapse from the bulk and lowering the concentration to 1 mM resulted in a
clear solution. As the concentration was increased the strength of gel increased but
there was also an increase in gel turbidity.
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Figure 2.12 Hydrogelation of 2.22. Microwave heating concentrations between 1-10 mM for 5 mins
at 180 °C. (A) Before vial inversion. (B) After vial inversion.
When the carboxylic acid group was changed to a primary amide to give derivative
2.17 there was a marked decrease in solubility in water but at 8 and 10 mM
concentrations a self-supporting gel was formed (Figure 2.13). There was an increase
in the amount of gelator that precipitated from solution. The resulting gel was
inhomogeneous but a gel nonetheless, with 10 mM concentration corresponding to
0.74% w/w, which is still well within the 5% w/w concentration that is considered to
be the limit for classification as a low molecular weight organogelator.
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Figure 2.13 Hydrogelation of 2.17. Microwave heating concentrations between 2-10 mM for 5 mins
at 180 °C. (A) Before vial inversion. (B) After vial inversion.
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After inserting phenylalanine rather than glycine between Wang resin and cystine to
give 2.23, a waxy, heterogeneous gel was formed (Figure 2.14).
AA
OH
Figure 2.14 Hydrogelation of 2.23. Microwave heating concentrations between 0.25-8 mM for 5
mins at 180 °C. (A) Before vial inversion. (B) After vial inversion.
The resulting system had a large degree of aggregation in competition with gelation
at 2-8 mM, compared with glycine derivative 2.22, thus the addition of phenyl
groups resulted in an increase in aggregation. Lowering the concentration to 1 mM
produced a robust, albeit cloudy, gel and a partial gel resulted at 0.5 mM.
Changing the carboxylic acid groups to primary amides 2.18 resulted in a complete
loss of gel formation and instead resulted in formation of waxy precipitate, with little
difference between the concentrations of 2.18 (Figure 2.15).
Figure 2.15 Attempted hvdrogelation of 2.18. Microwave heating concentrations between 2-10 mM
for 5 mins at 180 °C. (A) Before vial inversion. (B) After vial inversion.
A cystine derivative with 4-fluorobenzoyl capping groups and substituted glycine
2.24 was synthesised. The result was a new "super-gelator", with a very robust, clear
gel being produced at 2 mM (Figure 2.16).
Figure 2.16 Hydrogelation of 2.24. Microwave heating concentrations between 1-10 mM for 5 mins
at 180 °C. (A) Before vial inversion. (B) After vial inversion.
When the concentration was increased above 2 mM there was evidence of
undissolved compound. Gel did not form when the concentration was reduced to 1
mM.
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Remarkably, when the carboxylic acid groups were changed for primary amide
groups with the diamide cystine derivative 2.19, all gelation ability was lost and there
was only evidence of "fluffy precipitation" (Figure 2.17).
A B
Figure 2.17 Attempted hydrogelation of 2.19. Microwave heating concentrations between 2-10 mM
for 5 ntins at 180 °C. (A) Before vial inversion. (B) After vial inversion.
For gelation to occur with the addition of the glycine moiety, a terminal carboxylic
acid was required to increase the solubility of the compound enough to allow
gelation.
4-fluorobenzoyl cystine phenylalanine acid derivative 2.25 gave gel that was
increasingly turbid across the concentration range (Figure 2.18).
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Figure 2.18 Hydrogelation of 2.25. Microwave heating concentrations between 2-10 mM for 5 mins
at 180 °C. (A) Before vial inversion. (B) After vial inversion.
It was evident that addition of phenyl groups resulted in a decrease in compound
solubility and the result was a waxy gel, a common feature for all gelators with
additional phenyl groups.
When the terminal carboxylic acid groups were changed to primary amide groups
giving 2.20 (Figure 2.19), gelation ability, that had been evident with the former
compound 2.25, was lost. Although after vial inversion the water remained in the
bottom of the vial, this was due to the formation of a "plug" of compound, possibly
as a result of compound remaining insoluble despite heating at high temperature and
pressure.
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Figure 2.19 Attempted hydrogelation of 2.20. Microwave heating concentrations between 2-10 mM
for 5 mins at 180 °C. (A) Before vial inversion. (B) After vial inversion.
A further modification on the original basic structure of cystine low molecular
weight gelators was the introduction of a carbamate group between the cystine and
the capping group 2.12. The CBZ group was coupled onto the free amine group from
the cystine. At all concentrations a turbid self-supportive gel was formed, which
meant that the addition of a carbamate group could be tolerated in a gel (Figure
2.20).
Figure 2.20 Hydrogelation of 2.12. Microwave heating concentrations between 2-8 mM for 5 mins at
180 °C. (A) Before vial inversion. (B) After vial inversion.
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2.5 Practical application of benzoyl cystine amide derivative 2.6
Although cystine based organogelators can be considered extremely fascinating and
worthy of investigation in their own right, their development is important for
practical use as three-dimensional cellular supports.
Benzoyl cystine diamide derivative 2.6 was chosen for this work because it forms a
clear, robust and quick-forming gel.
The HeLa-GFP cell line was selected for investigation because it had the advantage
of producing a fluorescent protein when cultured, which could be used as an
indicator of the suitability of the environment.
Cells require buffers rather than pure water and therefore attempts were made to gel
buffered solutions. Four different buffers: tris/EDTA (TE), 4-(2-hydroxyethyl)-l-
piperazineethanesulfonic acid (HEPES), Hank's balanced saline solution (HBSS) and
phosphate buffered saline (PBS), all at 50 mM and pH 7.4, were used for the first
gelation experiment to produce a 2 mM gel with derivative 2.6. The result is shown
in Figure 2.21, and it was observed that TE formed the strongest gel followed by
HEPES, whereas HBSS and PBS were not gelated. Additional experiments showed
that phosphate inhibited gel formation.
A B
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Figure 2.21 Attempts to gelate four different buffers (pH 7.4, 50 mM): TE, HEPES, HBSS and
PBS. 2 mM /V./V'-Ditbenzoyb-L-cystine diamide 2.6. (A) Before vial inversion. (B) After vial
inversion.
Figure 2.22 Attempted gelation of HEPES buffers at pH's 6, 7 and 8 (50 mM): 2 mM /V.JV-
Di(benzoyl)-L-cystine diamide 2.6. (A) Before vial inversion. (B) After vial inversion.
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The effect of varying pH was investigated with HEPES with a range of pH's between
6-8, the result of which can be seen in Figure 2.22, with clear gel formation at pH 6
and 7, which ceased at pH 8.
A B
Benzoyl cystine amide derivative 2.6 gel could be "broken up" into a clear, viscous
solution by shaking. However, this "gel solution" could be reheated (>90 °C) and
cooled to give a clear gel that was stable again to inversion. Thus, once the gelator
had dissolved (at high temperature and pressure), a much lower temperature was
needed to reform gel.
Three different 2 mM benzoyl cystine amide derivative 2.6 gel solutions were
produced in water, 50 mM HEPES (pH 7.4) and 50 mM TE (pH 7.4). "Gel solution"
(50 pi) was added to the wells in a 96-well plate. The gel was reformed in 96-well
plates by heating using a domestic microwave and the well-plate was checked under
a light microscope to look for gelation. The gel was seeded using HeLa-GFP cells in
media and incubated for 24 hours at 37 °C and examined using a pseudo-confocal
microscope (Figure 2.23).
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Figure 2.23 Brightfield microscopy images. Well-plates containing three different gels in A. water,
B. HEPES (50 mM, pH 7.4) and C. TE (50 mM, pH 7.4) seeded with HeLa-GFP cells and media.
(Left) 24 h after seeding. (Right) 48 h after seeding.
In gels with TE buffer, cells were either dead or unhealthy. However with pure water
the cells appeared to be very healthy and were spreading and attaching. Cells were
also healthy in HEPES buffered gel.
These preliminary studies show that the benzoyl cystine amide 2.6 gel was not only
non-toxic but supported cell division.
A pseudo-confocal microscope was used to capture three-dimensional images
through the gels. HeLa-GFP cells were present throughout the gel (Figure 2.24).
Cells seeded in the gel had penetrated through the gel to a depth of 30 pm.
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Figure 2.24 Pseudo-confocal microscopy images. Three-dimensional slices through HeLa-GFP
seeded in gel and gel solution. (Taken through a depth of 30 pm from the surface.)
2.6 Gel study on a microarray format
A principle test for the assessment of gel formation is a study at the macroscopic
level, where a gel is defined by its ability to be gravitationally self-supporting. There
are numerous reasons why the inversion test is a fairly poor method of evaluation.
For a start it is obvious that the ability of a gel to be self-supporting depends upon the
cross-section of the vial in relation to the mass of the bulk gel. The irreproducibility
of forming gel in glass vials is also contributed to by irregularities in the glass used.
For example, the vial may have a slightly concave form upon which a weaker gel
could form and remain self-supporting. An analogy would be two identical beam
bridges, one having a purely linear structure crossing two points in a straight fashion,
the other with several support trusses. The bridge with the support is obviously going
to be stronger. The same principle applies to the effect of the container on the gel. In
0|
some publications ' gels are displayed horizontally, most likely because the gel is
too weak to be a fully self-supporting gel when in a vertical position.
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If novel gels are to be developed through a parallel library approach,71 a higher
throughput screening method is required if a very significant bottle-neck is to be
82avoided. The microarray format has been adapted to many novel applications and
the basic philosophy remains that small molecules, biomaterials, enzymes or cells
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can be printed onto a 2D surface at defined locations in tiny amounts. A high-
throughput gelation study on a microarray format has the potential to allow hundreds
of gelation experiments to be investigated on one glass chip. The advantages of using
a microarray format are obvious: high-throughput, only very small amounts of
material are required and potential savings in time of analysis.
There are several practical considerations that must be developed in order for
gelation to be achieved on a microarray. The major problem is determining whether a
gel has been formed or whether there is solution or even a precipitation. Microarrays
means a decrease in the amount of material involved in each sample but this means
that it is no longer possible to see macroscopic results, although it is still possible to
do an "inversion test". It is extremely difficult to subject a gel on the surface of a
glass substrate to any kind of physical analysis. Volumes that are very small are
vulnerable to evaporation due to a large surface area to volume ratio, making it
difficult to ascertain the precise concentration that is being dealt with. One of the
issues inherent with microarray printing is how to control rates of evaporation or
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even to exploit it to achieve better results. A second problem inherent with the
transfer of gelation from a glass container to the surface of a glass substrate is the
process that is used to form the gel. Gelators produce thermoreversible gels, which
means to form a gel the gelator needs to be heated until fully dissolved and then the
solution allowed to cool down. A primary concern when switching gel formation
from a vial to a glass surface is dissolving the gelator. The secondary problem is then
how to prevent the solution from completely evaporating before the molecules of
gelator can organise themselves.
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2.6.1 Environmental dyes
Environmental chromophoric probes were first applied around 50 years ago to study
the polarity of internal protein environments.85 One of these chromophores was 1-
anilino-8-naphthalene sulfonate (ANS), particularly interesting as it emits only very
weak green fluorescence in water but intense blue fluorescence when present in a
highly hydrophobic environment (e.g. adsorbed by serum albumin).86 In the case of
ANS, dependence of the Xmax on the polarity of the solvent results from a
reorientation of the solvent shell around the chromophore when it is excited. The
excited state of ANS has more dipolar character than the ground state and interacts
with a polar solvent so that the solvent dipoles are aligned. In a nonpolar solvent the
solvent shell is less disturbed. This means that in a polar solvent some of the
solvation energy of the excited state of ANS is lost when the chromophore returns to
the ground state, which results in a lower energy photon being emitted than in a
85
nonpolar solvent where there has been no reorientation of solvent molecules.
ANS has been used as a chromophoric environmental probe for the study of
hydrogels.87'88 Changes in emission wavelength and intensity of ANS being directly
correlated with the formation of fibres in the hydrogel.88
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Figure 2.25 Luminescence spectra of 8-anilino-l-naphthalenesulfonic acid (ANS) (10 pM) in aqueous
solutions containing various concentrations of 2.27, where [2.27] (mM): a: 0; b: 0.01; c: 0.05; d: 0.1;
e: 0.15; f: 0.5; g: 1.00; h: 1.50; i: 2.00; j: 3.00; k: 5.00; 1: 7.00; m: 10.0. 88
Figure 2.25 shows the luminescence spectra obtained after increasing the
concentration of low molecular weight organogelators up to 0.5 mM and showing a
gradual decrease in Xmax, after which there was an increase in emission fluorescence
intensity but little change in Xn,ax.
The theory proposed to explain this phenomenon was that the ANS dye was
incorporated into the hydrophobic interior of the strands of self-assembled nanofibres
as they were forming. The fact that there was a decrease in maximum emission
wavelength followed by an increase in intensity suggested that there were two stages
involved. The initial sharp blue-shift occurred as the concentration of gelator was
increased up to 0.5 mM and the explanation for this was that gelator molecules pre-
self-assembled into aggregates that had hydrophobic pockets. The concentration at
which luminescence intensity began to increase was around 1 mM, where the gelator
self-assembled into completely closed aggregates where there was no exposure to
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surrounding water. This theory correlates closely with luminescence behaviour
around the critical micelle concentration of surfactant systems.89
For the purposes of this work, it was decided to see what happens when dyes are
incorporated into gels. The first experiments performed were attempts to form gels
on a relatively large scale in glass vials along with each of the dyes chosen (Figure
2.26), to ascertain if gelation tolerated the presence of dyes. The napthoyl cystine
amide was selected for these initial experiments on the basis of its ability to rapidly
form a gel and because it forms a weak gel, it can be considered to be sensitive to the
addition of other compounds. The concentration of gel was kept constant at 2 mM
with a final solvent composition of 25% DMSO/fFO. A range of dyes were used to
give final concentrations between 0-0.5 mM. A gel was formed at every
concentration of both the dyes studied (Rhodamine B and Cy5), meaning that
gelation was dye independent.
Figure 2.26 Fluorescent dyes. Rhodamine B (Left) and Cy5 (Right).
2.6.2 Gel formation on glass slides
Napthoyl cystine amide gelator 2.7 (2 mM) along with Rhodamine B (0.5 pM) were
dissolved in DMSO (2 pL) and spotted onto oxygen plasma treated plain glass slides.
The glass slides were then placed in an incubation chamber, which was then sealed
with water (2 mL) in the base-well, and the chamber placed in an oven at 80 °C for 1
h (Figure 2.27). This system provided a means of introducing the water component
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Figure 2.27 Gelation of A',A',-Di(2-naphthoyl)-L-cystine diamide 2.7. Light microscopy images: (a)
gelator dissolved in DMSO, prior to incubation and (b) following incubation (80 °C, 1 h.) in the
presence of water. Scale bars 2 mm.
The first observation was that the original gelator spots were non-uniform and the
majority had spread across the surface of the slide. There was also condensation
across the surface of the slide. When the slides were examined under a light
microscope it was clear that a transformation had occurred in the gelator spots.
These initial results suggested that gelation could be studied on a microarray format
but the system obviously needed to be optimised further with the principle
requirement for a much more robust system for containment of gelator spots.
2,6.3 Hydrophobic printed slides
Thermo Scientific produce microscope slides coated with a hydrophobic Teflon
mask that are designed to eliminate cross contamination by keeping fluids within
"wells" (Figure 2.28).
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Hydrophilic "window" or "well" - 2 mm
diameter
Hydrophobic coating
Figure 2.28 Teflon coated microarray slide (26x76 mm).
When applied, wells prevented DMSO spots from spreading across the surface of the
chip, effectively containing the spotted material. Another advantage was that the
hydrophobic coating surrounding each well would contain a controlled volume (3
pL). Mixtures of napthoyl cystine amide derivative 2.7 and Rhodamine B in DMSO
were spotted into the hydrophilic wells on the Teflon coated microarray slides. In
order to optimise the process the slides were incubated in the chamber using different
conditions, with different volumes of water in the incubation well and by varying the
incubation temperature. Qualitative observation of the slides and fluorescence
analysis showed the best results were obtained at 80 °C. Incubation at 90 °C gave
higher background fluorescence on the slide, suggesting that the hydrophobic coating
was not stable at this temperature. Between 80-60 °C spot morphology became less
pronounced as the temperature decreased and below 60 °C there was no difference
between the morphology of spots on an incubated slide and a slide immediately after
printing. A range of dye concentrations was investigated and it was found 0.5 pM
gave a fluorescence intensity that could be measured by the fluorescence scanner,
above this fluorescence intensity was saturated.
Figure 2.29 shows the fluorescence image resulting from a slide incubated in
optimised conditions. The first observation was that after incubation there was a
massive change in the morphology of printed spots with gelator added. It was clear
that the dye became incorporated into the gelled state.
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Figure 2.29 Glass slide gelation of iV,Af'-Di(2-naphthoyl)-L-cystine diamide 2.7. Fluorescence
imaging: A. DMSO: B. 0.5 pM Rhodamine B; C. Mixture of 2 mM gelator and 0.5 pM Rhodamine
B. Scale bars 2 mm.
Figure 2.30 shows an experiment performed when different concentrations of
napthoyl cystine amide derivative 2.7 were spotted onto an array. After incubation
there was a very significant change in morphology across the range of concentrations
of gelator (it was noteworthy that the morphology of duplicates at each concentration
showed similar features that were characteristic for the printed concentration). The 4
mM material showed evidence of faint fluorescent fibres, which became more
pronounced at 8 mM. At 8 and 10 mM concentrations the fluorescence intensity was
spread evenly across the fibrous network, whereas at 15 mM the fluorescence was
much more irregular. These qualitative observations suggested that a fibrous network
was clearly forming at around 4 mM, with the fluorescence intensity of fibres
increasing as the spotted concentration increased. This correlated with theoretical
expectations that fibre formation is stronger at higher gelator concentration. At >15
mM a blotchy fluorescence intensity suggested that precipitation was occurring.
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Figure 2.31 Different concentrations of Ar,A"-Di(2-naphthoyl)-L-cystine diamide 2.7 spotted on
an array. Initial spotted concentrations of gelator (0-15 mM) with 0.5 pM Rhodamine B. Control =
DMSO. A. Before gelation; B. After gelation. Scale bar 2 mm.
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Figure 2.31 shows an investigation of the behaviour of a known non-gelator
(di(butyryl)-L-cystine diamide 2.11) compared with the napthoyl cystine amide
derivative 2.7. After incubation the fluorescence intensity of the butyl derivative 2.11
was almost identical to the dye only, as was morphology. The napthoyl derivative 2.7
at the same concentration showed the formation of a fibrous network. When there
was no molecular aggregation, the dye was not concentrated into the hydrophobic




Figure 2.31 Scanning of a non-gelator and a gelator. A. DMSO; B. 0.5 pM Rhodamine B; C. 10
mM di(butyryl)-L-cystine diamide 2.11 and 0.5 pM Rhodamine B; D. 10 mM di(2-naphthoyl)-L-
cystine diamide 2.7 and 0.5 pM Rhodamine B (shown enlarged and in greyscale). Scale bars 2 mm.
However, experiments were carried out repeatedly using Teflon coated slides there
were obvious inconsistencies with the levels of fluorescence intensities achieved (see
Figure 2.32) with the coating/its adhesion influencing fluorescence. An alternative to
Teflon coated slides was desirable that could answer these problems.
Figure 2.32 Inconsistencies in printed spots of di(butyryl)-L-cystine diamide 2.11. 10 mM cystine
derivative and 0.5 pM Rhodamine B. A. Before incubation; B. After incubation. Scale bar 2 mm.
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2.6.4 In-House micro-patterned slides production
Hydrophobic glass slides patterned with hydrophilic areas were produced by printing
a sucrose masking solution onto areas of slides where a hydrophilic surface was
required, followed by the application of a hydrophobic slide coating.
2.6.4.1 Mask application - Ink-jet printing vs contact printing
Two methods were considered for printing sucrose in defined arrays on glass
substrates. The first method employed contact-printing using pins to physically
transfer sucrose solution from a well plate to the surface of the glass substrate. This
approach proved to be problematic due to evaporation effects. Different
concentrations of sucrose solution were investigated but when the concentration was
low, the resulting film that was deposited was inconsistent and produced features that
lost their shape upon drying. When the concentration of sucrose was increased to
achieve a better coverage the solution became increasingly viscous during the
printing procedure resulting in trails of sucrose between the contact pins and the
substrate. Sucrose solution drying on the pins during printing resulted in a loss of
precision producing very inconsistent and unsatisfactory results.
The second approach involved inkjet printing sucrose solutions using a piezo-electric
nozzle, with no contact between the print head and the substrate, to form dried
patterns following solvent evaporation. In 2007 Cull demonstrated how inkjet
printing could be used to produce liquid crystal libraries using three liquid crystals,
mixed in situ in ratios controlled via the number of drops deposited by the nozzle at
each position on the matrix.90 231 different liquid crystal formulations were
fabricated on a 30 x 30 mm substrate with 1.9 mm spacing between spots (100 drops
per spot).
Stroboscopic cameras can be used to monitor droplet formation. This allows accurate
control of the volume of deposited materials according to the number of drops
printed in any given location. In a review of inkjet printing platforms, De Gans and
Schubert concluded that the Autodrop platform possesses a drop volume error of less
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than 1% and a positional accuracy of (10+3) pm,91 which is accurate enough for
spot-on-spot printing.
The resolution of a printed pattern is determined by the density of printed spots,
where the distance between each spot printed in the X and Y directions can be
reduced until individual spots merge with each other. Sucrose solutions are generally
very viscous and this can be problematic for printing. A high sucrose concentration
was desirable because at a higher concentration evaporative effects cause fewer
problems. This meant that when a high sucrose concentration was printed the droplet
remained at the position it was printed and had less inclination to "bleed" into
adjacent spots and areas on the glass substrate surface. The effect of varying the
sucrose concentration was investigated and it was found that the most reliable results
were produced with 40% sucrose w/v. Figure 2.33 shows the generation of an
individual droplet of sucrose and it is notable that the droplet that is produced is
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Figure 2.33 Inkjet printing. Generation of an individual droplet of 40% sucrose in water by inkjet
printing.
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In-house arrays were fabricated according to the following protocol (Figure 2.34).
Glass microscope slides (76 x 25 mm) were first rinsed in solvents to remove
manufacturing debris and etched using an oxygen plasma (Europlasma NV Junior
System, Frequency: 50 Hz, R/Power: 100 W). A sucrose mask (40% w/v sucrose in
H20) was printed with defined locations on the array using an inkjet printing system
(Microdrop Technology, Norderstedt, Germany). This printing system consisted of a
piezo-electric printing nozzle (70 pm diameter), an automated XYZ stage and a
stroboscopic video camera. Printing parameters and printing density were optimised
to achieve homogenous patterning of uniform squares printed in organised arrays.
Following printing, slides were dried at 60 °C for 1 h and coated with tridecafluoro-
1,1,2,2-tetrahydrooctyl dimethylchlorosilane (TFCS) using a K bar coater (0.05 mm
diameter wire, 2.5 cm/sec). Slides were then washed with H20 to remove the mask
along with excess TFCS and dried under a stream of nitrogen leaving a chip with
defined hydrophilic and hydrophobic areas.
Slides with the following sizes of hydrophilic squares were produced and tested: 4.5

































Figure 2.34 Slide patterning. (A) Sucrose (40% in H20) mask printing; (B) Glass surface
modification with tridecafluoro-1,1,2,2-tetrahydrooctyl dimethylchlorosilane; (C) Mask dissolution.
Figure 2.35 shows the corner of a sucrose printed region that has dimensions of 1.5 x
1.5 mm (it is possible to see the individual droplets that were printed at the print
edge).
Figure 2.35 Corner of a sucrose masked printed area. Scale bar 1 mm.
Figure 2.36 shows examples of how water can be "contained" within the hydrophilic
regions generated by the masking/coating method even when an excessive volume of
water is added.
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Figure 2.36 Hydrophilic "window" filled with H20. Scale bar 0.75 mm.
Figure 2.37 shows images of a chip containing 21 sucrose printed squares (each of
4.5 x 4.5 mm).
Figure 2.37 Images of a sucrose array. Taken from different perspectives. Scale bars 4.5 mm.
It was possible to comfortably accommodate 100 1.5 x 1.5 mm sucrose squares, and
these gave the best results initially so were used in subsequent experiments.
A series of experiments were performed using the hydrophobic/hydrophilic patterned
arrays. An experiment was carried out with 14 varying concentration of napthoyl
cystine amide derivative gelator 2.7 printed on one chip (Figure 2.38). DMSO
solutions containing the dissolved gelator and Rhodamine B were printed rapidly in
precise and reproducible volumes into the hydrophilic areas on modified slides. The
printing parameters were optimised to ensure that the printing time could be reduced
to a bare minimum (the aim was to print an entire chip in less than 10 minutes). This
was very important to prevent evaporation.
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Figure 2.38 Different concentrations of /V,/V'-Di(2-naphthoyI)-L-cystine diamide 2.7 printed on a
patterned glass slide. 0-50 mM of gelator and 0.5 pM Rhodamine B. Scale bars 1.5 mm.
A gradual increase in fluorescence intensity was observed as the concentration of
napthoyl derivative 2.7 increased. At 40 mM and 50 mM the overall fluorescence
intensity was much greater than the control, thus Rhodamine B is clearly acting as an
environmental sensor regarding gelation.
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Figure 2.39 Influence of changing gelator 2.7 concentration on fluorescence intensity of
Rhodamine B.
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Between 0-7.5 mM napthoyl gelator 2.7 there was a rapid increase in fluorescence
intensity corresponding to a transition from a liquid state through a jelly state to a
low-density gelled state. Above 7.5 mM the rate of increase of fluorescence intensity
levelled off. Above 30 mM there was a second increase in fluorescence intensity.
The initial increase in fluorescence intensity was caused by increasingly more
complete gel fibre formation. Between 10-30 mM I hypothesise that complete fibre
formation has occurred and that there is no further arrangement of fibre molecules; a
tertiary structured fibre has been achieved. Between 30-50 mM concentration there
was a further transformation occurring in the gelled state going from a low-density
gelled state to a high-density gel.
As a comparison to a microarray gelation investigation, a range of concentrations of
napthoyl cystine amide derivative 2.7 were made in glass vials on a macro-scale, the
result (Figure 2.40).
0.25 0.5 0.75 1 1.5 2 4 5 7.5 10
mM
Figure 2.40 Range of A,iV'-Di(2-naphthoyl)-L-cystine diamide 2.7 concentrations in vials. Gels
consisting of 25% DMSO, 75% water. A. Inverted vials side-view. B. Inverted vials seen from above.
At 0.25 mM the gel was too weak to be self-supporting and collapsed under gravity.
At 0.5 mM a weak gel was formed that was self-supportive. The resulting gel
appeared to be clear up to a 1.5 mM, after which point the resulting gel became
increasingly opaque as the concentration increased. Between 1.5-4 mM the gel
became more inhomogeneous. This was believed to be because of difficulties in the
practical handling of the gel. The gel forms very rapidly, in less than one second
upon adding water and so it was possible that a gel was formed from the water that
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made first contact with the gelator solution in DMSO, followed by disruption of this
primary gel by the addition of the last portion of water. It could be that when the gel
was made in large volumes with 10% DMSO/H2O it was not possible to add the full
aliquot of water to give the desired concentration. In these cases a small volume of
dense gel was formed followed by water that failed to incorporate. I hypothesise that
the weakening effect seen on a macro-scale (1.5-4 mM gelator) can be correlated
with what was seen on the microarray between an initial print concentration of 10-30
mM. Between 5-10 mM an increasingly "lumpy gel" was formed that become more
solid-like and precipitous rather than liquid in nature.
2.6.5 Effect of dye on gel morphology
An experiment was performed using three different dyes on the microarray with two
different initial print concentrations of napthoyl cystine amide gelator 2.7. The
concentration of each dye used was optimised by printing concentration ranges of
dye in DMSO. In the case of Rhodamine B and Cy5 dyes, the morphology was the
same for both dyes at identical concentrations of gelator (see Figure 2.41). This
suggested that the mechanism for incorporation of dye into a gel was the same for




Figure 2.41 Gelation attempted with two different fluorescent dyes: A. Rhodamine B (0.5 pM);
B. Cy-5 (5 pM). Initial concentration of M/V'-Di(2-naphthoyl)-L-cystine diamide 2.7 either 0, 5 or 10
mM. Scanned using BioAnalyzer 4F/4S white light scanner using: A. Cy3 filter and B. Cy5 filter.
Scale bars 1.5 mm.
2.6.6 Mixed gelators on an array
It was thought that the disulfide bond from the cystine could be exploited by
encouraging disulfide exchange between cystine derivatives with different capping
groups to study the effects of mixed disulfides on gelation morphology. By
performing this study on a microarray an enormous amount of information
concerning the morphology of mixed gelators could be gathered in just a few
experiments. Ink-jet printing enabled printing of a set number of droplets of the first
gelator into hydrophilic areas on a hydrophilic/hydrophobic masked chip, followed
by printing of an identical number of droplets of the second gelator directly on top of
the first set. Three different conditions were employed for the series of experiments.
In one experiment, a stoichiometric quantity of dithiothreitol (DTT) was printed on
the mixture of cystine derivatives and the chip was incubated for one week. The chip
was then incubated in the usual way in the presence of water for 1 h at 80 °C. DTT
was printed onto mixtures of cystine derivatives on another chip but was introduced
into the incubation chamber immediately in the presence of water for 1 h at 80 °C.
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Another chip was prepared with mixtures of cystine derivatives but this time pure
DMSO was printed onto the mixed cystine derivative spots and the chip was

















Figure 2.42 Scheme of mixed gelator production on a microarray. A. Glass slides printed with
Gelator A dissolved in DMSO (100 drops, 35 mM). B. Gelator B dissolved in DMSO (100 drops, 35
mM) spots printed on top of Gelator A spots. C. Printing of DTT in DMSO (100 drops, 210 mM)
spots on top of mixed gelator spots (DMSO only printed for experiments excluding DTT). D.
Rhodamine B in DMSO (50 drops. 3.5 pM) printed on top of mixed gelator spots with DTT. E.
Incubation at 80 °C for either 1 h. or 6 days. F. Incubation chamber allowed to cool to 20 °C. G.
Slides scanned using BioAnalyzer 4F/4S white light scanner, Cy3 filter.
The five capping groups chosen are given in Figure 2.43 along with the results from
the experiments. The methoxybenzoyl derivative 2.10 was selected because it had
previously been shown to precipitate in DMSO/FFO and form a lumpy gel so it was
interesting to see the resulting morphology in comparison to the known good
gelators. The napthoyl derivative 2.7 formed a gel rapidly and had been studied in
previous experiments. The benzoyl 2.6, 4-fluorobenzoyl 2.8 and 4-bromobenzoyl









Figure 2.43 Set of mixed gelators. Gelator (NAP 2.7, FLU 2.8, BEN 2.6, BRO 2.9, MOB 2.10) (20







Figure 2.44 Set of mixed gelators with DTT added. Gelator (NAP 2.7, FLU 2.8. BEN 2.6. BRO
2.9. MOB 2.10) (20 mM), Rhodamine B (0.5 |aM) and DTT (60 mM). Gelation conditions: 80 °C, 1

















Figure 2.45 Set of mixed gelators with DTT added with incubation. Gelator (NAP 2.7, FLU 2.8,
BEN 2.6, BRO 2.9, MOB 2.10) (20 mM), Rhodamine B (0.5 pM) and DTT (60 mM). Gelation
conditions: 80 °C, 6 days.; Scale bars 1.5 mm.
Figures 2.43-2.45 show a selection of results with the fifteen different possible
combinations of cystine derivatives at three different conditions; a total of 45
different types of gel. An observed general trend from the morphology of spots after
incubation with no DTT was the absence of any evidence of fibrous morphology in
spots with methoxybenzoyl derivative 2.10, apart from the mixture with napthoyl
derivative 2.7. The napthoyl derivative 2.7 formed a highly fluorescent gel in all
cases after incubation where no DTT had been used, which indicated that gel
formation between molecules of napthoyl derivative 2.7 was the overriding process
when it was mixed with other gelators. There was evidence of a strongly fluorescent
fibrous morphology when napthoyl derivative 2.7 was combined with 4-
bromobenzoyl derivative 2.9 and the fluorescent gel pattern that resulted could be
considered to be a compromise between the morphologies formed by the individual
unmixed gelators (shown in Figure 2.46).
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NAP-NAP NAP-BRO BRO-BRO
Figure 2.46 Mixed cystine derivative (NAP-BRO) compared with single gelators on microarray.
Scale bars 1.5 mm.
The 4-bromobenzoyl derivative 2.9 formed a strong fluorescent fibrous network in
all mixtures and when mixed with the methoxybenzoyl derivative 2.10 the gel was
very dense and compact, indicated on the microarray by a small, round, highly
fluorescent spot with the media surrounding the gel spot having a background level
fluorescence intensity.
Gel mixtures that didn't contain DTT had more intense fluorescent patterns than
those that did. Incubating gel mixtures with DTT for 6 days generally resulted in a
complete loss of morphology from gel spots that showed strong gel morphology in
the absence of DTT. When DTT was added directly prior to gelation there was
evidence of a reduction in the intensity of the fluorescent network compared with
gels that contained no DTT. However, when DTT was mixed with gelator solutions
with no incubation period, there was no loss of the resulting fluorescent gel pattern.
1. 2. 3. 1. 2. 3.
# M. &
Figure 2.47 Mixed gelator combinations (20 mM) and Rhodamine B (0.5 pM) treated with three
different conditions: 1. DTT (60 mM), 80 °C, 6 days; 2. DTT (60 mM), 80 °C, 1 h.; 3. No DTT,
80 °C, 1 h.; Scale bars 1.5 mm.
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In the case of mixed FLU-BRO derivative and mixed BEN-BRO there was a
complete loss of morphology when DTT was present and left over an incubation
period (Figure 2.47). When DTT was added and gelation was induced immediately
with no incubation period morphology characteristic of formed gel was observed.
Fibres appeared to be longer in mixed FFU-BRO derivative when DTT was added
without incubation compared with gelator in the absence of DTT. This was also seen
in BRO-BRO derivative.
A "mixed-cap" (BEN-BRO) cystine derivative 2.26 was synthesised to confirm the
microarray observation on a macro-scale. Cystine 2.26 was synthesised according to
the synthetic scheme outlined earlier, by coupling Fmoc-Cys(Trt)-OH with a
polystyrene Rink amide resin and capping with a 1:1 mixture of benzoic acid and 4-
bromobenzoic acid. The attempt to gelate water using 2 mM 2.26 is shown in Figure
2.49. The result was a fine lumpy precipitate in solution with no evidence of fibre
formation, which is consistent with the morphology observed in the mixed gelator
combination (BEN-BRO) incubated with DTT (shown in Figure 2.48).
A B
Figure 2.48 Attempted hydrogelation of "mixed-cap" cystine derivative 2.26. 2 mM BEN-BRO
derivative 2.26 in H20 following microwave heating at 180 °C for 5 mins. (A) Before vial inversion.
(B) After vial inversion.
2.7 Degradation ofcystine-based hydrogels
Cystine-based hydrogels were remarkably stable when handled carefully, surviving
intact for over 2 years in the majority of cases. Gels liquefied in seconds when
subjected to mechanical agitation. Gel stability was studied using the "ball drop"
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method. Benzoyl cystine diamide 2.6 (2 mM) hydrogel was formed using microwave
heating and a steel ball bearing (diameter = 4 mm, 84 mg) was placed onto the gel
surface. Addition of DTT solution (1 M, pH 8.2) resulted in complete liquefaction
after 7 days by which time the ball fell a distance of 40 mm. Without the addition of
DTT the ball fell 3 mm in the same time. When the concentration of DTT solution
added was increased (4 M, pH 8.2), complete liquefaction occurred in a little over 4
hours.
The possibility of proteolytically degrading modified cystine hydrogels was
investigated by adding trypsin to napthoyl cystine glycine 2.15 (2 mM) hydrogel but
no degradation was observed.
2.8 Conclusions
A structurally diverse library of cystine derivatives has been accessed using an
efficient and straightforward solid phase route. Microwave heating at high
temperatures and pressures has allowed the production of novel hydrogels at
remarkably low concentrations and the study of gelation ability in relation to
compound structure. Preliminary experiments have shown that cells can be
successfully incorporated into these hydrogels.
A novel method of visualising gels from low-molecular weight gelators has been
demonstrated for the first time. Low-molecular weight gelators were inkjet-printed as
arrays onto hydrophobic glass slides modified with defined hydrophilic areas and
gelated in the presence of a fluorescent dye, allowing subsequent gel morphology to
be directly observed. This high-throughput technique has enormous potential for the
future study of low-molecular weight gelators.
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Chapter 3:
Protein and Peptide Chemical Cross-linking Reagents
3.1 Introduction
Protein-protein interactions play a key role in a multitude of cellular and biological
processes, with abnormal protein-protein interactions having been implicated in
various disease states. Some cervical cancers are caused by specific human
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papillomavirus infections , where viral E2 proteins target the cellular protein Brd4,
forming a physical tether between the viral "plasmid" and the host cell mitotic
chromosomes. This leads to the virus persisting for a long time, maintaining the
transformation status of affected cells.93
Figure 3.1 Potential targets for papilloma virus E2 inhibition. Arrows indicate potential targets for
inhibition of papilloma virus infection.1'4
Reproduced with permission (copyright Elsevier, 2005).
Staphylococcus aureus and Streptococcus pyogenes are two important human
pathogens that adhere to and invade host cells via a protein-protein interaction
between fibronectin-binding proteins anchored in the bacterial cell wall and host
fibronectin.95 Protein-protein interactions are implicated in T-cell leukaemia and
breast cancer. LIM domains are protein structural domains, named after their initial
discovery in the proteins Linl 1, Isl-1 and Mec-3.96 LIM-domain containing proteins
play roles in cytoskeletal organisation, organ development and oncogenesis. LIM-
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domains mediate protein-protein interactions critical to cellular processes. The key
targets of the LIM-domain-binding protein ldbl are the LIM-only (LMO) and LIM-
homeodomain proteins. A direct link has been made between overexpression of
LM02 in T cells and the onset of T-cell acute lymphoblastic leukaemia in children,
due to competition for ldbl by ectopically expressed LM02 and endogenous LM04
in T cells.97 Huntington's disease is one of several neurodegenerative poly-glutamine
(polyQ) disorders, where the abnormal expansion of polyQ regions in proteins causes
the proteins (huntingtin in the case of Huntington's disease) to associate, forming
insoluble protein deposits in the brain.94 Due to this fact there is a desire not just to
understand which proteins are interacting with each other but to be able to develop
QO
small molecules that are capable of blocking specific protein-protein interactions.
Determining the protein interaction network is one of the major problems facing
functional proteomics and one of the most challenging problems of the post-genomic
era. There is a huge amount of information available concerning protein structures
and this is steadily increasing with regards to protein-protein interactions. However,
the rate of structure determination of protein-protein complexes using experimental
methods such as X-ray crystallography and NMR spectroscopy is seriously lagging
behind that for conventional single protein structures.99 X-ray crystallography and
NMR spectroscopy both yield detailed information on protein structure however
NMR spectroscopy requires large quantities of pure protein and for X-ray studies the
protein has to be crystallised, which demands considerable skill and a large time
investment. Another limitation of these techniques is that they are considered to have
a low throughput. A large-scale study designed to obtain 3D protein structures from
across the human genome using X-ray or NMR analysis resulted in a success rate of
only 3-5%.100 Sensitive techniques are thus required to perform large-scale protein
and protein-protein analysis, ideally in a high-throughput manner, because sample
amounts are often limited. Mass spectrometry is a fantastically powerful tool for
these studies and has the potential to fulfil such a role.101 Indeed, there are a growing
number of mass spectrometric techniques that are being used for structural studies of
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proteins: hydrogen-deuterium exchange, analysis of intact non-covalent complexes
in the gas phase103 and chemical cross-linking.104
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3.2 Chemical Cross-linking
Chemical cross-linking is a well established method in protein chemistry. The aim of
performing intramolecular chemical cross-linking is to gain knowledge and
clarification of how a protein folds and an understanding of site-site interactions. The
objective of intermolecular cross-linking between different proteins is to
simultaneously identify which components interact and how and where they are
physically connected to each other by residue-residue contacts between interacting
proteins. This means that chemical cross-linking can be considered as a low-
resolution complimentary approach to NMR spectroscopy and X-ray crystallography
based methods. The advantages of chemical cross-linking coupled with mass
spectrometry however are huge: Unlike other techniques, it can be used on analytes
at low concentrations, it does not require protein crystals or proteins in a specific
solvent and it is fast because data analysis can be automated, all benefits that allude
to greater throughput.
Figure 3.2 Chemical cross-linking of a model protein. Bovine basic fibroblast growth factor
((FGF)-2) cross-linked with the lysine-specific cross-linking agent bis(sulfosuccinimidyl) suberate
(BS3) (the 14 lysines of (FGF)-2 are shown in red, observed cross-links are indicated by yellow
dashes.).105
Reproduced with permission (copyright. 2000. National Academy of Sciences, U.S.A.).
The nature of protein-protein interactions can vary depending on the function of the
proteins involved and the biological process that they are involved in. A requirement
of multiprotein complexes is that the interactions between intracellular proteins are
stable, whereas when two or more proteins associate in the catalytic step of a
biosynthetic or signal-transduction pathway, the interactions involved are more
67
commonly transient.106 Chemical cross-linking is a direct method of identifying both
transient and stable interactions. Chemical cross-linking involves the formation of
covalent bonds either between two or more proteins in the case of inter-molecular
cross-linking or one protein that has been intra-molecularly cross-linked. Chemical
cross-linkers are usually bifunctional reagents containing two reactive end groups
that react with two functional groups from amino acid residues that are present
throughout proteins, most commonly primary amines and thiols. Two proteins can
only be covalently cross-linked together if they are physically interacting. Observing
cross-links between two distinct proteins is direct evidence that the proteins must be
in close proximity to each other.
Cross-linking of proteins began with Mother Nature; cross-linking imparts rigidity
on loosely folded, floppy proteins or flimsy protein complexes.107 Man also had the
same intentions; Quiocho and Richards showed that cross-linking of enzyme crystals
with gluteraldehyde increased their mechanical stability.108 The first identification of
a cross-link with regards to interest in protein structure was carried out by Zahn in
1958, cross-linking the N-terminal groups of the two peptide chains of insulin.109 The
next advance in the field came in 1966, with the introduction of bis-alkyl imidates as
a reactive cross-linking chemistry,110 followed by a demonstration in 1970, of how
SDS gel analysis of cross-linked proteins could indicate the quaternary structures of
proteins quickly and simply."1 A breakthrough in proteomics came in 1988 with the
introduction of new mass spectrometry techniques for introducing large, intact
molecules into the gas phase.112 Reported examples of the application of chemical
cross-linking in conjunction with mass spectrometry to protein complexes followed.
One of the first examples involved the identification of members of the yeast nuclear
pore complex, in which the complex component Nup85p was tagged and a six-
membered complex identified following analysis using matrix-assisted laser
desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF-MS).113
Another seminal work involved mapping molecular interfaces between homodimeric
DNA binding protein ParR and the glycoproteins CD28 and CD80.114 These
demonstrations of the potential of the cross-linking approach were followed up with
a determination of the interaction regions in complexes between calmodulin and a
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cloned fragment of the giant muscle protein nebulin115 and the interacting regions in
complexes of microtubule-destabilising protein Op 18 and tubulin.116 Interaction sites
have been identified in the light-activated complex between transducin and a number
of single cysteine rhodopsin mutants,117'118 in the yeast mitochondrial prohibitin
complex consisting of subunits PHB1 and PHB2,119 in assembled tubes of capsid
protein of HIV-1120 and in homodimers of apolipoprotein A1 in reconstituted HDL
particles.121 Interacting regions were identified between the HIV envelope protein
gpl20 and its cellular receptor CD4122 and between paxillin and its binding
partners.122 Further reports have identified intermolecular contact regions between
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interleukin-6 (IL-6) chains in interleukin-6-dimer, between two DNA repair
proteins Rad6/Radl8,124 between monomeric subunits in the homodimer of
i <yc ...
aminoacylase 1 and between components of the heterodimeric protein complex
1 9 f\
negative cofactor 2.
There is now no question that the chemical cross-linking combined with mass
spectrometry approach is of tremendous value to proteomics, enabling low-resolution
three-dimensional protein mapping. Thus it has been used to determine the low-
resolution three-dimensional structure of fibroblast growth factor (FGF)-2, revealing
the folding patterns of the protein family.105 A number of publications have reported
amino acid distance constraints within cytochrome c5127'128 lysozyme,128 ribonuclease
1 97 1 9Q 1 TO
A and ubiquitin. ' Cross-linking products have been identified in
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haemoglobin, neurofibrillary tangles from the brain of an Alzheimer's disease
191 199 199
patient, tyrlysbradykinin and neurotensin.
3.2.1 Mass spectrometric analysis of cross-linking products
Mass spectrometry is now the method of choice for detecting tiny quantities of
proteins.107 The power of the field has been enabled by the advent of the soft
ionisation techniques MALDI133 and ESI134 that can be applied to either large
biomolecules or to allow accurate MS analysis of smaller peptides.
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(i). MALDI-TOFMS - Matrix-assisted laser desorption/ionisation time-of-flight mass
spectrometry is a very sensitive method for analysing proteins and gives solid,
reproducible results. Interestingly the mechanisms of ion formation in MALDI are
still being debated.135'136,137'138 Sample (analyte) is deposited on a probe by co-
crystallisation with a matrix (typically aromatic acids, of which the most commonly
used being: 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid)139, a-cyano-4-
hydroxycinnamic acid (alpha-cyano or alpha-matrix)140 and 2,5-dihydroxybenzoic
acid (DHB)141 and then introduced to the vacuum chamber. Ionisation is induced by
firing short pulses of laser light focussed on the sample probe. MS/MS experiments
of cross-linked peptides, where post-source decay (PSD) analysis can be
performed,142 can reveal primary structure information of proteins as well as
abundant fragment ions directly at the site or sites of cross-linker modification.105
MALDI-TOFMS has been used for the analysis of a number of cross-linking
studies.105'113-119'122'124"126'143




Figure 3.3 The MALDI process. Laser induced desorption is followed by ionisation, the exact
mechanism is not fully understood.
(ii). ESI-MS - The principle of ESI is that liquids are sprayed through a needle with a
carrier gas in the presence of a strong electric field, such that they form small and
highly charged droplets. The droplets undergo desolvation, which decreases the
diameter of the droplets. This leads consequentially to charge density increasing on
the surface of the droplet, until Coulombic repulsion becomes the same order as
surface tension. At this point there is a "Coulombic explosion" whereby the droplet
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becomes unstable and splits to form daughter droplets that also begin to evaporate
and decrease in size. This sequence of events is repeated until the electric field
generated by the surface charge density of the droplet is strong enough to desorb ions
from the droplet into the ambient gas. There have been massive developments in
mass spectrometer technology resulting in improved sensitivity, reduced flow rates
and miniaturisation of the electrospray technique by using narrower spray capillaries
to introduce smaller droplets into the mass spectrometer.144
Quasi-
molecular ion
Figure 3.4 Electrospray mass spectrometry.134 Ion formation occurs following evaporation of the
initial droplet solvent followed by desolvation in a sequence of Coulomb explosions.
A peptide mixture is normally introduced into a mass spectrometer following
application of a separating technique such as liquid chromatography (LC) or
capillary electrophoresis (CE). Complex mixtures of peptides are commonly
separated prior to analysis using RP-HPLC or by 2D-HPLC, which is usually the
combination of a strong cation-exchange step and an RP chromatographic step.145
ESI-MS/MS is usually used to obtain amino acid sequence information that is of
high-quality and provides structural information. MS/MS, also known as tandem
mass spectrometry, involves two stages of mass analysis. In the first stage an ion is
isolated by separating it in time in a single mass spectrometer or separating it in
space where individual mass spectrometer elements are separated. Ion separation can
be achieved in an ion trap, a triple quadrupole (QqQ) or quadrupole time-of flight
Self-generated electric
field leads to desolvation
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(QqTOF) instruments.146 After the first stage of analysis, isolated ions are subjected
to ion activation whereby energetic gas-phase collisions are applied, which leads to
fragmentation of the peptide ions. The second stage of analysis measures m/z values
of the fragmentation products. Cross-linked protein products have been analysed
many times using ESI-QIT (quadrupole ion trap), ESI-QqTOF or ESI-TOF (time-of-
flight) instruments.157'147'148449
3.2.2 Cross-linking strategies
Intra and intermolecular cross-linking - low-resolution 3D structure
mapping of proteins and mapping protein interfaces
3.2.2.1 The strategy
A cross-linking reaction can be performed using either homobifunctional or
heterobifunctional cross-linkers. These cross-linkers provide intramolecular distance
constraint information because they will only bridge defined distances through space,
as opposed to so-called (see later) zero-length cross-linkers that merely show direct
contacts. The value and great potential of chemical cross-linking does not lie solely
with the ability to elucidate the three-dimensional folding patterns of proteins. The
technique is remarkably powerful for mapping molecular interfaces in protein


























Figure 3.5 General cross-linking analytical strategy. " Mapping three-dimensional structures of
proteins by intramolecular cross-linking.
The process of intramolecular cross-linking and analysis proceeds according to the
following steps:
(i) Cross-linking reaction: Usually cross-linker concentrations, reaction times and
buffer pH must be optimised to get a high yield of cross-linked product.
(ii). Assessment of cross-linking products: One-dimensional gel electrophoresis as
well as matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry
(MALDI-TOFMS) are used to assess whether high molecular mass aggregates have
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been formed by intermolecular cross-linking, thus also giving an indication of cross-
linking reaction efficiency. Size-exclusion chromatography can be applied, as an
alternative to gel electrophoresis, in order to separate intramolecular cross-linking
products from the higher molecular mass aggregates that are made by intermolecular
cross-linking.
(iii). Processing of cross-linking products: Gel bands containing the desired cross-
linked proteins are excised from the gel and in-gel proteolytic digestion performed
using trypsin. The peptide mixture that results from digestion with trypsin is typically
complex in nature. It consists of peptides that remain unmodified by cross-linking,
intramolecular cross-linking products, that are both inter- and intrapeptide cross-
linked, as well as intermolecular cross-linking products (cross-links between two
proteins); all types of cross-linking products present in a large range of different
combinations. Intramolecular cross-links give valuable information on how the
proteins fold within a complex. Intermolecular cross-linked products give
information on protein-protein interactions.
After a cross-linking reaction there are a huge number of cross-linked products. A
cross-linker (depending on its structure) can react at one or two different amino acid
side chain groups as well as the amino and carboxyl termini of the protein. There are
three main types of cross-linked peptide that can be formed:
1. One end of the cross-linker reacting with an amino acid side chain or protein
termini, with the other end having hydrolysed. This type of "cross-linked" product
has been referred to as 'dead-end', 'decorated', 'end-capped' or 'hanging'.
Peptides that are modified by hydrolysed cross-linker are considered to be
undesirable because they do not yield any information concerning distance
constraints within a protein, however they can still be of use because they do
provide information on surface accessibility.
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2. Both ends of the cross-linker have reacted and an intrapeptide cross-link has
been formed where two amino acid side chain groups from the same peptide have
reacted.
3. Both ends of the cross-linker have reacted and two independent peptide chains
have been united to produce an interpeptide cross-link.
Of course the cross-linked peptide product mixture can be complicated further with
multiple modifications. It is quite possible for a peptide to contain more than one
hydrolysed cross-linker molecule. It is also possible for a peptide to contain a
hydrolysed cross-linker and either an inter- or intrapeptide cross-link. Every cross-
linking experiment produces such an enormous range of outcomes; the subsequent
data analysis and interpretation is a daunting task.
(iv). Analysis: The peptide mixture is analysed by combinations of liquid
chromatography and electrospray ionisation mass spectrometry (LC/ESI-MS) and by
MALDI-TOFMS.
(v). IT solutions: Finally, sophisticated computer software processes the data and
compares the signals that are present in the mass spectra of cross-linking products
but that are not present in non-cross-linked proteins. When cross-links have been
identified they can be assigned to parts of the proteins. This leads to the
determination of intramolecular distance constraints within the protein.
3.2.3 Cross-linking reagents
3.2.3.1 Homobifunctional cross-linkers
Homobifunctional cross-linking reagents, in particular cross-linkers that react
specifically with primary amine groups, have been used extensively. They are
typically soluble in aqueous solvents and are able to form stable inter- and intra-
subunit covalent bonds. Over the past 20 years the variety of available
homobifunctional cross-linking reagents has greatly increased and now a wide range
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of reagents, with different spacer lengths and reactivities, are available commercially,
to suit particular cross-linking requirements. Some cross-linkers have "cleavable"
linkages whereas others are non-cleavable, which means that cross-links are
irreversible.
One major drawback intrinsic with homobifunctional reagents is that a large range of
poorly defined products are generated, because homobifunctional reagents will react








Spacer length = 11.4 A
Ethylene glycol bis Na03S ,0
O Oo
(sulfosuccinimidyl succinate)
(sulfo-EGS) O o O
O
Spacer length = 16.1 A
S03Na
Figure 3.6 Homobifunctional cross-linking reagents. Examples of three such cross-linking
reagents: sulfo-DST, BS3 and sulfo-EGS.
3.2.3.2 Heterobifunctional cross-linkers
Heterobifunctional conjugation reagents contain two different reactive groups that
can couple to two different functional groups on proteins.151 For example, one part of
a cross-linker may contain an amine-reactive group while the other end may consist
of a sulfhydryl-reactive group. The main benefit that comes from the different
reactivities of heterobifunctionality is that the cross-linking process can be
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controlled. This means that whereas with homobifunctional cross-linkers there is the
possibility that everything gets conjugated and there is a large degree of high
molecular mass aggregate formation, the use of heterobifunctional cross-linkers
makes cross-linking a more controlled process. When using a heterobifunctional
cross-linker, one reactive group can be allowed to react and a purification step can be
performed. Then the reaction conditions can be changed so that a coupling with the
other reactive group is favourable. Heterobifunctional cross-linkers can contain a
photoreactive group that is non-selective to target molecules and is only fixed with
UV light. The non-selective nature of photoreactive groups makes their use suitable
for characterising binding sites between receptors and ligands because the
photoreactive groups will not react prior to UV treatment, allowing equilibrium to
establish before being fixed for analysis. In contrast, amine-reactive cross-linkers
will typically react with the first reactive target group that they encounter.
3.2.3.3 Zero-length cross-linkers
So-called zero-length cross-linkers are the smallest type of cross-linkage that can
exist because they simply mediate direct cross-linking between/in proteins. The most
common zero-length cross-linking system utilises a carbodiimide (such as l-ethyl-3-
(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC)) to provide an amide
linkage between a carboxylate and an amine or a phosphoramidate linkage between a
phosphate and an amine.152 Zero-length cross-linkers are apparently excellent tools
for mapping contact regions in/between proteins.153
3.3 Current cross-linker chemistry
Although there are now hundreds of reported cross-linkers in the literature151 and a
wide range of commercially available reagents, their action is based on a small
number of reactions. Consequently the protein functionalities that react with such
cross-linkers are equally small. The most common cross-linker target functionality is
the amino group, present on the side chain of lysines and the free iV-termini of
proteins. Sulfhydryl groups are the second most common cross-linker functionality
targeted, especially in the design of heterobifunctional cross-linkers. Photoreactive
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cross-linkers which react after exposure with UV light and insert non-specifically
into the chemical bonds of target molecules are much less common and typically
target double bonds, where an addition reaction can occur, and C-H and N-H sites
whereby the photoreactive moiety undergoes an insertion reaction.
3.3.1 Amine-reactive cross-linkers
3.3.1.1 N-hydroxysuccinimide (NHS) esters - The concept of using NHS esters on
the reactive ends of a homobifunctional cross-linker was first introduced in the mid-
1970s.1 4'155 NHS esters react readily with nucleophilic amines at physiological pH
(Figure 3.7), which is one of the reasons why they are used today in the vast majority
of cross-linkers.
Figure 3.7 NHSS active ester reactions. Hydrolysis of the NHSS ester competes with nucleophilic
attack by free amine containing compounds.
NHS esters react to produce stable amide bonds with primary or secondary amines
and the NHS group released (as a good leaving group). Many NHS esters are
insoluble in aqueous buffers, which often means that they must be first dissolved in
DMSO. Sulfo-NHS esters are water soluble alternatives that allow a cross-linker to
be dissolved directly into an aqueous buffer. NHS esters have half-lives in the order
of hours at physiological pH but when the pH is increased, so is the rate of hydrolysis
and amine reactivity. It has been reported that NHS esters can react with the
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sulfhydryl groups of cysteines and with hydroxyl groups such as those found in
serine and threonine, and that the products are unstable and the subsequent thioester
or ester products hydrolyse very quickly in aqueous solution.156 Studies have
demonstrated that while sulfo-NHS esters react with lysine residues and the N-
terminus, they also react with ammonium ions (via NH3) that can contaminate
buffers, as well as with serine and tyrosine residues.157 Another study showed that
although NHS esters preferentially react with primary amines, unexpected side
reactions with the hydroxyl groups of tyrosine, threonine and serine can be
detected.158 The reactivity of amino acid hydroxyl groups is dependent on pH and the
amino acids in proximity. Histidine and arginine both increase reactivity of
neighbouring serine, threonine and tyrosine by formation of an intermediate cross¬
link.159 In acidic conditions (pH 6.0) the yields of the side reactions can be greater
than the reaction with lysine. In basic conditions (pH 8.4) the preference is for
reactions involving the A-terminus and the amino groups present on lysine residues.
3.3.1.2 Imidoesters - The application of imidoesters in homobifunctional amine-
reactive cross-linkers predates the use of NHS esters.110 Imidoesters are the most
specific acylating agents available for modifying primary amines and have minimal
reactivity with other nucleophiles in comparison with most other cross-linking
reagents. The A-termini primary amines and lysine side chains of proteins are
targeted by imidoesters and reaction occurs at between pH 7-10, with optimal
reaction occurring at a pH between 8 and 9. The product of the reaction is an
imidoamide (also known as an amidine), which is protonated at physiological pH.
The major reason why imidoesters have fallen out of favour in recent years is their
slow and modest cross-linking efficiency compared with NHS esters. NHS esters are
much more reactive than imidoesters and give much better cross-linking efficiency.
nh2+ t2+
r-nh2 + r.^x .ch3 + ch3oh0 H
Amine Imidoester Amidine
Compound Compound Linkage
Figure 3.8 Imidoesters. Reaction between an amine and imidoester compound producing an amidine.
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3.3.2 Sulfhydryl-reactive cross-linkers
The second most commonly exploited reactive groups used for cross-linking and
modification are those that target sulfhydryl-containing molecules. Sulfhydryl-
reactive groups are frequently present as one of the two reactive ends of
heterobifunctional cross-linkers, with the other end usually being an amine-reactive
group rather than being the sole functionality in a homobifunctional cross-linker.
Most of the reagents that undergo reaction with sulfhydryl groups are stable in
aqueous environments, allowing a two-step conjugation strategy to be used. The
major coupling reactions involving sulfhydryl reactive groups are either by
alkylation or disulfide exchange, resulting in stable thioether or more labile disulfide
bonds. One of the problems with sulfhydryl-reactive groups is that while they target
and react with the free thiol groups of cysteines, reduction of disulfide bonds in order
to create the necessary free thiol groups carries the inherent risk of distorting the
three-dimensional structure of a protein.160'161
3.3.2.1 Maleimides - Maleimides, also known as maleic acid imides, target
sulfhydryl groups and are widely used in heterobifunctional cross-linkers. The
thiolate anion is added to the maleimide in a 1,4-addition and the reaction is specific





Figure 3.9 Maleimides. Reaction between a thiol and a maleimide producing a thioether bond.
At pH 7.0, the reaction of the maleimide with sulfhydryls proceeds at a rate 1000
times faster than its reaction with amines. However at more basic pH, there is some
cross-reactivity with amino groups and above pH 8 hydrolysis of the maleimide





Figure 3.10 Maleimide hydrolysis.
3.3.3 Photoreactive cross-linkers
Photoreactive groups can be used in highly controlled reactions, because they do not
react with target molecules until they are exposed to UV light, and prior to exposure
they are typically non-reactive in usual thermochemical processes. Photoreactive
groups are normally very reactive and insert indiscriminately into any type of
residue. The groups used have to be stable in the dark and must become reactive
when exposed to light of a wavelength that does not induce photolytic damage in
biological samples. The vast majority of photoreactive reagents are based on nitrene
or carbene chemistry where the photolabile precursors are azides, diazirines, diazo
compounds and benzophenones.
3.3.3.1 Aryl azides - Aryl azides are the most popular type of photosensitive
functional group. Following photolysis of an aryl azide, a short-lived nitrene is
formed that is able to insert non-specifically into the chemical bonds of a target
molecule, including undergoing addition reactions with double bonds and insertion
reactions into active hydrogen bonds at C-H and N-H sites.164 Evidence has shown
that after an aryl nitrene has formed it immediately undergoes ring expansion
creating a dehydroazepine intermediate that reacts with nucleophiles, in particular
with amines.
H
Phenylazide Nitrene Formation Dehydroazepine Nucleophilic
Intermediate Addition
Figure 3.11 Aryl azides. Photo-activation of an aryl azide and subsequent nucleophilic addition by an
amine.
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Aryl azides that contain a perfluorinated ring structure form the desired nitrene more
efficiently so that the addition and insertion reactions occur in preference to
nucleophilic addition.165 The major disadvantage of aryl azides is that once they have
been activated, the created nitrene reacts with everything.
3.3.3.2 Diazirines - Diazirines display similar photoreactivity to diazo groups. The
photosensitive diazirine consists of a three-membered ring system that contains two
nitrogen atoms connected through a double bond. Diazirines come second in terms of
the popularity of photoreactive cross-linking reagents after the aryl azides and were
developed slightly later.166
Diazirine Carbene
Figure 3.12 Diazirines. Photo-activation of a diazirine results in formation of a carbene, which inserts
into an N-H bond.
The diazirine is photolysed at wavelengths of around 360 nm, which generates a
carbene that is highly reactive and capable of inserting into C-H or N-H bonds. The
major problem with diazirines is that photolysis can lead to diazo isomers that are
strongly alkylating and are responsible for undesired reactions in the dark.167 Despite
this flaw, diazirines have been successfully used in heterobifunctional crosslinkers to
attach macromolecules to surfaces such as polystyrene and glass (Figure 3.13).168
Photoreactive active amino acid analogs (photo-leucine and photo-methionine) that
exploit diazirine groups have been used to study protein interactions within cells.169
Figure 3.13 Diazirine containing heterobifunctional cross-linker. Structure of MAD (N-(4-
maleimidobutyryl)-A-[3-(trifluoromethyl)diazirin-3-yl]phenyl amide) cross-linker.168
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3.3.3.3 Benzoph.enon.es - A benzophenone photoreactive group after exposure to UV
light, gives a triplet-state ketone intermediate (production of a biradical) that is
highly reactive.170 The resulting radicals can insert into C-H bonds and other groups
to give covalent linkages with target molecules. Whereas decomposition or decay of
the photoactive species leads to deactivation of aryl azides, benzophenones that have
become deactivated without forming a covalent bond with a target can be reactivated
by photolysis to the active state. Activation of benzophenones does not follow a
photo-dissociative mechanism, which makes its activity reversible. This means that
benzophenones have more chance to react with the intended targets than aryl azides,










Figure 3.14 Benzophenones. Photo-activation of benzophenone followed by insertion into a reactive
hydrogen containing compound.
3.4 Problems with the chemical cross-linking approach
The sheer complexity of digested cross-linked material poses a huge problem. One of
the greatest challenges that needs to be answered, before chemical cross-linking of
proteins can be considered to be a truly effective tool, is how to identify cross-linked
peptides amongst an ocean of non-cross-linked or partially linked background
peptides. It is the question of how to find the 'needles in the haystack'. Figure 3.15
shows a FT-MS scan of a cross-linked digest of just the yeast 20S proteasome that
demonstrates the gravity of the problem. Cross-linked peptides are generally low-
intensity and have a limited elution window. The likelihood of them being sequenced
in a complex sample is low because in practical terms cross-linked peptides will be
over-looked.
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E070823 04 #4376 RT: 82.87 AV: 1 NL: 1.04E6
Figure 3.15 Mass spectrum showing a cross-linked peptide. Cross-linking of a yeast 20S
proteasome digest, carried out using (deuterated Bis[Sulfosuccinimidyl] glutarate - BS2G-d(|/d4). Top
pane: Red arrow indicates position of a cross-link fragment at 706.33 with the elution window of 7.5
s. Bottom pane: Zoom of double isotope cluster corresponds to cross-linked peptides.
There are two approaches that can be taken to help to pick-out only the cross-linked
peptides:
(i). Introducing a discriminating feature on the cross-linked products to make
identification of cross-linked peptides easier.
(ii). Develop an enrichment strategy to filter out or even remove any undesired,
non-cross-linked background product.
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3.4.1 Strategies to improve detection of cross-linking products
3.4.1.1 Cleavable cross-linkers
The cleavable cross-linkers that are currently available can either be cleaved
chemically or during MS/MS experiments if they contain bonds that fragment using
low-energy activation. Such cleavable cross-linkers facilitate the identification of a
cross-linked product but only if it is not obscured by background data from the
experiment. In other words, cross-linked products will only be identified if they are
in very high proportion with respect to the total sample. The principle is that spectra
can be compared before and after the cross-linker is cleaved and following cleavage,
the disappearance of a peak can mark it out as a cross-linked product.
(i). Chemical cleavage with periodate - Cross-linkers that contain a diol such as
disuccinimidyl tartrate (DST) can be cleaved using periodate with each hydroxyl
group being oxidised to an aldehyde.
x x^.Vv
OH H H
Figure 3.16 Periodate cleavage. Diol is cleaved producing two aldehydes.
One drawback of this chemistry is that it is then possible for the resulting aldehydes
to produce secondary unwanted reactions, especially Schiff base formation with any
free amine groups that are available. Another disadvantage is that sodium periodate
is also capable of oxidising other amino acids, in particular tryptophan and
methionine residues. A benefit of employing periodate as a cleavage agent is that
disulfide bonds are preserved, which means that tertiary structure of proteins and
other molecules is usually unaffected so that any protein bioactivity can be retained.
(ii). Chemical cleavage of disulfide bonds - Formation of disulfide bonds between
cross-linked molecules is an important feature in many conjugation chemistries and
two examples of cross-linkers that can be cleaved via their disulfide bonds following
peptide cross-linking are shown in Figure 3.17.
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SPDP SMPT
Figure 3.17 Disulfide cleavable hetero-bifunctional cross-linkers. SPDP (7V-succinimidyl-3-(2-
pyridyldithio)propionate) and SMPT (succinimidyloxycarbonyl-a-methyl-a-(2-pyridyldithio)toluene).
The NHS ester reacts with a primary amine. The other end of the cross-linker then



















Figure 3.18 Reaction of SPDP. SPDP cross-links two molecules via a disulfide and an amide.
The incorporation of a disulfide into the cross-linker means that the cross-linker can
be specifically cleaved after conjugation by either a strong reductant such as sodium
borohydride or through disulfide interchange with a compound containing one or
more free thiols.
The thiol-cleavable cross-linker DTSSP (3,3'-dithio-Z?zs(succinimidylpropionate))
119 121 172
has been used to map interfaces of a number of protein complexes ' ' and to
map the three-dimensional structure of a number of proteins. 173,174 MALDI-TOF-MS
and ESI-QTOF-MS were used to produce peptide maps of digested reaction mixtures
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before and after reduction and the masses were compared. Cross-links were
confirmed on the basis of observing the corresponding peptide 'halves' of cross-
linked products that had been previously identified prior to reduction. However there
are major limitations with this technique as sometimes it is possible to see peptides
before reduction but not after, suggesting that actual cross-links are not present, and
vice-versa. The biggest concern with the technique is that cross-linked peptide
products may still be obscured amongst a huge amount of background material.
(Hi). MS/MS cleavage - An amine-reactive homobifunctional cross-linker N-
benzyliminodiacetoyloxysuccinimide (BID) was used to cross-link model peptides as
well as components of a protein complex. The cross-linker aided detection of cross-
linked products due to a marker ion being produced (m/z 91) during triple-
quadrupole and QTOF tandem MS experiments (Figure 3.19),131 with observation of
the marker ion indicating that cross-linking had occurred.
Figure 3.19 iV-benzyliminodiaeetoyloxysuccinimide (BID) cross-linker. Production of a marker
ion indicates that cross-linking has occurred.131
A novel type of cross-linker was synthesised that has two MS/MS cleavable bonds
within the spacer chain. The cross-linker system was named PIR (protein interaction
reporter) was synthesised using solid-phase chemistry exploiting lysine chemistry
and the Rink linker.106 After MS/MS cleavage, a reporter ion was released of m/z 711
that indicated that a cross-linked product was present. The PIR cross-linker was used
to cross-link ribonuclease S (RNase S), a non-covalent complex of S-peptide 1-20
and S-protein 1-104 that are the hydrolysis products from ribonuclease A (RNase A)














Figure 3.20 PIR (protein interaction reporter) cross-linker. Contains two MS/MS cleavable bonds
that release a reporter ion indicating cross-linking upon MS/MS cleavage.
Perhaps the biggest downfall of the PIR cross-linking system is that its spacer chain
length is 43 A in its most extended conformation and this coupled with its high
flexibility casts doubts over whether any structurally meaningful information can be
obtained.
3.4.1.2 Affinity enrichment systems
Probably the best way to solve the problem of the complexity of the cross-linked
product mixtures is to isolate cross-linked products from the enormous background.
Using an affinity enrichment system to specifically isolate products probably holds
the greatest potential for solving the complexity issue.
(i). Enrichment via hiotin - The extremely strong noncovalent conjugation between
(strept)avidin and biotin has been exploited in a number of enrichment strategies.
Avidin interacts with biotin with one of the strongest noncovalent affinities known,
with a dissociation constant of about 1.3 x 10~15 M.175 Avidin is a tetrameric protein
and when biotin is bound to avidin, the interaction promotes even greater stability to
the complex. In fact the interaction in the avidin-biotin complex (ABC) is resistant to
break down in the presence of up to 8 M guanidine, to achieve complete dissociation
6-8 M guanidine at pH 1.5 is required. The ability of biotinylated molecules and
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avidin conjugates to "find" each other and subsequently bind and complex together
under extreme conditions is remarkable.
The great interaction between avidin and biotin has been capitalised on for the
synthesis of some trifunctional cross-linkers, composed of biotin containing
heterobifunctional cross-linkers, which allowed enrichment of cross-linked products
by affinity purification on monomeric avidin beads.176'177 Cross-linkers (Figure 3.21)
containing aryl azide photoactivatable groups such as sulfo-SBED
(sulfosuccinimidyl-2-[6-(biotinamido)-2-(p-azidobenzamido)hexanoamido]ethyl-
l,3'-dithiopropionate) have been developed commercially (Fujimoto) and used to
map the interface regions between calmodulin and its target peptide, derived from the
skeletal muscle myosin light-chain kinase.177
Thiol/amine-reactive site
Figure 3.21 Biotin derivative trifunctional cross-linkers for enrichment. Amine reactive sulfo-
SBED (sulfosuccinimidyl-2-[6-(biotinamido)-2-(/?-azidobenzamido)hexanoamido]ethyl-1,3'-
dithiopropionate and a thiol reactive derivative.
The great strength of the non-covalent interaction between avidin and biotin makes it
extremely useful in bioconjugate chemistry, but its lack of reversible enrichment is
its major downfall. Variations in buffer salt, pH, the presence of denaturants or
detergents and extremes of temperature will not allow reversibility of the interaction.
Another crudity with the avidin-biotin complex conjugation system is that it is
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fundamentally based on the principle of using a huge protein to "fish-out" something
that is relatively small. Another downside to these cross-linkers is that they are
hydrophobic and relatively large, limiting their water-solubility. The reagents are
soluble in solvents such as DMF and DMSO, but relatively insoluble under aqueous
reaction conditions, which make them impractical for use with proteins in their
native environment.
(ii). "Click Chemistry" based enrichment - The most recent advance in attempts to
have practical cross-linked peptide enrichment is the introduction of so-called
alkyne-azido click chemistry as the mechanism for selectively retrieving cross-linked
peptides.178
The premier click reaction is undoubtedly the Huisgen 1,3-dipolar cycloaddition of
1 "7Q
alkynes and azides to yield triazoles (Figure 3.22), which has been made more
1 RO
practical by the use of copper catalysis, reported by Meldal.
N® -N.-
Mffi 1 N Nn® + r2-^=-R3
R3 R2
Azide Alkene Triazole
Figure 3.22 General Huisgen reaction. Cycloaddition of an azide with an alkyne, resulting in the
formation of a triazole ring.
An azide containing cross-linker, BAMG (bis(succinimidyl)-3-azidomethyl
glutarate), was first used as a marker tag in order to aid the identification and
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separation of cross-linked peptides from complex mixtures.
o o
Figure 3.23 BAMG (bis(succinimidyl)-3-azidomethyl glutarate). An azide-containing
homobifunctional cross-linker.
The reduction of the azide to primary amine competed with a chemo-selective
peptide-bond cleavage at the site of the non-natural amino acid azidohomoalanine
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with use of the reducing agent TCEP (tris(2-carboxyethyl)phosphine). The
observation of both reactions was meant to facilitate cross-link identification from
background protein because cross-linked products would have different retention
times by reverse-phase HPLC than the parent compound cross-linked with an azide
functionality present.













































Figure 3.24 Phosphine induced reactions in BAMG cross-linked peptides. Two parallel reaction
pathways occur in the presence of the phosphine reducing agent TCEP (tris(2-
carboxyethyl)phosphine). TCEP either reduces the azido group to an amino group or to a leaving
group that is displaced by one of the two amide groups by an intramolecular Sn2 reaction to form an
imido ester, which is then hydrolysed to give a lactone. Both reactions are meant to aid in
identification of cross-linked peptides.
In reality this approach was flawed because it over-complicates the range of cross-
linked products that are obtained but more importantly it doesn't solve the problem
of low abundance of cross-linked products. The principle relied on diagonal
chromatography where huge losses of interesting species are made when only very
small amounts of starting material are available.181 Further problems with this
strategy are that free cysteines are able to prematurely reduce and cleave BAMG
cross-linked peptides and disulfide-linked peptides will also be reduced in the
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presence of TCEP and will end up in shifted fractions after diagonal
chromatography.
The BAMG cross-linker was used in a click-chemistry based enrichment system.
Azide-containing cross-linked peptides were captured on resin via "strain-promoted"
(3+2)-cycloaddition.178 Following a washing step, peptide products were detached
from the resin by reduction of the disulfide linker located between the solid-support









Figure 3.25 Click-chemistry based capture and release of azide containing cross-linked peptides.
(a) Capture of azide containing cross-linked peptide products via a Huisgen reaction between the azide
on the cross-linked peptides and solid-supported cyclooctyne (PL-DMA = polydimethylacrylamide
resin), 72 h., 40 °C; (b) Release of captured peptides via reduction (i) 5 mM TCEP, 50 mM PBS pH
7.5, 1 h, rt; (ii) 55 mM iodoacetamide, 30 min, rt.
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Although useful the method has numerous downfalls. The incubation time for
capture was up to 72 hours and even after this time only 50% yield was achieved.
Coupled with this is another major flaw in that the resulting peptides following
cleavage from the resin have a massive hydrophobic modification, which causes
quite heavy insolubility issues.
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Chapter 4: Boronate Ester Conjugate Enrichment
4.1 Cross-linked peptide enrichment via boronate esterformation
Phenylboronic acids can form reversible, pH-dependent complexes with a variety of
1 89 1 83 1 84 1 8S 1 8f\
polar groups such as dicarboxylic acids, ' a-hydroxy carboxylic acids ' and
diols187 to form boronate esters in aqueous media.188 The most common complex is
with 1,2- and 1,3-diols to form either 5- or 6-membered heterocycles (Figure 4.1).
Reversible boronate ester chemistry with immobilised phenylboronates has already
been exploited in affinity chromatographic purification of carbohydrates,
glycoproteins, RNA,189 AMP, glycated proteins (such as glycated haemoglobin
found in diabetes) 190, and a range of small molecules containing 1,2- and 1,3-
diols,191'192 hydroxyl acids,193 hydroxylamines, hydroxyamides194 and
hydroxyoximes, as well as various sugars containing these species. The interaction
between catechol derivatives and phenylboronic acid has also been exploited in the
development of an electrochemical dopamine sensor.195
Figure 4.1 Boronate ester formation. Reaction between phenyl boronic acid and an unspecified 1,2-
diol.
A whole range of solid-supports and linkers have been developed to provide a means
for immobilising boronic acids, to facilitate purification and manipulation,196'197
driven by the difficulties that are often encountered when isolating or removing
boronic acids from aqueous and/or organic solvent systems (Figure 4.2).
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Figure 4.2 Solid-supported diols. A range of diols developed for the capture of boronic acids.
Boronic acid chemistry has been used for the manipulation of gold nanoparticles,198
whereby a solid-supported boronic acid was used to attract gold nanoparticles via a
thiol-derivatised catechol,199 with thiols reacting with the surface of gold
nanoparticles through Au-S interactions and the catechol forming a boronate ester
with solid-supported boronic acid. More recently, boronic acid functionalised gold
nanoparticles have been used to enrich cis-1,2- diol containing glycoproteins and
glycopeptides.200 Similarly a MALDI target plate was covered with an array of
similar gold nanoparticles, allowing MALDI-TOF analysis of enriched glycopeptides
directly from the plate.
The interaction between phenylboronic acid derivatives and diol-like systems occurs
optimally in the pH range of 8-9 and is typically reversed at acidic pH or in the
presence of a high concentration of a competing ligand (Figure 4.3). Stolowitz
exploited the interaction potential in the design of a new chemoselective
bioconjugation reagent pair consisting of a phenylboronic acid (PBA) on one reagent
201and a salicylhydroxamic acid (SHA) on a second." Stolowitz proposed that each
reactant of the pair could be used to modify biomolecules, surfaces or other
compounds for subsequent conjugation or immobilisation through specific PBA-
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SHA ring formation.202 The major product of the reaction is a 6-membered ring,
which is formed by the boron atom of PBA along with one of its oxygen atoms
coordinated with the SHA's hydroxy! oxygen and hydroxamate nitrogen atoms. It is
also possible to form a 5-membered ring structure with the boron interacting with the
hydroxamate hydroxyl and carbonyl oxygens on the SHA but NMR has shown this
to be a minor product.203
Salicylhydroxamate
(SHA)
Figure 4.3 Boronate ester from salicylhydroxamic acid. Reaction between phenylboronic acid and
a salicylhydroxamate.
Complex formation between the PBA group and SHA group occurs across a wide
range of pHs (5 to 9) and high salt concentrations and can tolerate the presence of
moderate quantities of water-miscible solvents, detergents, chaotropes and
denaturing agents, such as are used when working with protein solutions. The
interaction is reversed by lowering the pH, the value of which depends on the type of
boronate ester involved. One study looking at pH dependence of boronic acid-diol
affinity in aqueous solution found that complexation between phenylboronic acid and
4,5-dihydroxynaphthalene-2,7-disulfonate (as shown in Figure 4.4) even occurs at
pH l.204
OH
Figure 4.4 4,5-dihydroxynaphthalene-2,7-disulfonic acid disodium salt.
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Interactions between solid supported SHA groups and ligands containing PBA
groups have been investigated for immobilisation of antigen molecules for antibody
205
protein purification.
For the work in this chapter, a catechol derivative was selected as the 1,2-diol
component for a boronate ester pairing along with a phenylboronic acid derivative
because of their rigid planar structures.206 Planarity leads to a stronger interaction
with conjugation occurring due to overlap between the lone pair of electrons on the
oxygen and the empty p-orbital on the boron.207
4.2 Aims
The aim of the work in this chapter was to develop novel peptide/protein reactive
cross-linkers and tags that would allow the enrichment of cross-linked products from
complex mixtures of peptides by exploiting the reversibility of boronate ester
chemistry.
4.3 Overview
The enrichment concept is shown in Scheme 4.1. The initial idea was that either the
boronic acid or the diol component could be immobilised onto a solid-support and






Scheme 4.1 Boronate ester based enrichment. Enrichment strategy exploiting boronate ester
formation between a solid-supported phenylboronic acid and catechol tagged reaction products that
result from a catechol /V-hydroxysuccinimide (NHS) active ester reacting with a peptide or protein.
Scheme 4.1 shows an NHS-active-ester modified catechol reacting with free amino
groups from a peptide or protein. The resulting mixture is then introduced to a solid-
supported boronic acid at high pH, whereupon a boronate ester conjugate is formed.
Unmodified material is then washed away, with only the modified material
remaining attached to the solid support. When the pH is lowered, the diol-modified
material is released from the solid-support and the 'enriched' material is then ready
for MS analysis and subsequent data interpretation.
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4.3.1 Synthesis of NHS activated esters
The NHS active ester of 3,4-dihydroxyhydrocinnamic acid was synthesised using an
excess of NHS and the water-soluble coupling reagent 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride) (EDC) (Scheme 4.2).
OH (a)
4.1
Scheme 4.2 Catechol tag NHS ester (4.1). Activation of 3,4-dihydroxyhydrocinnamic acid,
(a) 1.2 eq EDC, 1.5 eq NHS, DMF, 71%
To compliment this, an NHS active ester of 4-carboxyphenylboronic acid was also








Scheme 4.3 Boronic acid tag NHS ester. Activation of 4-carboxyphenylboronic acid,
(a) 1.2 eq EDC, 1.5 eq NHS, DMF, 67%
4.3.2 Synthesis of solid-supported component
4.3.2.1 Choice of CPG as the solid support
For a study involving such a sensitive technique as mass spectrometry, any solid-
support involved prior to analysis had to be resistant to leaching and give low
background signals. The solid-support also had to be compatible with a wide range
of aqueous buffers as well as organic solvents.
CPG or controlled pore glass is produced from borosilicate glass that has been held
at a high temperature for a prolonged length of time, which results in separation of
the borates from the silicates to give a rigid nonabsorptive matrix. Boronate, which is
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soluble in acid, is leached from the material in a controlled process to create a silica
glass with very uniform pores that have a narrow size distribution range, hence the
use of the term "controlled-pore". CPG is stable to aggressive reagents and extremes
of temperature and pressure that are often used in synthesis. The biocompatibility of
particularly suitable for continuous flow synthesis because of the rigidity of its
structure and it was decided that for these reasons, CPG would be the most suitable
solid-support for this work.
Trisoperl supplied aminopropyl functionalised CPG of 50-100 pm diameter with 55
nm pore size (0.22 mmol/g free amino group loading). Experience in Professor
Bradley's lab has indicated that functionalisation of aminopropyl CPG is sluggish.
Initially a DIC/HOBt coupling protocol was employed for the coupling of 4-
phenylboronic acid to aminopropyl CPG. Reactions were monitored by a ninhydrin
reaction209 and repeated couplings were necessary before complete coupling was
observed. Coupling with HBTU were also attempted but there was no increase in
reaction efficiency. Coupling with IIDQ gave greater coupling efficiency and could
910
be forced with gentle microwave heating.
Scheme 4.4 CPG supported components. Coupling of either 4-phenylboronic acid or 3,4-
dihydroxyhydrocinnamic acid to aminopropyl functionalised CPG using IIDQ.
(a) 3 eq 4-phenylboronic acid, 3.3 eq IIDQ, acetonitrile;
(b) 3 eq 3,4-dihydroxyhydrocinnamic acid, 3.3 eq IIDQ, acetonitrile.
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4,3.3 Synthesis of modified peptides for a model system
Peptides were initially assembled via solid phase synthesis using the Wang linker
resin and Fmoc-protected amino acids and consisted of a control peptide with no
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modification 4.7, a boronic acid modified peptide 4.8, a catechol-modified peptide
4.9 and a derivative containing a salicylhydroxamic acid group 4.10 (Scheme 4.5).
The peptide sequence in each case was LLEYLKR. The sequence was chosen from a
range of peptides used in an earlier study that were most easily identified as being
synthetic peptides after having been spiked into protein digests, run on the mass
spectrometer and processed with a database searching program.
Initial loading of the resin was achieved by forming a symmetrical anhydride with
DIC/DMAP and Fmoc-Arg(Pbf)-OH. Following an Fmoc test to assess the degree of
loading, the Fmoc group was removed using 20% piperidine in DMF to give 4.5.
Subsequent synthesis was achieved using HBTU-mediated coupling cycles, which
has been shown to facilitate rapid reaction times and produce clean products with
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even very difficult to synthesise sequences. 4-Carboxyphenylboronic acid was
coupled to the N-terminus of 4.6 using HBTU coupling chemistry to achieve a
boronic acid modified peptide 4.8 and with 3,4-dihydroxyhydrocinnamic acid to
achieve the catechol modification 4.9.
The salicylhydroxamic acid peptide derivative 4.10 was generated by coupling the
commercially available NHS-active ester-THP-protected salicylhydroxamic acid
derivative (SHA(THP)-X-NHS) 4.11 under basic condtions.
o
4.11
Figure 4.5 SHA(THP)-X-NHS 4.11. Structure of 4-(3-hydroxy-4-(tetrahydro-pyran-2-ylcarbamoyl)-
















H " = H " = H " = H








Scheme 4.5 Solid-phase synthesis of tagged peptides.
(a)(i) 10 eq Fmoc-Arg(Pbf)-OH, 5 eq DIC, 0.1 eq DMAP, 2 h; (b) 20% piperidine in DMF, 2
cycles of 10 min; (c) 5 eq Fmoc-AA-OH, 5 eq HBTU/HOBt, DMF (0.2 M), 10 eq DIPEA, 1
h; (d)(i) When R = boronic acid or catechol, 5 eq 4-carboxyphenylboronic acid or 3,4-
dihydroxyhydrocinnamic acid, 5 eq HBTU/HOBt, DMF (0.2 M), 10 eq DIPEA, 1 h,
followed by an additional step when R = catechol, 20% piperidine/DMF, 10 min; (ii) When
R = salicylhydroxamic acid derivative, 2 eq SHA(THP)-X-NHS, 5% DIPEA in DMF (0.2
M); (g) TFAATIS/H20 (95:2.5:2.5), 2 h;
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All peptides were released from the resin using a solution of TFA/TIS/H20
(95:2.5:2.5) for 2 h, which simultaneously removed all protecting groups and cleaved
the peptides from the resin.
4.4 Behaviour ofcatecholfunctionalised peptides on phenylboronic acid
functionalised controlledpore glass (PBA-CPG)
Decomposition of all catechol derivatives under basic, aqueous conditions was a
common feature, whether the catechol was present as an NHS-ester tag, a cross-
linker or a direct peptide modification. Degradation was rapid and the degree of
decomposition could be ascertained by analytical HPLC (Figure 4.6).
Figure 4.6 HPLC chromatograms. a. Crude catechol derivative peptide 4.9; b. Decomposition of
crude catechol derivative peptide following 30 minutes in 100 mM (pH 8.4) PBS.
The addition of 2 equivalents of dithiothreitol (DTT) relative to peptide 4.9, in pH
8.4 buffer, slowed the rate of decomposition but after 24 hours all catechol modified
peptide had fully decomposed. Stability of the catechol was achieved following
addition of 5 mM fm(2-carboxyethyl)phosphine (TCEP) and working with a 0.6 mM
peptide concentration, with the pH of the solution lowered to 7.60.
Capture of catechol modified peptide 4.9 was ascertained by measuring the UV
absorbance of peptide that remained in solution following addition of PBA-CPG 4.3
and converted into a percentage based on the absorbance of peptide in the input
solution (Figure 4.7). 20 equivalents of PBA-CPG 4.3 resulted in almost complete
capture of peptide 4.9.
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Figure 4.7 Peptide uptake. Percentage of peptide 4.9 remaining in solution following either 1 or 10
minutes exposure to varying equivalents of boronic acid-supported CPG 4.3.
A study of the relationship between mixing time and number of equivalents of PBA-
CPG 4.3 showed that the level of uptake was high (>77% with 10 equivalents PBA-
CPG 4.3) after only 1 minute of mixing (Figure 4.7).
This suggested that boronate ester formation was fast and the rate limiting factor was
mixing and diffusion of the peptide solution. After 10 minutes mixing with 20
equivalents of PBA-CPG 4.3 the amount of peptide 4.9 remaining in solution was
negligible (<3%) and uptake could be considered complete.
Elution of catechol derivatised peptide 4.9 from PBA-CPG 4.3 was achieved using
1% TFA in water (pH 1) and was assessed by measuring the absorbance (282 nm) of
catechol derivatised peptide 4.9 released (Figure 4.8).
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Figure 4.8 Peptide elution. Absorbance of peptide 4.9 eluted from boronate conjugated CPG 4.3
using 1% TFA in H;0 for varying lengths of time.
Peptide elution from boronate conjugated CPG using 1% TFA in water was rapid,
with maximal release observed after only 1 minute of mixing time and less than 10
seconds required to achieve 80% release. Furthermore, peptide released from the
PBA-CPG 4.3 was very clean with respect to the crude catechol derivatised peptide
4.9 that had been introduced as the input solution (Figure 4.9).
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Figure 4.9 HPLC chroniatograms. a. Crude catechol derivative peptide 4.9; b. Recovered catechol
derivative peptide 4.9 following 1% TFA elution from PBA- CPG 4.3.
Full elution of peptide 4.9 was achieved with two successive 1 minute treatments
with 1% TFA in water.
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4.4.1 Enrichment of a tagged peptide in a complex mixture
Tagging and enrichment of a peptide using the catechol NHS ester tag (4.1) from a
complex mixture was carried out by Lau Sennels in the Wellcome Trust Centre for
Cell Biology in the School of Biological Sciences, University of Edinburgh. A crude
synthetic peptide (H-EFYEKPTTER-OH 4.12, 30 pmol) was labelled with 4.1 to
give peptide derivative 4.13 and spiked into 1 pg of E.coli extract (E.coli lysate in 2
M urea was reduced with DTT and cysteines carbamidomethylated with
iodoacetamide, followed by overnight incubation with trypsin (1 pg trypsin to 20 pg
protein) at 37 °C). Enrichment of crude-labelled peptide 4.13 from the E.coli extract
was carried out by incubating the peptide/digest mixture in loading buffer (25 mM
TEAB, 20% acetonitrile) for 15 minutes along with 20 mg of boronic acid-
functionalised CPG 4.3. The CPG was washed three times with loading buffer.
Elution of labelled peptide from the CPG was carried out using aqueous 1% TFA in
20% aq acetonitrile. Eluted fractions were desalted with a C18 stage tip and injected
into the mass spectrometer via an online nano-LC and compared with injections of
crude-labelled peptide 4.13 (control) and the labelled peptide in the E.coli extract
mixture (Figure 4.10).
30 pmol 4.13 in 1 ng E. coli extract enrichment
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(b) peptide 4.13 + E. coli input (I)
5 1641 PSMs (score >19)
(c) peptide 4.13 + E. colleluate (E)
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Figure 4.10 NanoLC traces showing catechol tag modified peptide 4.13 enrichment using CPG
supported boronic acid 4.3. (a) Crude peptide 4.12 after modification with 4.1 (peptide 4.13). (b) 30
pmol of peptide 4.13 spiked into 1 pg E. coli extract, (c) Eluate from CPG 4.3 after enrichment from
E. coli extract.
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Following analysis using in-house database search software Xi, the 4.1-labelled
peptide 4.13lE.coli extract mixture yielded 1641 peptide sequence matches with high
confidence. Following enrichment there were only 35 peptide sequence matches,
which demonstrated that the enrichment system could be successfully applied to a
complex biological mixture.
4.5 Cross-linkers
The next goal was to develop cross-linkers with built in enrichment functionality, as
shown in Scheme 4.6.
Scheme 4.6 Boronate ester conjugate enrichment of a cross-linked protein. A boronate ester
would be formed between a solid supported boronic acid and peptides cross-linked with a catechol
functionalised cross-linker. Unmodified peptides would be washed away leaving only cross-linked
peptides. Elution from the solid support would allow analysis of cross-linked peptides.
X3 Wash S
■* n .—/ P
HI
The concept was that a homo-bifunctional amine-reactive NHS ester cross-linker
would be introduced into a protein or protein complex, followed by proteolytic
digestion using trypsin. The resulting mixture of peptide products would then be
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exposed to the solid-supported capture tag followed by washing steps and finally
elution of cross-linker modified peptides and MS analysis.
4.5.1 Initial attempts at solid-phase cross-linker synthesis
I decided to pursue a catechol-boronic acid conjugate approach for cross-linker









Scheme 4.7 Solid-phase synthesis of a glutamic acid-based catechol derivative diacid 4.14.
(a) 10 eq Fmoc-Glu(OlBu)-OH, 5 eq DIC, 0.1 eq DMAP, 2 h; (b) 20% piperidine/DMF, 2
cycles of 10 min; (c) 3 eq 3,4-dihydroxyhydrocinnamic acid, 3.3 eq EEDQ, 2 h; (d) 4 M HC1
in dioxane, 1.5 h;
Synthesis was achieved by making an ester linkage between Wang linker and Fmoc-
protected glutamic acid with a tBu-protected side chain (Scheme 4.7). Fmoc
deprotection gave the free amine onto which the catechol derivative, 3,4-
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dihydroxyhydrocinnamic acid was coupled and cleavage from the resin was achieved
following treatment of the resin with acid to give diacid 4.14.
Generally, the solid-phase approach for synthesis of catechol derivative cross-linkers
was unsuccessful. TFA (in CH2CI2) cleavage from resin, with and without
scavengers (H2O and triisopropyl silane (TIS)) produced very messy results, and
little or no product could be observed by LC-MS. Relatively clean HPLC product
traces were generally achieved using 4 M HC1 in dioxane for resin cleavage. Use of
Fmoc-Asp(OlBu)-OH in place of Fmoc-GluCO'Bu^OH resulted in failure to achieve
the desired products as did use of more acid-labile 4-chlorotrityl polystyrene resin
rather than Wang linker polystyrene resin.
The failure of the solid-phase approach led to several efforts to achieve the glutamic
acid derivative cross-linker via solution phase reactions, firstly by forming a mixed
anhydride with isobutyl chloroformate (and tV-methylmorpholine (NMM))212 and
also by exploiting the NHS-active ester of the catechol derivative.
Scheme 4.8 Solution-phase synthetic attempts at a glutamic acid-based catechol derivative cross-
linker.
(a)(i) Isobutyl chloroformate, NMM, THF; (ii) L-glutamic acid, Et3N, DMF;
(b) L-glutamic acid, Et3N, DMF;
The conclusion drawn from this work was that the inherent instability of the catechol
derivative (which was also observed with catechol peptide 4.9 (Figure 4.6)) and its
tendency to decompose under basic conditions meant that an alternative functionality
was required.
4.5.2 Boronic acid cross-linker synthesis
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Because of the problems incurred during synthesis of a catechol-modified cross-
linker it was decided to use a reverse system whereby a solid-supported diol could be
used to enrich a boronic-acid functionalised cross-linker.
Fujii reported a novel homobifunctional amine reactive cross-linker with a biotin
functionality, with the advantages of having a symmetrical backbone with
bifunctional amine reactivity, built around a central amide core (Figure 4.11).213 The
addition of a hydrophilic PEG linker greatly increases the water-solubility of the
cross-linker. The strategy has the benefit of allowing the backbone length to be
varied, which means that a range of different cross-linker lengths could be produced.
Hydrophilic PEG linker
The principles behind this synthetic strategy were taken and used to produce the
boronic-acid containing cross-linker 4.19 (Scheme 4.9).
A dialkylation reaction between benzylamine and ethyl 4-bromobutyrate gave 4.15 in
good yield. The de-benzylation proceeded readily with hydrogen and palladium but
the reaction was much cleaner and time efficient when the H-Cube Tutor was
employed, which generates hydrogen in situ and relies on a flow-reaction rather than
a batch approach. The resulting secondary amine 4.16 was coupled to 4-
carboxyphenylboronic acid and a number of coupling strategies were tested, HBTU
with DIPEA, solid-supported (polystyrene) cyclohexylcarbodiimide (PS-DCC) and
EDC. The best results were achieved using EDC to give 4.17. Saponification yielded
the diacid compound 4.18, which was activated with PS-DCC and N-
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hydroxysulfosuccinimide (NHSS) to give cross-linker 4.19. The sulfonate group on
the active ester significantly enhances cross-linker water solubility.
Scheme 4.9 Boronic acid functionalised cross-linker 4.19.
(a) Benzylamine, K2C03, DMF, 40 °C, 20 h, 77 %; (b) H-Cube Tutor 10 % Pd/C/H2, MeOH,
100 %; (c) 4-carboxyphenylboronic acid, EDC, HOBt, DMF, 18 h, 53 %; (d) NaOH aq,
MeOH, 18 h, 40 %; (e) NHSS, DMF, 24 h, 100 %.
4.5.2.1 Conclusion from boronic acid derivative cross-linking
Cross-linked protein was observed following application of the boronic acid
derivative NHSS active ester 4.19, which was indicated by gel electrophoresis
(Figure 4.12). However following tryptic digestion of gel bands containing cross-










Figure 4.12 Gel electrophoresis of 4.19 cross-linked protein. Chicken lysozyme cross-linked with
4.19 (equivalents used: lOOx, 200x, 400x, 600x and 800x) and BS2G (equivalents used: 400x and
800x). Control = no cross-linker.
Trypsin is a serine protease and peptide boronic acids have been shown to be potent
214-inhibitors of this particular class of enzyme. In view of this it is possible that
digestion of boronic acid modified cross-linked peptides using trypsin would not be
possible with the boronic acid in an unprotected state. This was confirmed using
boronic acid modified peptide 4.8. Boronic acid modified peptide 4.8 in the presence
of trypsin resulted in inhibition of protein digestion, which indicated that it was the
free boronic acid moiety that was responsible for the lack of observable boronic acid-
modified cross-linked peptides in the cross-linking experiments. Simple arylboronic
acids by themselves have been found to be inhibitors of serine proteases."
Preliminary experiments with boronic acid supported CPG (PBA-CPG) 4.3 and the
catechol and salicylhydroxamic acid modified peptides (4.9 and 4.10 respectively)
showed that conjugates could be formed readily with both moieties. Due to the
stability problems previously encountered with catechol derivatives, it was decided
to pursue salicylhydroxamic acid derivatives as the cross-linker affinity tag.
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4.6 Hydroxamic acid chemistry
4.6.1 Synthesis of salicyl hydroxamic acid moiety as a conjugation
reagent
Stolowitz et al. reported the ability to manipulate phenylboronic acid and
salicylhydroxamic acid bioconjugates for protein immobilisation (Scheme 4.10).
Protein modification reagents were synthesised from 3-aminophenylboronic acid to
prepare phenylboronic acid bioconjugates that have affinity for a support-bound
203





Scheme 4.10 Boronate ester conjugate via salicylhydroxamic acid. Immobilisation of
phenylboronic acid (PBA) derivatised alkaline phosphatase (AP) by salicylhydroxamic acid modified
sepharose. The illustration represents an oversimplification due to the fact that immobilisation may
result from interaction involving several boronic acid complexes.
Hydroxamic acids can be readily synthesised from their corresponding methyl
esters.216
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Scheme 4.11 Synthesis of hydroxamic acids from methyl esters.
(a) 50 % NH2OH in H20, MeOH
A synthetic strategy based on the conversion of methyl esters to hydroxamic acids






Scheme 4.12 Salicylhydroxamic acid NHS ester derivative 4.23 synthesis.
(a) MeOH, 1.5 eq H2S04 conc., pwave 130 °C, 1 h, 75 %; (b) succinic anhydride, CH2C12,
pwave 100 °C, 10 min, 94 %; (c) 50 % NH20H/H20, MeOH, 18 h, 98 %; (d) 1.5 eq NHS,
1.2 eq EDC, DMF, 18 h, 44 %.
Methyl ester protection of 5-aminosalicylic acid was followed by conversion of the
amine group of 4.20 via reaction with succinic anhydride to provide the acid 4.21.
Conversion of the methyl ester of 4.21 to give the hydroxamic acid was achieved
using a 50% aqueous solution of hydroxylamine. Over-exposure of the hydroxamic
acid to basic conditions resulted in hydrolysis to the carboxylic acid.
4.6.2 Synthesis of salicylhydroxamic acid modified test-model peptides
The methyl ester tag 4.21 was added to the previously synthesised peptide sequence
4.6 (see section 4.3.3). Clean conversion of the methyl ester derivative 4.24 to a
functional hydroxamic acid moiety was achieved as before using a 50% aqueous
hydroxylamine solution at room temperature. The reaction was monitored by ELSD-
HPLC; a 1 Da mass increase according to LC-MS confirmed the conversion to





Scheme 4.13 Solid-phase synthesis of salicylhydroxamic acid modified peptide 4.25.
(a) 5 eq 4-{(4-hydroxy-3-(methoxycarbonyl)phenyl]amino}-4-oxobutanoic acid 4.21, 5 eq
HBTU/HOBt, DMF (0.2 M), 10 eq DIPEA, 1 h; (b) TFA/TIS/H20 (95:2.5:2.5), 2 h; (c) 50%
hydroxylamine/H20, 24 h;
4.6.2.1 Enrichment ofa salicylhydroxamic acid peptide by a CPG-supported
boronic acid
Binding of hydroxamic modified peptide 4.25 to PBA-CPG 4.3 (Figure 4.13) was
demonstrated in a set of studies using varying equivalents of PBA-CPG 4.3 in one
experiment (Figure 4.14) and using fixed quantities of PBA-CPG 4.3 for different
time periods (Figure 4.15).
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Figure 4.13 Boronate ester via hydroxamic acid. Formation of a boronate ester between a controlled
pore glass supported boronic acid and a hydroxamic acid.
Uptake was determined by measuring the UV absorbance of peptide 4.25 that
remained in solution following addition of PBA-CPG 4.3 (Figure 4.14). When 5
equivalents of PBA-CPG 4.3 were used 98% uptake was achieved.
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Figure 4.14 Peptide 4.25 uptake. Percentage of peptide 4.25 remaining in solution after 30 minutes
with varying numbers of equivalents of PBA-CPG 4.3 resin (n=3).
Results indicate that there is a gradual decrease in peptide 4.25 that remains in the
solution as the number of equivalents of boronic acid increased.
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The relationship between number of equivalents of PBA-CPG 4.3 and mixing time
was investigated by using three different numbers of equivalents, (4, 10 and 20) and
applying peptide 4.25 solution, again in PBS buffer at pH 8.4, after 0.5, 1, 2, 4, 10
and 30 minutes (Figure 4.15). Using higher boronic acid equivalents resulted in close
to 99% uptake onto the CPG beads after 30 minutes.
70%
■ 4 eq
0.5 1 2 4 10 30
Interaction time / minutes
Figure 4.15 Peptide 4.25 uptake. Percentage of peptide 4.25 remaining in solution after different
interaction times with various numbers of equivalents of PBA-CPG 4.3 (n=3).
Significantly when 20 equivalents of boronic acid were used, only 11% of peptide
4.25 remained in solution after just 30 seconds of mixing, and after 1 minute, only
4% of peptide remained in solution showing that boronate ester formation is rapid.
The study suggests that the enrichment process could be suited to a continuous flow
system rather than the batch-wise system that was under investigation here. PBA-
CPG 4.3 could be packed into columns which would reduce the errors associated
with handling batches of loose beads.
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4.6.2.2 Elution ofsalicylhydroxamic acidfunctionalised peptides from PBA-
CPG
Elution of bound hydroxamic acid modified peptide 4.25 was achieved by adding 1%
TFA in water (pH 1) to the CPG beads and mixing for 25 minutes at room
temperature. TFA was removed by evaporation and 9.29 pmol of peptide 4.25, was
retrieved by lyophilisation (from an initial theoretical loading of 14 pmol), equating
to an effective working capacity for the PBA-CPG 4.3 of 66%.
4.6.3 Synthesis of salicylhydroxamic acid modified cross-linker
The incorporation of a base-sensitive methyl ester head-group onto the cross-linker
backbone rather than a boronic acid meant that an alternative protecting group
strategy was needed for the carboxylic acid groups that would become active esters.
Thus the carboxylic acid groups of the cross-linker arms were protected with the tert-
butyl protecting group, which could be removed under acidic conditions.
Protection of the carboxylic acid group of 4-bromobutyric acid was achieved using
trifluoroacetic anhydride and tert-butyl alcohol using the method of Patel to give
4.26 (Scheme 4.14).217
4.26
Scheme 4.14 Synthesis of tert-butyl protected cross-linker arm 4.26.217
(a) THF, (CF3C0)20, tert-butyl alcohol, 16 h, 90%;
The synthesis of methyl-ester derivative cross-linker was essentially the same as the
previous synthesis (Scheme 4.15). Dialkylation of benzylamine with tert-butyl-4-
bromobutyrate 4.26 gave 4.27. De-benzylation (Pd/EF) gave the secondary amine
4.28, onto which the methyl ester protected salicylic acid derivative 4.21 was
coupled using a water-soluble carbodiimide EDC and HOBt.
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Scheme 4.15 Methyl ester protected salicylic acid functionalised diacid 4.30.
(a) benzylamine, K2C03, DMF, 60 °C, 20 h, 47 %; (b) 10 % Pd/C/H2, MeOH, 90 %; (c)
4.21, EDC, HOBt, DMF, 18 h, 22 %; (d) TFA/CH2C12/TIS/H20 (47.5:47.5:2.5:2.5) 2 h, 48
%;
The coupling of the methyl ester derivative 4.21 and cross-linker backbone 4.28
resulted in a very poor yield for 4.29. Coupling reactions involving secondary amines
are generally more sluggish than with primary amines but the most significant
limiting factor here was deemed to be the succinic spacer group undergoing
intramolecular ring formation before coupling could be achieved. This was routinely
observed by LC-MS as a major side product during coupling. The carboxylic acid
groups of 4.30 were cleanly revealed following treatment at room temperature with a
cocktail of TFA in dichloromethane along with triisopropylsilane and water acting as
scavengers. The tert-butyl protecting groups could also be removed using an
equimolar amount of sulphuric acid but the reaction was slower and not as clean as
with the TFA cocktail. The methyl ester dicarboxylic acid derivative 4.30 was
purified by Prep FIPLC and lyophilised to produce a fluffy white lyophilisate.
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Conversion of the methyl ester 4.30 to hydroxamic acid 4.31 was achieved with a
50% aqueous hydroxylamine solution (Scheme 4.16).
0 4.32 °
Scheme 4.16 Salicylhydroxamic acid cross-linker 4.32 synthesis. Conversion of methyl ester 4.30
to hydroxamic acid derivative 4.31 followed by activation to cross-linker 4.32.
(a) 50% hydroxylamine in H20, rt, 24 h. 100 %; (b) PS-DCC, NHSS, DMF, 24 h, 100%.
Conversion was monitored by analytical HPLC (Figure 4.16) and was shown to be
complete with very few side reactions. Attempts to speed up the reaction by applying
microwave heating led to ester hydrolysis. The hydroxamic acid derivative 4.31
could be isolated by Prep-HPLC, however there were indications that the compound
was not stable and was prone to decomposition, indicated by the appearance of
impurities following HPLC purification and lyophilisation.
















Figure 4.16 HPLC chromatograms. Conversion of the methyl ester derivative 4.30 to the
corresponding hydroxamic acid derivative 4.31.
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Following solid-supported DCC mediated NHSS ester activation using the
previously applied method, the resulting activated cross-linker 4.32 was applied to
the previously synthesised peptide, H2N-LLEYLKR-OH 4.7, under basic conditions.
The resulting mixture was analysed by LC-MS but the predominant product
corresponded to internally cross-linked peptide 4.33 with the hydroxamic acid group
hydrolysed back to the carboxylic acid. It is likely that the cross-linking conditions
used are basic enough to cause hydrolysis of the hydroxamic acid. During the
conversion step it seems most likely that the methyl ester group is converted to a
hydroxamic acid and is then hydrolysed back to a carboxylic acid rather than the
occurrence of hydrolysis of the methyl ester.
4.33 H*N NH
Figure 4.17 Intrapeptide cross-link. Synthetic test peptide modified with an internal cross-link and
hydrolysis of the affinity tag to a non-binding carboxylic acid derivative 4.33.
Another major concern involved with NHS ester activation of a hydroxamic acid
containing derivative is that hydroxamic acids are capable of reacting readily with
dicyclohexyl carbodiimide to form a bimolecular "anhydride".218 Yet another issue is
that of the hydroxamic acid undergoing an intramolecular nucleophilic attack on the
activated NHSS esters. Following cross-linking experiments on proteins, protein
dimers were observed according to gel electrophoresis of cross-linking products but
cross-linked peptides with a hydroxamic acid modification could not be identified.
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At this stage the cross-linking strategy was reconsidered. Attempts to synthesise
activated hydroxamic acid derivative cross-linker 4.32 and perform cross-linking
experiments were abandoned in favour of synthesising the stable activated ester of
the methyl ester cross-linker derivative 4.34 (Scheme 4.17) using solid-supported
DCC and ,/V-hydroxysulfosuccinimide.
4.30 0 4.34 °
Scheme 4.17 Activation ofmethyl ester derivative 4.30 with PS-DCC and NHSS to produce
cross-linker 4.34.
(a) PS-DCC, NHSS, DMF, 24 h, 100 %.
4.6.3.1 Cross-linking experiments with methyl ester derivative 4.34
Following a 2 hour cross-linking reaction with the activated NHSS ester of the
methyl ester derivative 4.34, cross-linked beta-lactoglobulin was identified by gel
electrophoresis and subjected to overnight protease digestion in-solution using
trypsin. Cross-linked peptide products were treated with a 50% aqueous
hydroxylamine solution and peptides were analysed by mass spectrometry before and
after treatment, revealing a mass difference following conversion of 1 Da, indicating
conversion of the cross-linker tagging group of 4.34 to the corresponding
hydroxamic acid. Data was analysed using the computer software programs Mascot
and an in-house developed software Xi and detected cross-linked peptides were
visualised and validated using the in-house developed software program Xaminatrix
(Figure 4.18). Beta-lactoglobulin peptide 155-164 was found cross-linked to another
beta-lactoglobulin peptide 155-164; an example of an intermolecular cross-link.
[22
(a)
Figure 4.18 Cross-linked peptide analysis. Output from Xaminatrix software showing analysis of
fragmented cross-linked peptide (a) modified with methyl ester derivative cross-linker 4.34 and (b)
following conversion of the methyl ester of 4.34 to the corresponding hydroxamic acid derivative.
Residues denoted in red have reacted with cross-linker. Blue markers indicate the positions of y ions,
which are represented on the chart with the corresponding peptide number (PI or P2) shown in
parentheses. Green markers indicate the positions of b ions.
4.6.4 Synthesis of methyl ester derivative active ester tag
The relative stability of the methyl ester derivative 4.34 led to the synthesis of an
NHS active ester tag that could be used as part of the dual tagging system rather than
the hydroxamic acid. Having an active ester of the methyl ester derivative,
effectively an affinity tag precursor, also carries the advantage that following dual
tagging with a complimentary affinity tag, the first enrichment step can be performed
while the second affinity tag is effectively inert. The methyl ester derivative tag is
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"activated" by conversion with hydroxylamine to give a hydroxamic acid that will
bind with solid-supported boronic acid with strong affinity.
4.21 4.35
Scheme 4.18 NHS ester activation of 4.21 to give methyl ester protected salicyclic acid tag 4.35.
(a) 1.2 eq EDC, 1.5 eq NHS, DMF, 79%.
4.6.5 Next generation cross-linker - solutions to hydrophobicity
Precipitation of cross-linked peptides due to hydrophobicity was a major concern and
cause of sample loss during cross-linking experiments. An improved cross-linker was
sought that would give better cross-linking efficiency.
4.6.5.1 Synthesis ofa novel methyl ester derivative
Due to intramolecular ring formation occurring when activating methyl ester 4.21, an
alternative was sought. Astles et al.219 had previously demonstrated that selective
modification of 2,4-dihydroxy benzoic acid at the para hydroxyl group could be
achieved via methyl ester protection of the acid followed by benzylation under
Finkelstein conditions. Initial attempts at alkylation using CS2CO3 and tert-butyl
bromoacetate resulted in a mixture of both regio-isomers (proven by NOESY
experiments). Alkylation using Finkelstein conditions and microwave heating
resulted in modification of the desired para-OH group (Scheme 4.19).
Scheme 4.19 Alkylation via a methyl ester derivative
(a) MeOH, conc. H2S04, reflux, 66 h, 96 %; (b) tert-butyl bromoacetate, K2C03, KI, TBA-
Cl, acetone, gwave 90 °C, 75 min, 74%; (c) TFA/CH2C12/TIS/H20, 1 h, 89%.
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Removal of the tert-butyl protecting group was carried out with TFA along with TIS
and water as scavengers. In most cases the acid could be obtained cleanly, simply by
removing the TFA in vacuo followed by lyophilisation.
4.6.5.2 Synthesis ofan Fmoc-protected PEG spacer
220PEG groups are frequently used to increase hydrophilicity of surfaces and small
molecules.221 Synthesis of an Fmoc-protected PEG amino acid 4.43 was
222
straightforward and carried out as per Visintin et al (Scheme 4.20). The PEG
spacer was chosen because it could be conveniently inserted between the cross-linker
















Scheme 4.20 Fmoc-8-amino-3,6-dioxaoctanoic acid 4.43 synthesis.
(a) 2 eq BnBr, 2.5 eq K2C03, CH3CN, 90 °C, 50 h, 85%; (b) 4 eq NaH, 1.5 eq a-bromoacetic
acid, dry THF, 0 °C to rt, 16 h, 80%; (c) 10% Pd/C/H2, MeOH, rt, 1 atm, 20 h, 98%; (d) 2 eq
K2C03, 1 eq Fmoc-OSu, H20, 43%.
The amino group of the amino acid 4.39 was protected by dibenzylation using benzyl
bromide and potassium carbonate as base, followed by alkylation of the hydroxyl
group with a-bromoacetic acid to provide a terminal carboxylic acid group to yield
4.41. The amine was revealed by Pd/H2 and re-protected with an Fmoc group to give
4.43.
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4.6.5.3 Synthesis ofnovel methyl ester derivative NHS ester tag
The NHS ester active ester 4.44 of the methyl ester derivative 4.38 was made using
the established method involving the water-soluble carbodiimide EDC and NHS,
which were easily removed following reaction with a quick basic and acidic wash.
Scheme 4.21 Synthesis of methyl ester salicylic acid derivative NHS active ester tag 4.44.
(a) 1.2 eq EDC, 1.5 eq NHS, DMF, 87%.
4.6.5.4 Synthesis ofa novel hydrophilic methyl ester derivative NHSS active
ester cross-linker - 4.49
Synthesis of a second generation cross-linker with increased hydrophilicity started
with an amide forming coupling, mediated with HBTU, between the secondary
amino backbone 4.28 used in the previous cross-linker and the Fmoc-protected
amino acid PEG spacer compound 4.43. This was followed by removal of the Fmoc
protecting group using piperidine in DMF to reveal a free amine 4.46, onto which
was coupled the novel methyl ester derivative 4.38 developed previously. Removal
of the tert-butyl protecting groups was achieved using a cocktail of TFA/CH2CI2
along with H2O and TIS acting as scavengers. The resulting diacid 4.48 was purified




4.48 O 4.49 O
Scheme 4.22 Methyl ester derivative 4.49 synthesis.
(a) {2-[2-(Fmoc-amino)ethoxy]ethoxy}acetic acid 4.43, HBTU, DIPEA, DMF, 1.5 h, 67%;
(b) 20% piperidine in DMF, 40 min, 100%; (c) [3-hydroxy-4-
(methoxycarbonyl)phenoxy]acetic acid 4.38, HBTU, DIPEA, DMF, 1.5 h, 86%; (d)
TFA/CH2C12/TIS/H20 (47.5:47.5:2.5:2.5) 2 h, 30%; (e) PS-DCC, NHSS, DMF, 24 h, 100 %;
4.6.5.5 Cross-linking experiments with methyl ester derivative 4.49
Cross-linking and cross-linked peptide enrichment was carried out by Lau Sennels in
the Wellcome Trust Centre for Cell Biology in the School of Biological Sciences,
University of Edinburgh.
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Beta-lactoglobulin was cross-linked with the hydrophilic methyl ester derivative
cross-linker 4.49 using the same cross-linking protocol that was used for 4.34. Cross-












Figure 4.19 Gel electrophoresis. Beta-lactoglobulin cross-linked with 4.49 (X) ran against a marker
lane (M).
Following separation of cross-linked protein by gel electrophoresis, protein bands
were excised from the gel and digested with trypsin. The resulting peptides were
analysed by mass spectrometry as for 4.34 cross-linked peptides. Interestingly, the
intermolecular cross-linked peptide sequence (ALKALPMHIR) observed using 4.34
was also observed with 4.49 (Figure 4.20). Five cross-linked peptides from beta-
lactoglobulin were observed, consistent with the distance constraints between lysines
present in the protein. The methyl ester tag of 4.49 cross-linked peptide products was
converted using hydroxylamine solution to give hydroxamic acid modified cross-
linked peptides ready for enrichment (as with 4.34 cross-linked peptide products).
Hydroxamic acid modified cross-linked peptides in PBS (pH 8.4) were bound to
phenylboronic acid CPG 4.3, unbound material was filtered from the resin and
enriched peptides were eluted from the resin using I % TFA/H^O. Unbound material
was analysed by HPLC and mass spectrometry and compared with peptides that had
been bound and released from CPG 4.3 (Figure 4.21). The result was enrichment of
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Figure 4.20 Cross-linked peptide analysis. Output from Xaminatrix software showing analysis of
three identified fragmented cross-linked peptides (a)-(c) modified with methyl ester derivative cross-
linker 4.49. Residues denoted in red have reacted with cross-linker. Blue markers indicate the
positions of y ions, which are represented on the chart with the corresponding peptide number (PI or
P2) shown in parentheses. Green markers indicate the positions of b ions.
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4.7 Conclusions
A functional system for enrichment of tagged and cross-linked peptides and proteins
via boronate ester chemistry has been demonstrated. A set of modified peptides were
synthesised and enabled a study showing the reversibility of interactions occurring
between a solid-supported phenylboronic acid and a 1,2-diol system. Capture and
release of modified peptides via boronate ester chemistry was shown to be quick and
effective. A series of affinity tag labelled cross-linkers have been synthesised and
used to cross-link model proteins allowing selective enrichment of cross-linked and
modified peptides from mixtures.
In conclusion, the preliminary cross-linking experiments conducted have shown that
enrichment of cross-linked peptides via boronate ester chemistry holds great promise





UV-visible spectrophotometer: Agilent 8453 UV (Agilent Technologies)
BioAnalyzer 4F/4S white light scanner and FIPS software (LaVision BioTech)
Biosafety cabinet: HERAsafe KS 18 class II (Heraeus)
Incubator: HERAcell 150 (Heraeus)
Vacuum oven: Vacutherm VT6025 (Heraeus)
Europlasma NV Junior System
K Control Coater (R K Print-Coat Instruments Ltd.)
Autodrop inkjet printing system (Microdrop Technology, Norderstedt, Germany)
The Smith Synthesiser (Personal Chemistry), Initiator™ (Biotage) and Sanyo EM-
SI 553 were used to perform microwave irradiations.
Dry solvents were obtained by passing through an alumina column. Reagents were
used as purchased from commercial sources unless otherwise specified. TLC analysis
was carried out using foil-backed sheets coated with silica gel (0.25 mm). Flash
column chromatography was performed, on Sorbsil C60, 40-60 mesh silica.
Amino acids were of the L-configuration unless otherwise stated.
All buffers were prepared using commercial reagent grade chemicals.
RP-HPLC was performed on an Agilent 1100 Chemstation analytical system with a
Supelco Discovery® C18 ODS, 5 pm, 50 mm x 4.6 mm i.d. column coupled to a
Polymer Laboratories 100 ES evaporative light scattering detector. The following
eluents were used: (A) H20 + 0.1% TFA; (B) CH3CN + 0.04% TFA; (C) H20 +
0.1% FA; (D) MeOH + 0.1% FA. HPLC grade eluents were employed at a flow rate
of 1 mL min"1 with samples prepared to a concentration of about 1 mg mL"1 and
filtered prior to injection.
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The following methods were used:
Method 1: (6 min) 90% (A) to 10% (A) in (B) over 3 min, then 10% (A) in (B) over
1 min, then 10% (A) in (B) to 90% (A) over 1 min, then 90% (A) over 1 min,
detection by UV at 230, 254, 260 and 280 nm.
Method 2: (6 min) 95% (C) to 5% (C) in (D) over 3 min, then 5% (C) in (D) over 1
min, then 5% (C) in (D) to 95% (C) over 1 min, then 95% (C) over 1 min, detection
by UV at 230, 254, 260 and 280 nm and ELSD (evaporative light scattering
detection).
Method 5: (10 min) 95% (C) to 5% (C) in (D) over 6 min, then 5% (C) in (D) over 3
min, then 5% (C) in (D) to 95% (C) over 0.05 min, then 95% (C) over 0.95 min,
detection by UV at 230, 254, 260 and 280 nm and ELSD (evaporative light scattering
detection).
LC-MS were carried out on an Agilent LCMSD 1100 equipped with an Supelco
Discovery® C18 ODS, 5 pm, 50 mm x 4.6 mm i.d. column, flow rate: 1 mL min"1 as
per Method 3.
LRES mass spectra were recorded using a VG Platform Quadrupole Electrospray
Ionisation mass spectrometer, measuring monoisotopic masses.
HRES mass spectra were recorded using an LTQ-Orbitrap Classic
(ThermoElectron, Germany) mass spectrometer.
Preparative RP-HPLC was performed on an Agilent Technologies HP 1100
Chemstation eluting with (A) H20 + 0.1% TFA and (B) CH3CN + 0.1% TFA on a
Phenomenex (Prodigy) ODS-3 column (250 mm x 10 mm i.d., 5 pm), at a flow rate
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of 5 mL min"1, using the methods below. Fractions were collected using an Agilent
1200 Series Fraction Collector.
Method 4\ (35 min) 95% (A) to 50% (A) in (B) over 20 min, then 50% (A) in (B) to
5% (A) in (B) over 5 min, then 5% (A) in (B) over 3 min, then 5% (A) in (B) to 95%
(A) over 2 min, then 95% (A) over 5 minutes, detection by UV at 230, 254, 260 and
280 nm.
Method 5: (33 min) 100% (A) to 60% (A) over 5 min, 60% (A) to 30% (A) in (B)
over 20 min, 30% (A) in (B) to 100% (B) over 4 min, 100% (B) to 100% (A) over 4
minutes, detection by UV at 214, 254 and 440 nm.
1H NMR and 13C NMR spectra were recorded on Bruker ARX-250 (250 and 63
MHz respectively), DPX-360 (360 and 90 MHz respectively) and AVA-800 (800
and 200 MHz respectively). Chemical shifts (5), referenced to the residual protonated
solvent as an internal standard, are quoted in ppm, coupling constants (J) are reported
in Hz.
IR spectra were recorded on a Fourier transform IR Bruker Tensor 27 Spectrometer
(FTS) fitted with a Specac single reflection diamond attenuated total reflection
(ATR) Golden Gate. All samples were run neat, frequencies are reported in cm"1 and
only frequencies corresponding to significant functional groups are reported.
Microscopy and Confocal microscopy were performed on a Zeiss Axiovert 200M
pseudo confocal microscope with a 100 W Hg lamp or a Leica Inverted Confocal
Microscope with a DM IRE2 microscope stand and analysed using Improvision
Volocity acquisition software.
Microarray imaging was carried out on a BioAnalyzer 4F/4S white light scanner
(LaVision Bio Tech) equipped with Cy3, Cy5 and FITC filters. The BioAnalyzer
was capable of imaging a standard microscopy slide (26x76 mm) in a single scan.
Fluorescence intensity was integrated over a circular area of diameter 250 pm.
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Melting points were determined using a Gellenkamp melting point apparatus.
Inkjet printing was carried out using an Autodrop inkjet printing system (Microdrop
Technology, Norderstedt, Germany), using (unless specified) the following printing
parameters: 120 V, 28 ps and 100 Hz with a AK-501 micropippette (70 pm nozzle).
5.2 General resin procedures
5.2.1 Calculation of theoretical loading
The theoretical loading of a resin after a reaction was calculated using Equation 5.1:
New loading (mmol/g) = [Old loading /(l+(01d loading x Mass added x 10"3)]
Equation 5.1. Theoretical loading of a resin following a reaction, Where: "old loading" is
the loading of the starting resin (mmol/g) and "mass added" is the mass of compound added
onto the resin.
5.2.2 Quantitative ninhydrin test
A known mass of resin (ca. 5 mg) in a small test tube was treated with 6 drops of
reagent A (preparation described below) and 2 drops of Reagent B (preparation
described below) and heated in an oil bath at 110 °C for 10 min. The test tube was
cooled and 60% aqueous EtOH (2 mL) added to the mixture. The resin was removed
by filtration through glass wool and the deep blue filtrate collected in a 25 mL
volumetric flask. The resin was washed with a solution of Et4NCl (0.5 M in CH9CI2,
2 x 0.5 mL) and the sample made up to 25 mL with 60% aqueous EtOH. The
absorbance at 570 nm was then measured against a reagent blank using a
spectrophotometer. The level of amine present was calculated using Equation 5.2:
-2
Amount of amine present (mmol/g) = [(A57o x V) / (£570 xW)] x 10
Equation 5.2. Analysis of amine loading, where:
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A570 = Recorded absorbance at 570 nm (arbitrary units)
V = Volume of combined solution (mL)
g570 = Average molar extinction coefficient suitable for most peptides with the value 15000
M'cnf'
W = Weight of the resin sample (mg).
Ninhydrin Reagent A:
Solution 1 - Reagent grade phenol (40.0 g) was dissolved in absolute EtOH (10
mL) with warming and then stirred over Amberlite mixed-bed resin MB-3 (4.0 g) for
45 min. The mixture was then filtered.
Solution 2 - Potassium cyanide (65 mg) was dissolved in H20 (100 mL). A 2
mL aliquot of this solution was diluted with pyridine (38 mL, freshly distilled from
ninhydrin) and stirred over Amberlite mixed-bed resin MB-3 (4.0 g). The solution
was filtered and mixed with Solution 1 to give Reagent A.
Ninhydrin Reagent B:
Ninhydrin (2.5 g) was dissolved in absolute EtOH (50 mL).
5.2.3 TNBS test (2,4,6-trinitrobenzensulfonic acid)223
A few beads were suspended in 2 drops of a solution of 10% DIPEA in DMF and 2
drops of a solution of 1% TNBS in DMF (commercially available). After a few
minutes, the beads were washed with DMF to remove the red solution. A positive
test was indicated by red beads and confirmed the presence of primary amines.
5.2.4 Estimation of level of first residue attachment - Quantitative Fmoc
Test224
To a known mass of dry Fmoc amino acid-resin (approximately 5 pmol with respect
to Fmoc, {e.g. 5 mg)) was added a solution of 20% piperidine in DMF (1 mL), and
the mixture was shaken for 5 min. The cleavage solution was added to a 10 mL
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volumetric flask and the volume was made up to 10 mL with a solution of 20%
piperidine in DMF. The absorbance at 302 nm of the liberated dibenzofulvene-
piperidine adduct was measured twice against a blank solution of 20% piperidine in
DMF and the average value was used. The loading was calculated according to
Equation 5.3:
Loading (mmole/g) = [(A302 x V)/( £302 x m)] x 103
Equation 5.3. Analysis of amine loading, where "A302" is the recorded absorbance at 302
nm, "V" is the diluted volume (10 mL), "S302" is the extinction coefficient of the
dibenzofulvene-piperidine adduct (7800 M"1 cm"1) and "m" is the mass of resin (mg).
5.3 General methods for solid phase peptide synthesis
1 mL ofsolventper gram of resin was usedfor the followingprocedures.
5.3.1 Method A: Solid phase peptide coupling conditions - DIC/HOBt
Resin was swollen in a minimum amount of CH2CI2. A-Fmoc-amino acid (2 eq) and
HOBt (2 eq) were dissolved in CH2CI2 with a few drops of DMF and stirred for 10
min. DIC (2.2 eq) was added and the mixture stirred for 10 min before addition to the
resin. The resin was agitated for 1 h to effect coupling. The resin was washed with
DMF (x3), CH2CI2 (x3), MeOH (x3), Et20 (x2) and dried under vacuum for 30 min.
5.3.2 Method B: Solid phase peptide coupling conditions -
HBTU/DIPEA
Resin was swollen in a minimum amount of CH2CI2. A-Fmoc-amino acid (5 eq) and
HBTU (4.9 eq) were dissolved in DMF (0.1 M). DIPEA (10 eq) was added and the
resulting mixture was immediately added to the resin. The resin was agitated for 40
minutes to affect coupling. The resin was washed with DMF (x3), CH2CI2 (x3),
MeOH (x3), EtaO (x2) and dried under vacuum for 30 min.
5.3.3 Method C: TV-terminal Fmoc removal
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Fmoc removal was performed using 20% piperidine in DMF with two sequential
treatments of 20 min. The resin was then filtered and washed with DMF (x3),
CH2CI2 (x3), MeOH (x3), Et20 (x2) and dried under vacuum for 30 min.
5.3.4 Method D: Cleavage of peptides from resin
Resin was swollen in a minimum of CH2C12. TFA/TIS/H20 (95/2.5/2.5) was added
and the resin agitated for 2h. The TFA solution was removed, concentrated to ca. 1
mL and added to cold (4 °C) Et20 in a centrifuge tube. The resulting precipitate was
collected by centrifugation and washed with Et20 (x4).
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5.3.5 Method E: Intra-resin disulfide bond formation
ArCONH-Cys(Trt)-Rink amide resin was shaken with a solution of iodine (10 eq) in
DMF for 1.5 h. The resin was then washed with DMF (10 mL x 5), CFI2CI2 (10 mL x
5), MeOH (10 mL x 5) and Et20 (10 mL x 3).
5.3.6 Method F: Attachment of Fmoc amino acids to Wang linker resin
Resin was swollen in a minimum of DMF for 30 min. Fmoc amino acid (10 eq) was
dissolved in dry CH2CI2 and a solution of DIC (5 eq) in dry CH2CI2 was added. The
mixture was stirred for 20 min at 0 °C, followed by removal of the CH2CI2 in vacuo.
The residue was dissolved in the minimum of DMF and the solution added to the
swollen resin. DMAP (0.1 eq) in DMF was added to the resin mixture, which was
agitated for 2 h. The resin was then filtered and washed with DMF (x3), CH2CL (x3),
MeOH (x3), Et20 (x2) dried under vacuum for 30 min and the level of attachment
estimated using the quantitative Fmoc test (Section 5.2.4).
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5.4 General cell procedures
5.4.1 Cell culture
HeLa cells were cultivated in T-75 flasks (Nunc) to 70% confluency in Roswell
Park's Memorial Institute (RPMI-1640, Sigma-Aldrich) medium supplemented with
10% foetal bovine serum (FBS, Biosera), 100 U/mL penicillin and streptomycin and
4 mM L-glutamine (Gibco) at 37 °C / 5% CO2. At this time, the old growth media
was removed and the cells were washed with PBS (10 mL) and harvested via
trypsination (trypsin (0.050% w/v)/EDTA (0.20% w/v), Gibco) (1 mL) at 37 °C.
Detached cells were collected in fresh growth media (4 mL) and diluted using more
fresh growth media to give the appropriate cell density for experiments.
5.4.2 Haemocvtometry
Haemocytometry was used to determine cell densities. An aliquot (10 pL) of cells
detached from a T-75 flask and collected in growth media (total volume: 5 mL) was
mixed with 0.2% trypan blue (40 pL, Sigma-Aldrich) and pipetted into a Bright
Line™ haemocytometer (an etched glass device with an H-shaped moat forming two
cell-counting areas (with 4 quadrants in each area), with surface features enhanced
by Neubauer rulings, Sigma-Aldrich). Cell concentration and the densities required
for experiments were determined by Equations 5.4 and 5.5 respectively.
Concentration (cell/mL) - (N / Q) x 5xl04
Equation 5.4. Concentration of cell/mL by haemocytometry, where "N" is the total number
of cells counted and "Q" is the number of quadrants counted.
Vexp (mL) = (Vxot X Cwell) X (1000 / Vwell) / Cxot
Equation 5.5. Volume of cells detached from T-75 flask "Vexp" required in an experiment, a
total medium volume of "VTot" and a concentration per well of "CWeii"- "Vweii" is the volume
required per well and "CTot" is the concentration of cells/mL as calculated in Equation 5.4.
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5.5 Experimentalfor Chapter 2
5.5.1 Synthesis of compounds
Fmoc-Rink-PS (2.2)
Amino polystyrene resin (5.00 g, 8.00 mmol, 1 eq) was coupled to Fmoc-Rink amide
linker (8.11 g, 16.0 mmol, 2 eq) using Method A (Section 5.3.1). Qualitative
ninhydrin test negative.
H-Rink-PS (2.3)
Resin 2.2 was Fmoc-deprotected using Method C (Section 5.3.3). Qualitative
ninhydrin test positive.
H-Cys(Trt)-Rink-PS (2.4)
Resin 2.3 (3.58 g, 2.40 mmol, 1 eq) was coupled to Fmoc-Cys(Trt)-OH (2.81 g, 4.80
mmol, 2 eq) using Method A (Section 5.3.1). Qualitative ninhydrin test negative.
Quantitative Fmoc test gave a loading of 0.608 mmol/g. Resin was deprotected using
Method C (Section 5.3.3). Qualitative ninhydrin test positive.
Cystine diamides (2.6-2.12)
Resin 2.4 (0.427 g, 0.300 mmol, 1 eq) was coupled to carboxylic acids (2.5)
according to Method A (Section 5.3.1). Qualitative ninhydrin test negative. Resins
were treated according to Method E (Section 5.3.5) and cleaved with Method D
(Section 5.3.4).
yV,A'-Di(benzoyl)-L-cystine diamide (2.6)34
Yield: 95%; RP-HPLC (k254): 7.0 min (100%) (Method 3); m/z (ES+): 447.0
(M+H)+, 469.0 (M+Na)+; 'H-NMR (DMSO-J6, 250 MHz): 5 8.65 (d, 2H, J = 8 Hz,
NH), 7.95 (dd, 4H,3J = 6.8 Hz, 2ArH-2 + 2Ar//-6), 7.65-7.50 (m, 8H, NH2 + 2ArH-




Yield: 92%; LCMS (A254): 8.4 min (100%) (Method 3); m/z (ES+): 569.3 (M+Na)+;
'H-NMR (DMSO-</6, 250 MHz): 5 8.85 (d, 2H, J = 8 Hz, NH), 8.58 (s, 2H, 2AxH-
2), 8.09-8.00 (m, 8H, 2AxH-4 + 2AxH-5 + 2Ar//-6 + 2Ar//-7), 7.72-7.68 (m, 6H,
NH2 + 2AxH-9 + 2Ar//-10), 7.38 (br s, 2H, N//2), 4.95-4.85 (m, 2H, CH), 3.25-3.15
(m, 2H, Cystine-Cfi^a), 2.60-2.55 (m, 2H, Cystine-//p)
A,A'-Di(/?-fluorobenzoyl)-L-cystine diamide (2.8)34
Yield: 75%; LCMS (X254): 6.9 min (100%) (Method 3); m/z (ES+): 483.0 (M+H)+,
505.0 (M+Na)+; Rf: 0.44 (CHCl3/MeOH, 9/1); IR (neat): vmax: 1688, 1636, 1602 cm"
'; XH-NMR (DMSO-J6, 250 MHz): 5 8.61 (d, 2H, J = 8.5 Hz, N/7), 7.95 (dd, 4H, J =
9 Hz, 4Jhf = 5 Hz, 2AxH-2 + 2Ar//-6), 7.60 (br s, 2H, NH2), 7.28-7.24 (m, 6H,
2Ar//-3 + 2Ar//-5 + NH2), 4.72-4.68 (m, 2H, Cystine-//2a), 3.30 (dd, 2H, J = 4 Hz,
Cystine-//2p).
N,N'- Di(p-bromobenzoyl)-L-cystine diamide (2.9)34
Yield: 52%; LCMS (X254): 8.4 min (100%) (Method 3); m/z (ES+): 627.2.0 (M+Na)+
A,A'-Di(/?-anisoyl)-L-cystine diamide (2.10)
Yield: 35%; LCMS (X254): 7.1 min (100%) (Method 3); m/z (ES+): 529.3 (M+Na)+
Ar,N'-Di(butyryl)-L-cystine diamide (2.11)
Yield: 75%; LCMS (X254): 5.5 min (100%) (Method 3); m/z (ES+): 401.2 (M+Na)+
benzyl (2R,2/?)-3,3'-disulfanediylbis(l-amino-l-oxopropane-3,2-
diyl)dicarbamate (2.12)





Resin 2.4 (0.427 g, 0.300 mmol, 1 eq) was coupled to Fmoc-Gly-OH (0.179 g, 0.600
mmol, 2 eq) according to Method A (Section 5.3.1) followed by Fmoc deprotection
according to Method C (Section 5.3.3). 2-napthoic acid (0.103 g, 0.600 mmol, 2 eq)
was coupled according to Method A (Section 5.3.1) and the resulting resin was
treated according to Method E (Section 5.3.5) and cleaved with Method D (Section
5.3.4). Couplings and deprotections were monitored by qualitative ninhydrin test.
Yield: 56%; LCMS (X254): 7.6 min (100%) (Method 3); m/z (ES+): 661.1 (M+H)+
Synthesis of iV,./V'-(3,3'-(2/?,2'/?)-3,3'-disulfanediylbis(l-amino-l-oxopropane-
3,2-diyl)bis(azanediyl)bis(3-oxoethane-3,l-diyl))di-2-napthamide (2.14)
Synthesis was as for cystine 2.13 but Fmoc-P-Ala-OH (0.186 g, 0.600 mmol, 2 eq)
was coupled using Method A (Section 5.3.1) instead of Fmoc-Gly-OH. Yield: 77%;
LCMS (X254): 7.4 min (100%) (Method 3); m/z (ES+): 689.0 (M+H)+
Synthesis of /V,iV'-Di(napthoyl)-L-cystine N",N'"-Di(glycine) diamide (2.15)
Resin 2.3 (0.427 g, 0.300 mmol, 1 eq) was coupled to Fmoc-Gly-OH (0.178 g, 0.600
mmol, 2 eq) using Method A (Section 5.3.1). Resin was deprotected using Method C
(Section 5.3.3) and then coupled to Fmoc-Cys(Trt)-OH (0.352 g, 0.600 mmol, 2 eq).
This was followed with Fmoc-deprotection according to Method C (Section 5.3.3)
and capping with 2-napthoic acid (0.103 g, 0.600 mmol, 2 eq) using Method A
(Section 5.3.1). Couplings and deprotections were monitored by qualitative
ninhydrin test. Resin was treated according to Method E (Section 5.3.5) and cleaved
with Method D (Section 5.3.4). Yield: 37%; LCMS (^254): 7.5 min (100%) (Method
3); m/z (ES+): 661.0 (M+H)+, 883.0 (M+Na)+
Synthesis of iV,./V'-Di(napthoyl)-L-cystine yV",,/V"'-I)i(phenylalanine) diamide
(2.16) Synthesis was as for 2.15 except Fmoc-Phe-OH was coupled rather than
Fmoc-Gly-OH. Yield: 43%; LCMS (X254): complex mixture, m/z (ES+): 841.2
(M+H)+, 863.2 (M+Na)+
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Synthesis of iV,W-Di(benzoyl)-L-cystine /V",/V'"-Di(glycine) diamide (2.17)
Synthesis was as for 2.15 except benzoic acid was used as a capping group rather
than 2-napthoic acid. Yield: 100%; LCMS (X254): 5.5 min (100%) (Method 3); m/z
(ES+): 561.0 (M+H)+, 583.0 (M+Na)+
Synthesis of /V,/V'-Di(benzoyl)-L-cystine N",N"'-Di(phenylalanine) diamide
(2.18) Synthesis was as for 2.15 except Fmoc-Phe-OH was coupled rather than
Fmoc-Gly-OH and benzoic acid was used as a capping group rather than 2-napthoic
acid. Yield: 100%; LCMS (X254): complex mixture, m/z (ES+): 741.1 (M+H)+
Synthesis of /V,/V'-Di(p-fluorobenzoyl)-L-cystine W,/V'"-Di (glycine) diamide
(2.19) Synthesis was as for 2.15 except 4-fluorobenzoic acid was used as a capping
group rather than 2-napthoic acid. Yield: 79%; LCMS (A254): 6.6 min (91%)
(Method 3); m/z (ES+): 597.0 (M+H)+, 619.0 (M+Na)+
Synthesis of /V,/V'-Di(p-fluorobenzoyl)-L-cystine W,A""-Di(phenylalanine)
diamide (2.20) Synthesis was as for 2.15 except Fmoc-Phe-OH was coupled rather
than Fmoc-Gly-OH and 4-fluorobenzoic acid was used as a capping group rather
than 2-napthoic acid. Yield: 85%; LCMS (X254): 7.0 min (100%) (Method 3); m/z
(ES): 777.1 (M+H)\ 799.1 (M+Na)+
Synthesis of /V,/V'-Di(2-naphthoyl)-L-cystine (2.21) Fmoc-Cys(Trt)-OH (2.694 g,
4.6 mmol, 10 eq) was loaded onto polystyrene Wang linker resin (0.92 mmol/g, 0.46
mmol, 0.500 g, leq) using Method F (Section 5.3.6). An Fmoc deprotection
according to Method C (Section 5.3.3) was followed by coupling of 2-napthoic acid
using Method A (Section 5.3.1). Resin was treated according to Method E (Section
5.3.5) and cleaved with Method D (Section 5.3.4). Yield: 96%; LCMS (^254): 6.2
min (83%) (Method 3); m/z (ES"): 547.0 (M-H)~
Synthesis of /V,M'-Di(benzoyl)-L-cystine /V",/V'"-I)i(glycine) (2.22) Fmoc-Gly-
OH (6.00 mmol, 1.784 g, 10 eq) was loaded onto polystyrene Wang linker resin
(0.92 mmol/g, 0.60 mmol, 0.652 g) using Method F (Section 5.3.6). An Fmoc
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deprotection according to Method C (Section 5.3.3) was followed by coupling of
Fmoc-Cys(Trt)-OH (0.703 g, 1.2 mmol, 2 eq) using Method A (Section 5.3.1). Fmoc
deprotection as before was followed by coupling of benzoic acid (0.147 g, 1.2 mmol,
2 eq) according to Method A (Section 5.3.1). Resin was treated according to Method
E (Section 5.3.5) and cleaved with Method D (Section 5.3.4). Yield: 75%; LCMS
(X254): 6.7 min (100%) (Method 3); m/z (ES"): 561.0 (M-H)"
Synthesis of A(/V'-Di(benzoyl)-L-cystine 7V",Ar"'-Di(phenylalanine) (2.23)
Synthesis was as for 2.22 except Fmoc-Phe-OFl was coupled instead of Fmoc-Gly-
OH. Yield: 73%; LCMS (X254): 9.8 min (100%) (Method 3); m/z (ES"): 741 (M-H)"
Synthesis of iY,iV'-Di(p-fluorobenzoyl)-L-cystine iV",,/V'"-Di(glycine) (2.24)
Synthesis was as for 2.22 except 4-fluorobenzoic acid was coupled instead of
benzoic acid. Yield: 75%; LCMS (7,254): 7.2 min (100%) (Method 3); m/z (ES"):
597.0 (M-H)"
Synthesis of ./V,./V'-Di(p-fluorobenzoyl)-L-cystine TV",-/V'"-Di(phenylalanine)
(2.25) Synthesis was as for 2.22 except Fmoc-Phe-OH was coupled instead of Fmoc-
Gly-OH and 4-fluorobenzoic acid was coupled instead of benzoic acid. Yield: 62%;
LCMS (7,254): 7.0 min (100%) (Method 3); m/z (ES"): 777.0 (M-H)"
Synthesis of iV-p-bromobenzoyl-iV'-benzoyl-L-cystine diamide (2.26) Synthesis
was as for cystine diamides (2.6-2.12) except a mixture of 4-bromobenzoic acid (1
eq) and benzoic acid (1 eq) was coupled as capping groups. Yield: 78%; LCMS
(7,254): 7.0 min (50%, dibenzoyl derivative) and 7.6 min (50%, 2.26) (Method 3); m/z
(ES+): 469.0 (M+Na)+ (dibenzoyl derivative), 547 (M+Na)+ product.
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5.5.3 Gelation in well plate and seeding with HeLa cells
In a typical experiment, gel was broken up inside microwave vials by 30 seconds of
vigorous shaking. "Gel solutions" were then added to polystyrene 96-well plates
(Nunc) (two volumes were used: 50 and 100 pL). The well plates were then covered
using well plate covers, irradiated with microwaves (Sanyo EM-S1553) at 800 W for
15 s and left to stand for 10 min. Gel formation was confirmed principally by well
plate inversion. Cells were cultured as described (Section 5.4.1) and seeded directly
onto the surface of gels at a density of 1 x 104 cells/well (volume per well: 100 pL).
The last row of every well plate was used as a blank (no gel). Cells were incubated
(37 °C/5% C02) and well plates were examined after 24 and 48 h by microscopy.
5.5.4 Gelation on glass slides
In a typical experiment, glass slides spotted/printed with DMSO gelator solutions
were introduced to a 10-slide capacity chamber (Genetix; Product No. X2530), along
with H20 (2 mL) added to the base well, which was sealed and heated in an oven at
80 °C for 1 h. The chamber was removed from the oven and allowed to cool to room
temperature undisturbed. Slides were then scanned using a BioAnalyzer 4F/4S white
light scanner and the data analysed using FIPS software (LaVision BioTech).
5.5.5 Glass slide treatment and masking
Tridecafluoro-l,l,2,2-tetrahydroocctyldimethylchlorosilane (TFCS) was supplied by
Gelest. Standard microscope slides (76x26 mm) were used from Menzel GmbH.
Glass slides were initially rinsed in various solvents (hexane, DMF, acetone and
MeOH) to remove manufacturing grease and residues. The glass slides were then
etched using oxygen plasma, from a Europlasma NV Junior System (Frequency: 50
Hz, Rf Power: 100 W, stabilising time: 30 seconds), for 2 minutes at 200 mTr,
rotating after 1 minute. A 40% w/v sucrose masking solution was prepared by
dissolving sucrose in water. The solutions were printed on the glass surface using an
Autodrop inkjet printing system (Microdrop Technology, Norderstedt, Germany).
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This consists of an automated XYZ stage and a stroboscopic video camera. The
diameter of the nozzle used was 70 pm.
Table 5.1 shows the printing parameters used to produce sucrose squares with the
following diameters: 4.5 mm (30 x 30 spots/square), 3 mm (20 x 20 spots/square),
1.5 mm (10 x 10 spots/square) and 0.75 mm (5x5 spots/square):
Distance No. drops
between printed at
squares each Spots Maximum no.
Spots/square (mm) position printed/square squares/slide
30 x30 1.4 4 3600 36
20 x 20 1.6 4 1600 80
10 x 10 1.8 4 400 132
5x5 1.8 4 100 261
Table 5.1. Printing parameters used to print sucrose squares onto glass slides.
After printing, sucrose masked slides were dried in 60 °C for 1 h, allowed to cool to
room temperature and then coated with Tridecafluoro-1,1,2,2-
tetrahydrooctyl)dimethylchlorosilane (TFCS) (4 pL per slide) using a K Hand Bar
Coater (bar of 4.5 mm diameter with a 0.05 mm diameter wire and coating speed 2.5
cm/s). Finally, the slides were washed in water (3 x 200 mL) to remove the mask and
excess TFCS, and dried under a stream of nitrogen. The result was hydrophobic
patterned slides consisting of different sized arrays of hydrophilic features.
5.5.6 Gelator deposition using inkjet printing
Printing different concentrations of A,A'-Di(2-naphthoyl)-L-cystine diamide
0.5 pM Rhodamine B DMSO solutions containing different concentrations (0, 1, 2,
3, 4, 5, 7.5, 10, 20, 30, 40 and 50 mM) of A(A'-Di(2-naphthoyl)-L-cystine diamide
were prepared. Each concentration was deposited onto a slide patterned with a 1.5 x
1.5 mm hydrophilic feature array by piezo jet-printing 350 drops (0.4 pL) onto each
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defined hydrophilic feature using the printing parameters 115 V, 28 ps and 200 Hz.
Each concentration was printed in triplicate.
Mixed gelators printed on an array
35 mM solutions of gelators used in this study (2.6-2.10) were prepared in DMSO
and deposited in defined positions onto 1.5 x 1.5 mm hydrophilic features in an array
by piezo jet-printing 100 drops (0.11 pL) of each gelator solution. Each gelator
solution was printed in 5 positions on the array. The printing parameters were 115 V,
28 ps and 200 Hz. The printing pipette was cleaned between each gelator to avoid
contamination. The cleaning protocol involved filling the micropipette with DMSO,
applying an impulse (12500 Hz) frequency to the micropipette for 5 s and emptying
the micropipette. 100 drops of each 35 mM gelator solutions were then printed onto
the first set of printed gelators such that 25 different gelator combinations were
achieved. This was followed by printing 100 drops of 210 mM DTT solution
prepared in DMSO onto every gelator mixture combination and then printing 50
drops of 3.5 pM Rhodamine B in DMSO. Each gelator combination with DTT and
Rhodamine B was printed in triplicate on one slide. Gelation was induced according
to Section 5.4.4.
Mixed gelators printed on an array without DTT
The printing procedure was repeated as in the previous experiment but instead of
printing 100 drops of 210 mM DTT solution in DMSO, 100 drops of DMSO only
was printed along with gelator/Rhodamine B mixtures. Gelation was induced
according to Section 5.4.4.
Mixed gelators printed on an array and 6 day incubation
The printing procedure was repeated as in the previous experiment but gelation was
induced by holding the incubation chamber containing printed slides at 80 °C for 6
days before allowing it to cool.
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5.5.7 Gel degradation study
In a typical gel degradation experiment, 2.6 hydrogel (2 mM) was formed by heating
2.6 solid (10 pmol, 4.5 mg) in H20 (5 mL) in the microwave at 180 °C for 5 min and
allowing the resulting gelator solution to rest and cool down for 15 min. A steel ball
bearing (diameter = 4 mm, 84 mg) was carefully placed on the centre of the gel
surface (diameter =12 mm) and the movement of the steel ball over time and
distance measured. Gel degradation was studied following addition of 300 pL of
each of H20, 100 mM TEAA buffer (pH 8.15), 1 M DTT (0.3 mmol, 46.2 mg) in 100
mM TEAA buffer (pH 8.15) and 4 M DTT (1.2 mmol, 185 g) in 100 mM TEAA
buffer (pH 8.15).
A steel ball bearing (diameter = 4 mm, 84 mg) was carefully placed on the centre of
the gel surface (diameter =12 mm) of 2.15 hydrogel (5 mL, 10 pmol, 2 mM), which
was treated with 300 pL bovine trypsin (1 mg/mL) in PBS (pH 7.4) and the
movement of the steel ball over time and distance measured.
5.6 Experimentalfor Chapter 4
5.6.1 Synthesis of compounds
l-{[3-(3,4-dihydroxyphenyl)propanoyl]oxy}pyrrolidine-2,5-dione (4.1)
3,4-dihydroxyhydrocinnamic acid (0.50 g, 2.75 mmol) and yV-hydroxysuccinimide
(0.475 g, 4.13 mmol) were dissolved in DMF (28 mL), followed by addition of EDC
(0.63 g, 3.30 mmol). The mixture was stirred for 24 h at rt. The solvent was
evaporated in vacuo and the solid was dissolved in EtOAc (40 mL), which was then
washed with sat. NaHCCE (3 x 25 mL), 10% citric acid (3 x 25 mL), brine (2 x 25
mL), dried (MgSCL) and evaporated in vacuo to yield a straw-coloured solid (0.541
g, 1.94 mmol, 71%). *H-NMR (250 MHz, (CD3)2SO): 5H 8.70-8.30 (m, 2H, 2COH),
6.79-6.20 (m, 3H, 3ArH), 2.80-2.30 (m, 8H, (C//2CH2C(0) and (CH2C/72C(0) and
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2NC(0)C//2); 13C-NMR (63 MHz, (CD3)2SO): 5C 170.54 (CH2CH2C(0)), 168.73
(NC(0)), 145.40 (Ar-5-COH), 144.07 (Ar-4-COH), 130.56 (Q, 119.22 (Ar-2-CH),
116.15 (Ar-3-CH), 115.78 (Ar-6-CH), 32.50 (CH2CH2C(0)), 29.60 (CH2CH2C(0)),
25.77 (NC(0)CH2); HRMS (ES") for C13H12N06 (M-H)": calcd 278.0665, found
278.0668; Rf 0.39 (10% MeOH/CH2Cl2, KMn04).
4-phenylboronic acid yV-hydroxysuccinimide ester (4.2)
OH
i
4-carboxyphenylboronic acid (0.20 g, 1.21 mmol) and 7V-hydroxysuccinimide (0.21
g, 1.81 mmol) were dissolved in DMF (12 mL), followed by addition of EDC (0.28
g, 1.45 mmol). The mixture was stirred for 24 h at rt. The solvent was evaporated in
vacuo and the solid was dissolved in EtOAc (30 mL), which was then washed with
sat. NaHC03 (3 x 20 mL), 10% citric acid (3 x 20 mL), brine (2 x 20 mL), dried
(MgSCL) and evaporated in vacuo to yield a straw-coloured solid (0.211 g, 0.80
mmol, 67%). 'H-NMR (250 MHz, (CD3)2SO): 5H 8.06-8.05 (m, 2H, 2(HO)B-Ar-o-
CH), 8.03-8.02 (m, 2H, 2(HO)B-Ar-m-C/7), 2.91 (s, 4H, 2CH2); 13C-NMR (63 MHz,
(CD3)2SO): 5c 173.50 (2NC(0)), 165.10 (C(O)), 145.63 (2(HO)BC), 137.93
(2(HO)B-Ar-o-CH), 131.88 (2(HO)B-Ar-m-CH), 128.67 (CC(O)O), 28.68 (CH2);
HRMS (ES") for CiiH9N06B (M-H)": calcd 262.0523, found 262.0523; Rf 0.37
(10% MeOH/CH2Cl2).





Trisoperl CPG (500 mg, 0.22 mmolg"1, 110 pmol) in acetonitrile (4 mL) was treated
with 4-carboxyphenylboronic acid (164 mg, 990 pmol) and IIDQ (323 pL, 1090
pmol) and was heated at 60 °C for 2 h. The resin was drained, rinsed with
acetonitrile, DMF, CH2CI2 and MeOH (3 x 10 mL each) and vacuum dried.
Ninhydrin test: negative, Theoretical loading: 0.21 mmolg"1.
3-(3,4-dihydroxyphenyl)-iV-propylpropanamide CPG (4.4)
Trisoperl CPG (500 mg, 0.22 mmolg"1, 110 pmol) in acetonitrile (4 mL) was treated
with 3,4-dihydroxyhydrocinnamic acid (180 mg, 990 pmol) and IIDQ (323 pL, 1090
pmol) and was heated at 60 °C for 2 h. The resin was drained, rinsed with
acetonitrile, DMF, CFLCL and MeOH (3 x 10 mL each) and vacuum dried.
Ninhydrin test: negative, Theoretical loading: 0.21 mmolg"1.
H-Arg(Pbf)-Wang linker polystyrene resin (4.5)
H
Fmoc-Arg(Pbf)-OH (2.00 mmol, 1.30 g, 10 eq) was loaded onto polystyrene Wang
linker resin (0.92 mmol/g, 0.200 mmol, 0.220 g) using Method F (Section 5.3.6). An
Fmoc deprotection according to Method C (Section 5.3.3) gave resin 4.5.





Resin 4.5 was coupled to a succession of Fmoc protected amino acids (1.00 mmol, 5
eq): Fmoc-Lys(Boc)-OH, Fmoc-Leu-OH, Fmoc-Tyr('Bu)-OH, Fmoc-Glu('Bu)-OH
and 2x Fmoc-Leu-OH using Method B (Section 5.3.2) with Fmoc deprotection after
every coupling using Method C (Section 5.3.3). The completion of each coupling
was verified using the qualitative ninhydrin test. If needed, an extended cycle was





Resin 4.6 (0.0846 mmol, 79 mg) was cleaved using Method D (Section 5.3.4) and
lyophilised to afford 4.7 as a white solid (29 mg, 95% (based on 4.5)). m/z (ES+):
934.5 (M+H)+, 467.8 (M+2H)2+ (100%); HRMS (ES+) for C44H76N11O11 (M+H)+:





4-carboxyphenylboronic acid (0.185 mmol, 31 mg, 5 eq) was coupled to resin 4.6
(0.0370 mmol, 91 mg, 1 eq) using Method B (Section 5.3.2). Coupling was
confirmed using qualitative ninhydrin test. Peptide 4.8 was cleaved using Method D
(Section 5.3.4) and lyophilised to afford white solid (37 mg, 92% (based on 4.5). m/z
(ES+): 1082.5 (M+H)+, 541.7 (M-2H)2+ (100%); HRMS (ES+) for C5iH8iBNiiOi4





3,4-dihydroxyhydrocinnamic acid (0.182 mmol, 33 mg, 5 eq) was coupled to resin
4.6 (0.0364 mmol, 90 mg, 1 eq) using Method B (Section 5.3.2) followed by
treatment with 20% piperdine in DMF for 10 min and washing with DMF (3x1
mL), CH2CI2 (3 x 1 mL) and Et20 (2 x 1 mL). Coupling was confirmed using
qualitative ninhydrin test. Peptide 4.9 was cleaved using Method D (Section 5.3.4)
and lyophilised to afford white solid (51 mg, 92% (based on 4.5). m/z (ES+): 1096.6
(M-H)\ 547.7 (M-2H)2"; HRMS (ES+) for C53H84BNiiO,4 (M+H)+: calcd 1098.6199,







2,5-dioxo-pyrrolidin-l-yl ester (12.6 pmol, 6 mg, 2 eq) in DMF/DIPEA (200 pL,
95:5) was coupled to resin 4.6 (6.3 pmol, 16 mg, 1 eq) with mixing for 2 h. Peptide
4.10 was cleaved using Method D (Section 5.3.4) and lyophilised to afford white
solid (12 mg, 75% (based on 4.5). m/z (ES+): calcd 1212.7, found 1212.5 (M+H)+,
606.8 (M+2H)2+; RP-HPLC (X254): 2.68 min (Method 1).
2-(3-(3,4-dihydroxyphenyl)propanamido)pentanedioic acid (4.14)
Fmoc-Glu(OtBu)-OH (9.20 mmol, 4.08 g, 10 eq) was coupled to polystyrene Wang
linker resin (0.92 mmol, 1.00 g, 1 eq) using Method F (Section 5.3.6). A quantitative
Fmoc test revealed the loading to be 0.595 mmol/g. The Fmoc group was removed
using Method C (Section 5.3.3). 3,4-dihydroxyhydrocinnamic acid (2.87 mmol,
0.523 g, 3 eq) in DMF (5 mL) was added to the resin along with EEDQ (2.87 mmol,
0.711 g, 3 eq) and the resin was shaken overnight, after which the reaction mixture
was removed by filtration and the resin was washed with DMF (3x5 mL), CH2CI2
(3x5 mL), MeOH (3x5 mL) and Et20 (2x1 mL). A negative ninhydrin result
indicated that coupling was complete. The resin was treated with 4 M HC1 in dioxane
(3 mL) for 4 h, which was removed by filtration and evaporated in vacuo. The
residue was purified using silica gel chromatography eluted with 3-10 %
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MeOH/CH2Cl2 to yield a pale-yellow oil (180 mg, 0.579 mmol, 70%). 'H-NMR
(250 MHz, CD3OD): 5h 6.66-6.54 (m, 2H, Ar-o-CH and Ar-m-CH), 6.44-6.40 (m,
1H, o-CH), 4.35-4.30 (m, 1H, NCH), 2.65 (t, J = 7.5 Hz, 2H (CH2C//2C(0)NH)),
2.41 (t, J = 7.5 Hz, 2H, (C/72CH2C(0)NH)), 2.18 (t, J = 7.5 Hz, 2H
(CH2C//2C(0)0H)), 2.05-1.70 (m, (C/f2CH2C(0)0H)); 13C-NMR (63 MHz,
CD3OD): 5C 176.20 (C(O)NH), 175.19 (CHC(O)OH), 173.91 (CH2CH2C(0)0H),
146.61 (Ar-5-COH), 145.08 (Ar-4-COH), 121.04 (Ar-2-CH), 116.99 (Ar-3-CH),
116.77 (Ar-6-CH), 53.38 (CHC(O)OH), 39.26 (CH2CH2C(0)), 32.62
(CH2CH2C(0)0H), 31.25 (CH2CH2C(0)), 27.96 (CH2CH2C(0)0H); m/z (ES ):
310.0 (M-H)" (100%); RP-HPLC (A,254): 3.08 min (Method 1).
4-[Benzyl-(3-ethoxycarbonyl-propyl)-amino]-butyric acid ethyl ester (4.15)213
A mixture of ethyl 4-bromobutyrate (2.0 mL, 14.0 mmol, 1.94 eq), benzylamine
(0.760 mL, 7.20 mmol) and potassium carbonate (5.8 g, 42.0 mmol, 5.82 eq) in DMF
(30 mL) was stirred at 40 °C for 20 h. The majority of the DMF was then removed in
vacuo and the reaction mixture was then diluted with water (20 mL) and extracted
with ethyl acetate (3 x 30 mL). The pooled extracts were dried over MgS04,
evaporated and purified by silica gel chromatography with EtOAc in hexane (7:1
v/v) to give the title compound (1.86 g, 5.55 mmol, 77% yield). ^-NMR (500 MHz,
CDCI3): 5h 7.32-7.19 (m, 5H, Ar-H), 4.12 (q, J = 7.0 Hz, 4H, CH3C7720(0)C and
C(0)0C//2CH3), 3.54 (s, 2H, NC//2Ar), 2.43 (t, J = 7.0 Hz, 4H,
CH3CH20(0)CCH2CH2C/72N and NC//2CH2CH2C(0)0CH2CH3), 2.30 (t, J = 7.5
Hz, 4H, CH3CH20(0)CC//2CH2CH2N and NCH2CH2C//2C(0)0CH2CH3), 1.81
(quint, J = 7.2 Hz, 4H, CH3CH20(0)CCH2C7/2CH2N and
NCH2C//2CH2C(0)0CH2CH3), 1.26 (t, J = 7.1 Hz, 6H,
C//3CH20(0)CCH2CH2CH2N and NCH2CH2CH2C(0)0CH2C//3); 13C-NMR (150
MHz, CDC13): 5c 176.3 (CH3CH20(0)C and C(0)OCH2CH3), 131.6 (o-CH), 131.3
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(o-CH), 131.2 (C), 130.9 (m-CH), 130.2 (m-CH), 129.6 (p-CH), 63.2 (NCH2C), 61.1
(CH3CH20(0)C and C(0)0CH2CH3), 55.3 (CCH2CH2CH2N and NCH2CH2CH2C),
34.6 (CCH2CH2CH2N and NCH2CH2CH2C), 24.9 (CCH2CH2CH2N and
NCH2CH2CH2C), 16.9 (CH3); m/z (ES+): 336.1 (M+H)+ (100%); RP-HPLC
(ELSD): 3.21 min (Method 2); Rf 0.75 (10% MeOH/CH2Cl2, Ninhydrin).
4-(bis(4-ethoxy-4-oxobutyl)carbamoyl)phenylboronic acid (4.17)
4.15 (285 mg, 0.851 mmol) was dissolved in MeOH (60 mL) and passed through a
10 % Pd/C/H2 column on an H-Cube Tutor at 40 °C at 1 mL/min. The solvent was
removed in vacuo and the crude residue was re-dissolved in DMF (3 mL) and treated
with 4-carboxyphenylboronic acid (170 mg, 1.02 mmol, 1.2 eq) and EDC (212 mg,
1.11 mmol, 1.3 eq) and stirred for 18 h at rt. The DMF was evaporated in vacuo and
the resulting residue was dissolved in saturated NaHC03 solution (20 mL) and
extracted with EtOAc (3 x 15 mL). The organic layer was washed with KHSO4 (20
mL) and brine (20 mL) and dried over MgSCL followed by evaporation in vacuo.
The resulting dark yellow oil was purified by silica gel chromatography eluted with
3-10 % MeOH/CH2Cl2 to yield a pale-yellow oil (177 mg, 0.450 mmol, 53%). !H-
NMR (250 MHz, (CD3)2SO): 5H 8.12-8.06 (m, 2H, 2 x o-CH), 7.50-7.45 (m, 2H, 2 x
m-CH), 4.17-4.10 (m, 4H, CH3C//20 and OCtf2CH3), 3.38-3.29 (m, 4H,
NCtf2CH2CH2 and CH2CH2C/72N), 3.17-3.13 (m, 2H, NC//2CH2CH2), 2.35-2.30 (m,
4H, NCH2CH2CH2 and C//2CH2CH2N), 1.90-1.84 (m, 4H, NCH2Gtf2CH2 and
CH2Ctf2CH2N), 1.28-1.25 (m, 6H, Ctf3CH20 and OCH2C/73); 13C-NMR (63 MHz,
CD3OD): 5c 172.10 (C(O)O), 168.91 (NC(0)), 135.63 (NC(O)C), 128.83 (2 x o-
CH), 98.61 (2 x m-CH), 60.13 (C(0)0C//2CH3), 48.80 (NCH2CH2CH2), 46.55
(NCH2CH2CH2), 32.40 (0(0)CCH2CH2), 24.51 (0(0)CCH2CH2), 14.06
(C(0)0CH2C//3); m/z (ES+): 394.1 (M+H)+ (100%); HRMS (ES+) for Ci9H29BN07
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(M+H)+: calcd 394.2032, found 394.2033; RP-HPLC (X254): 2.79 min (100 %)
(Method 1).
4,4'-(4-boronobenzoylazanediyl)dibutanoic acid (4.18)
A mixture of 4.17 (177 mg, 0.450 mmol), MeOH (5.5 mL) and 1 N aqueous NaOH
solution (1.3 mL) was stirred at 45 °C for 18 h. The reaction mixture was carefully
acidified to pH 3-4 with IN HC1 and extracted with EtOAc (3 x 10 mL). The pooled
extracts were washed with water (15 mL) and brine (15 mL) and dried (MgS04) and
evaporated in vacuo to yield an off-white coloured gum (60 mg, 0.18 mmol, 40%).
JH-NMR (250 MHz, CD3OD): 8H 7.60 (d, J = 7.5 Hz, 2H, 2 x o-CH), 7.18 (d, J =
7.5 Hz, 2H, 2 x m-CH), 3.40 (t, J = 7.5 Hz, 2H, NC//2CH2CH2), 3.17-3.13 (m, 2H,
NC//2CH2CH2), 2.44 (t, J = 7.5 Hz, 2H, NCH2CH2C//2), 1.95 (t, J = 7.5 Hz, 2H,
NCH2CH2C/72), 1.86-1.82 (m, 2H, NCH2C772CH2), 1.65 (t, J = 7.5 Hz, 2H,
NCH2C/72CH2); 13C-NMR (63 MHz, CD3OD): 5C 180.40 (C(O)OH), 169.81
(NC(O)), 148.36-145.55 ((OH)2BC), 137.48 (NC(O)C), 129.43 (2 x o-CH), 99.45 (2
x m-CH), 48.75 (NCH2CH2CH2), 46.50 (NCH2CH2CH2), 34.70 (H0(0)CCH2CH2),
24.61 (H0(0)CCH2CH2); m/z (ES+): 336.0 (M-H)" (100%); RP-HPLC (X254): 2.61
min.
5-aminosalicylic acid methyl ester (4.20)
O
5-aminosalicylic acid (3.06 g, 20.0 mmol) in MeOH (40 mL) was treated with conc.
H2S04 (1.6 mL) and heated in the microwave at 120 °C for 1.5 h. The reaction was
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neutralised by adding NaHC03 powder and evaporated in vacuo. H20 (100 mL) was
added and extracted into CH2CI2 (150 mL). The CH2CI2 layer was washed with brine
(100 mL), dried (MgS04) and evaporated in vacuo to yield an off-white powder
(2.65 g, 15.9 mmol, 80%). *H-NMR (250 MHz, CDCI3): hH 10.20 (br signal, 1H, o-
OH), 7.14 (d, J = 2.8 Hz, 1H, o-CH), 6.89 (m, 2H, m-CH and p-CH), 3.91 (s, 3H,
CH3), 3.32 (br signal, 2H, NH2); 13C-NMR (63 MHz, CDC13): 5C 170.8 (CO), 155.2
(COH), 138.7 (CNH2), 124.7 (p-CH), 118.6 (p-CH), 115.1 (m-CH), 112.6 (Q, 52.6
(CH3); m/z (ES+): 168.0 (M+H)+ (100%); RP-HPLC (L220): 0.87 min; Rf 0.71 (10%
MeOH/CH2Cl2, Ninhydrin).
4-{(4-hydroxy-3-(methoxycarbonyl)phenyl]amino}-4-oxobutanoic acid (4.21)
4.20 (0.334 g, 2.00 mmol) in CH2CI2 (2.5 mL) was added to succinic anhydride
(0.180 g, 1.80 mmol) in CH2CL (2.5 mL). The reaction mixture was irradiated at 100
°C for 10 min and the resulting solid was filtered and re-crystallised in MeOH to
give the title compound as a pale-brown solid (0.455 g, 1.70 mmol, 94%). 1H-NMR
(250 MHz, (CD3)2SO): 8h 10.24 (s, 1H, o-OH), 9.94 (s, 1H, C(0)0H), 8.14 (d, J =
2.8 Hz, 1H, m-CH), 7.59 (dd, J = 9.0, 2.8 Hz, 1H, p-CH3), 6.90 (d, J = 9.0 Hz, 1H, o-
CH), 3.67 (s, 3H, CH3), 2.52-2.48 (m, 4H, H0(0)CC7f2CH2C(0) and
H0(0)CCH2C//2C(0)); 13C-NMR (63 MHz, CDC13): 8C 174.2 (C(O)OH), 170.2
(C(0)OCH3), 169.5 (NHC(O)), 156.2 (COH), 131.6 (CNH), 127.5 (o-CH), 120.2 (p-
CH), 117.9 (m-CH), 112.7 (CC(0)OCH3), 52.8 (CH3), 31.2 (H0(0)CCH2CH2C(0)),
29.1 (H0(0)CCH2C//2C(0)); m/z (EST): 266.0 (M-H)" (100%); HRMS (ES+) for
C,2Hi4N06 (M+H)+: calcd 268.0816, found 268.0817 ; RP-HPLC (A254): 2.62 min









4.21 (0.100 g, 0.375 mmol) in MeOH (9.4 mL) was treated with 50%
hydroxylamine/H20 (5.3 mL) and stirred overnight at rt, after which MeOH was
removed in vacuo and the remaining aqueous solution was acidified to pH 3-4 with 1
N HC1, followed by extraction with EtOAc (3 x 25 mL). The combined EtOAc
extractions were washed with brine (2 x 20 mL), dried over MgS04 and the solvent
removed in vacuo followed by purification by Prep HPLC to yield a cream solid (38
mg, 0.142 mmol, 38%). XH-NMR (800 MHz, (CD3)2SO): SH 12.22 (br signal, 1H,
C(O)NM)H), 11.51 (s, 1H, o-OH), 11.21 (s, 1H, C(0)NHO//), 9.91 (s, 1H,
C(0)0H), 7.94 (d, J = 2.4 Hz, m-CH), 7.57 (dd, J = 8.8, 2.4 Hz, 1H, p-CH3), 6.93 (d,
J = 8.8 Hz, 1H, o-CH), 2.60-2.59 (m, 4H, H0(0)CCA2CH2C(0) and
H0(0)CCH2C//2C(0)); 13C-NMR (200 MHz, (CD3)2SO): 5C 177.0 (C(O)OH),
173.0 (C(O)NHOH), 168.4 (H0(0)CCH2CH2C(0)NH), 156.9 (COH), 133.9 (CNH),
128.1 (o-CH), 122.4 (p-CH), 120.0 (m-CH), 118.6 (CC(O)NHOH), 33.9
(H0(0)CCH2CH2C), 31.9 (H0(0)CCH2CH2C); m/z (ES~): 267.0 (M-H)~ (100%);
HRMS (ES+) for CnH13N206 (M+H)+: calcd 269.0768, found 269.0768; RP-HPLC
$.254): 2.38 min (100 %) (Method 1).
5-({4-[(2,5-dioxopyrrolidin-l-yl)oxy]-4-oxobutanoyI}amino)-A,2-
dihydroxybenzamide (4.23)
4.22 (0.093 g, 0.347 mmol) and A-hydroxysuccinimide (0.060 g, 0.521 mmol) were
dissolved in DMF (3.5 mL), followed by addition of EDC (0.080 g, 0.416 mmol).
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The mixture was stirred for 24 h at rt. The solvent was evaporated in vacuo and the
solid was dissolved in EtOAc (10 mL), which was then washed with sat. NaHC03 (3
x 5 mL), 10% citric acid (3x5 mL), brine (2x5 mL), dried (MgS04) and evaporated
in vacuo to yield a straw-coloured solid (55 mg, 0.151 mmol, 44%). XH-NMR (800
MHz, (CD3)2SO): 8h 7.38 (d, J = 8.8 Hz, 1H, o-CH), 7.02 (d, J = 2.4 Hz, 1H, m-
CH3), 6.96 (dd, J = 8.8, 2.4 Hz, p-CH3), 2.77 (s, 4H, 2C//2C(0)NO(0)C), 2.66-2.63
(m, 4H, N0(0)CC//2CH2C(0) and N0(0)CCH2CH2C(0); 13C-NMR (200 MHz,
(CD3)2SO): 5c 180.1 (NO(O)C), 177.8 (C(0)N0(0)C), 174.4 (C(O)NHOH), 165.5
(N0(0)CCH2CH2C(0), 157.6 (COH), 133.7 (CNH), 131.5 (CC(O)NHOH), 124.2
(p-CH), 112.7 (o-CH), 112.2 (m-CH), 45.9 (2CH2C(0)N0(0)C), 31.6
(N0(0)CCH2CH2C); HRMS (ES~) for Ci5Hi4N308 (M-H)~: calcd 364.0781, found




Synthesis of peptide 4.24 was as peptide 4.7 but with additional coupling of 4.21
using Method B (Section 5.3.2). Cleavage from resin using Method D (Section 5.3.4)
resulted in peptide 4.24 as a white solid (227 mg, 96%). HRMS (ES+) for
C%H87N120,6 (M+H)+: calcd 1183.6358, found 1183.6358; RP-HPLC (ELSD): 3.52





Peptide 4.24 (0.0676 mmol, 80 mg) was treated with 50% NH2OH/H2O (1.5 mL) for
24 h. Solvent was removed in vacuo and the residue was dissolved in 50%
CH3CN/H2O and lyophilised to quantitatively yield 4.25 as a white solid. HRMS
(ES+) for C55H86Ni3016 (M+H)+: calcd 1184.6310, found 1184.6310; RP-HPLC
(ELSD): 3.74 min (100 %) (Method 2).
tert-butyl 4 bromobutanoate (4.26)225
Concentrated sulphuric acid (0.235 mL, 4.41 mmol) was added to a vigorously
stirred suspension of anhydrous magnesium sulphate (2.12 g, 17.65 mmol) in CH2C12
(18 mL). The mixture was stirred for 15 min, after which 4-bromobutyric acid (0.74
g, 4.41 mmol) was added. tert-Butanol (2.07 mL, 22 mmol) was added last. The
mixture was stoppered tightly and stirred under argon at 25 °C for 48 h. The reaction
mixture was quenched with saturated sodium bicarbonate solution (35 mL) and
stirred until all magnesium sulphate had dissolved. The organic layer was separated,
washed with H20, dried (MgS04) and then evaporated to afford, after purification by
column chromatography (silica; MeOH/ CH2CI2), the tert-butyl 4-bromobutyrate as a
pale-yellow oil (0.41 g, 1.86 mmol, 42%). IR (neat) 2973, 2927, 1727 (C=0), 1364,
1156, 842 cm"1; *H-NMR (250 MHz, CDC13): 5H 3.52 (t, J = 6.8 Hz, 2H, C//2Br),
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2.34 (t, J = 7.2 Hz, 2H, C(0)CH2), 2.00 (q, J = 6.8 Hz, 2H, CH2C//2CH2), 1.40 (s,
9H, (C//3)3C); 13C-NMR (63 MHz, CDC13): 8C 170.8 (CO), 155.2 (COH), 138.7
(CNH2), 124.7 (o-CH), 118.6 (p-CR), 115.1 (m-CH), 112.6 (Q, 52.6 (CH3); m/z (ES~
): 166.9 (M-H)~ (100%).
tert-butyl iV-benzyl A?(4-butyryloxy terf-butyl)-4-amino butyrate (4.27)
A mixture of tert-butyl-4-bromobutyrate (0.81 g, 3.63 mmol, 1.94 eq), benzylamine
(0.205 mL, 1.87 mmol) and potassium carbonate (1.5 g, 10.9 mmol, 5.82 eq) in DMF
(8.6 mL) was stirred at 40 °C for 20 h. The majority of the DMF was then removed
in vacuo and the reaction mixture was then diluted with water (15 mL) and extracted
with ethyl acetate (3 x 20 mL). The pooled extracts were dried over MgS04,
evaporated and purified by silica gel chromatography with EtOAc in hexane (7:1
v/v) to give the title compound (0.389 g, 0.995 mmol, 53% yield). 'H-NMR (250
MHz, CDC13): Sh 7.36-7.20 (m, 5H, Ar-CH), 2.42 (t, J = 7.5 Hz, 4H,
(0)CCH2CH2C//2N), 2.21 (t, J = 7.5 Hz, 4H, (0)CC//2CH2CH2N), 1.79 (dt, J = 7.5
Hz, 4H, (0)C-H2CH2CH2N), 1.41 (s, 18H, C(C//3)3); 13C-NMR (63 MHz, CDC13):
8c 173.5 ((CH3)3CO(0)CCH2CH2CH2N), 129.2 (o-CH), 129.1(o-CH), 129.0 (m-
CH), 127.9 (m-CH), 127.2 {p-CR), 80.4 ((CH3)3C0(0)CCH2CH2CH2N), 58.9
(NCH2C), 53.1 (CCH2CH2CH2N), 33.6 (CCH2CH2CH2N), 28.5 (CH3), 25.0
(CCH2CH2CH2N), 22.8 (CCH2CH2CH2N); m/z (ES+): 392.2 (M+H)+ (100%);
HRMS (ES+) for C23H38N04 (M+H)+: calcd 392.2795, found 392.2798; RP-HPLC




acid) 7V(4-butyryloxy ferl-butyl)-4-amino butyrate (4.29)
4.27 (0.582 g, 1.49 mmol) was dissolved in MeOH (15 mL) followed by the
introduction of 10% Pd/C (48 mg) and a H2 balloon. The reaction was stirred for 24 h
at rt, after which the Pd was removed by filtration over celite, and the MeOH was
removed in vacuo. The crude residue was re-dissolved in DMF (15 mL) and treated
with 4.21 (0.479 g, 1.79 mmol), EDC (0.372 g, 1.94 mmol) and HOBt (0.275 g, 1.79
mmol) and stirred overnight at rt. The DMF was evaporated in vacuo and the
resulting residue was dissolved in saturated NaHC03 solution (20 mL) and extracted
with EtOAc (3 x 15 mL). The organic layer was washed with KHSO4 (20 mL) and
brine (20 mL) and dried over MgS04 followed by evaporation in vacuo. The
resulting dark yellow oil was purified by silica gel chromatography eluted with 1-5
% MeOH/CH2Cl2 to yield yellow oil (178 mg, 0.324 mmol, 22%). 'H-NMR (250
MHz, CDCI3): 6h 10.57 (s, 1H, ArOH), 8.66 (s, 1H, NH), 8.06 (d, J = 2.8 Hz, 1H,
ArH-2), 7.49 (dd, J = 9.0, 2.8 Hz, 1H, Ar//-4), 6.89 (d, J = 9 Hz, 1H, ArH-5), 3.92
(s, 3H, COOCH3), 3.41-3.27 (m, 4H, (0)CC//2CH2CH2N and NCH2CH2C//2C(0)),
2.80-2.65 (m, 4H, (0)CCH2C/72CH2N and NCH2Gtf2CH2C(0)), 2.26-2.17 (m, 4H,
(0)CC/72CH2C(0) and (0)CCH2C/72C(0)), 1.92-1.73 (m, 4H, (0)CCH2CH2C//2N
and NC/72CH2CH2C(0)), 1.68 (s, 9H, C(C//3)3); 13C-NMR (63 MHz, CDC13): 5C
172.7 (NC(0)CH2CH2C(0)NH), 172.5 ((CH3)3C0(0)CCH2CH2CH2N), 172.2
(NCH2CH2CH2C(0)0C(CH3)3), 171.2 (CC(0)OCH3), 170.8
(NC(0)CH2CH2C(0)NH), 158.4 (o-COH), 130.6 (m-CNH), 128.7 (p-CR), 121.3 (o-
CH), 118.0 (m-CH), 112.3 (CC(0)OCH3), 81.3 ((CH3)3CO(0)C), 80.8
(C(0)0C(CH3)3), 52.7 (CC(0)OCH3), 47.6 (NCH2CH2CH2C(0)0C(CH3)3), 45.8
((CH3)3CO(0)CCH2CH2CH2N), 33.1 ((CH3)3C0(0)CCH2CH2CH2N and
(NCH2CH2CH2C(0)0C(CH3)3), 33.0 (NC(0)CH2CH2C(0)NH), 32.6
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(NC(0)CH2CH2C(0)NH), 28.5 ((CH3)3CO(0)C and C(0)0C(CH3)3), 24.3
((CH3)3C0(0)CCH2CH2CH2N), 23.5 (NCH2CH2CH2C(0)0C(CH3)3); m/z (ES+):
551.2 (M+H)+, 573.1 (M+Na)+; HRMS (ES+) for C28H43N209 (M+H)+: calcd
551.29631, found 551.29688; RP-HPLC (A,280): 3.12 min (100 %) (Method 2).
4,4'-(4-(4-hydroxy-3-(methoxycarbanoyl)phenylamino)-4-
oxobutanoylazanediyl)dibutanoic acid (4.30)
4.29 (0.178 g, 0.324 mmol) was treated with a cocktail of TFA/CH2C12/TIS/H20
(47.5:47.5:2.5:2.5) (2 mL) and stirred for 2 h at rt. The cleavage cocktail was
removed in vacuo and the resulting residue was re-dissolved in 30% acetonitrile/70%
H20 (10 mL) and freeze-dried prior to purification by Prep-HPLC to yield a
colourless oil (68 mg, 0.155 mmol, 48%). JH-NMR (800 MHz, CD3OD): 5H 7.90 (d,
J = 2.8 Hz, 1H, Artf-2), 7.54 (dd, J = 8.9, 2.8 Hz, 1H, Artf-4), 7.13 (d, J = 8.9 Hz,
1H, Artf-5), 4.00 (s, 3H, C(0)OCH3), 3.41-3.35 (m, 4H, CH2N and NCH2), 2.69 (t, J
= 7.91 Hz, 2H, (0)CCH2CH2C(0)), 2.62 (t, J= 6.9 Hz, 2H, (0)CCH2C//2C(0)), 2.41
(t, J = 7.0 Hz, 2H, HO(0)CCT/2), 2.31 (t, J = 7.0 Hz, 2H, C//2C(0)OH), 1.92 (dt, J =
14.9, 7.1 Hz, 2H, H0(0)CCH2C//2CH2N), 1.82 (dt, J = 14.6, 7.3 Hz, 2H,
NCH2C//2CH2C(0)0H); 13C-NMR (200 MHz, CD3OD): 5C 176.6 (C(O)OH), 176.4
(HO(O)Q, 175.2 (NC(O)), 174.5 (CC(0)OCH3), 171.7 (C(O)N-Ar), 163.9 (o-
COH), 132.6 (m-CNH), 126.9 (p-CH), 124.5 (o-CH), 121.8 (m-CH), 115.8
(CC(0)OCH3), 54.7 (CC(0)OCH3), 49.4 (NCH2CH2CH2C(0)OH), 47.5
(H0(0)CCH2CH2CH2N), 33.2 (H0(0)CCH2CH2CH2N), 32.7
(NCH2CH2CH2C(0)0H), 31.4 (NC(0)CH2CH2C(0)NH), 30.1
(NC(0)CH2CH2C(0)NH), 26.0 (H0(0)CCH2CH2CH2N), 25.2
(NCH2CH2CH2C(0)0H); m/z (ES+): 438.0 (M+H)+ (100%); HRMS (ES+) for
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C2oH27N209 (M+H)+: calcd 439.17111, found 439.17105; RP-HPLC (X254): 3.5 min
(100 %) (Method 1).
Methyl 5-({4-[(2,5-dioxopyrrolidin-l-yl)oxy]-4-oxobutanoyl}amino)-2-
hydroxybenzoate (4.35)
4.21 (0.500 g, 1.87 mmol) and TV-hydroxysuccinimide (0.323 g, 2.81 mmol) were
dissolved in CH3CN (19 mL), followed by addition of EDC (0.431 g, 2.25 mmol).
The mixture was stirred for 24 h at rt. The solvent was evaporated in vacuo and the
solid was dissolved in EtOAc (10 mL), which was then washed with sat. NaHC03 (3
x 5 mL), 10% citric acid (3x5 mL), brine (2x5 mL), dried (MgS04) and evaporated
in vacuo to yield a white solid (0.540 g, 1.48 mmol, 79%). ^-NMR (800 MHz,
(CD3)2SO): 5h 7.38 (d, J = 8.8 Hz, 1H, o-CH), 7.02 (d, J = 2.4 Hz, 1H, m-CH3), 6.96
(dd, J = 8.8, 2.4 Hz, p-CH3), 2.77 (s, 4H, 2C7/2C(0)N0(0)C), 2.66-2.63 (m, 4H,
N0(0)CC//2CH2C(0) and N0(0)CCH2C//2C(0); 13C-NMR (200 MHz, (CD3)2SO):
5c 180.1 (NO(O)C), 177.8 (C(0)N0(0)C), 174.4 (C(O)NHOH), 165.5
(NO(0)CCH2CH2C(0), 157.6 (COH), 133.7 (CNH), 131.5 (CC(O)NHOH), 124.2
(p-CH), 112.7 (o-CH), 112.2 (m-CH), 45.9 (2CH2C(0)N0(0)C), 31.6
(N0(0)CCH2CH2C); m/z (ES"): 365.0 (M+H)+, 387.0 (M+Na)+ (100%), 751.1
(2M+Na)+; HRMS (ES") for C,6Hi5N208 (M-H)": calcd 363.0828, found 363.0830;




2,4-dihydroxybenozic acid (10.0 g, 0.065 mol) in MeOH (75 mL) was treated with
cone. H2SO4 (2.5 mL) and refluxed at 70 °C for 66 h. The reaction was cooled to rt,
neutralised by adding NaHC03 powder and evaporated in vacuo. H20 (250 mL) was
added and extracted into CH2CI2 (300 mL). The CH2CI2 layer was washed with brine
(250 mL), dried (MgS04) and evaporated in vacuo to yield an off-white powder
(10.5 g, 0.062 mol, 96%) mp 113-114 °C (aq MeOH), lit.226\ 16-117 °C (benzene),
IR (neat) 3331 (m), 3176 (m), 1741 (w), 1637 (s), 1615 (s), 1434 (s), 1145 (s), 1095
(s) cm"1; 'H-NMR (250 MHz, CD3CN): 8H 10.86 (s, 1H, o-OH), 7.69 (d, J = 8.7 Hz,
1H, o-CH), 6.40-6.33 (m, 2H, m-CH), 3.86 (s, 3H, CH3); 13C-NMR (63 MHz,
CD3CN): 8C 170.0 (C=0), 163.2 (COH), 131.4 (o-CH), 107.0 (m-CH), 104.7 (Q,




In a method adapted from Astles et a/.,219 phenol 4.32 (1.00 g, 5.95 mmol) dissolved
in acetone (7 mL), treated with KI (0.51 g, 3.07 mmol), Bu4NC1 (11 mg, 38 pmol),
K2C03 (0.94 g, 6.83 mmol) and tert-butyl bromoacetate (0.870 mL, 5.88 mmol), was
irradiated at 90 °C in a microwave for 75 min. The mixture was filtered and the
filtrate evaporated in vacuo. The residue was purified by column chromatography
eluted with 1% MeOH/CH2Cl2 to give a white powder (1.25 g, 4.42 mmol, 74%
yield), mp 73 °C; JH-NMR (250 MHz, CDC13): 8H 11.20 (s, 1H, OH), 7.96 (d, J =
7.5 Hz, 1H, o-CH), 6.70-6.51 (m, 2H, 2 x m-CH), 4.74 (s, 2H, 0C//2C(0)0), 4.03 (s,
3H, C(0)0CH3), 1.70 (s, 9H, C(0)OC(073)3); 13C-NMR (63 MHz, CDC13): 8C
170.7 (C(0)OCH3), 167.6 (COH), 164.0 (C(0)0C(CH3)3), 131.8 (o-CH), 108.1 (m-
CH), 106.6 (CC(0)OCH3), 101.9 (m-CH), 83.2 (C(CH3)3), 65.8 (CH2), 52.4
(C(0)OCH3), 28.4 (C(0)0C(CH3)3); m/z (ES+): 283.0 (M+H)+ (100%), 587.1
(2M+Na)+; HRMS (ES+) for Ci4H1906 (M+H)+: calcd 283.1176, found 283.1178;
O
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RP-HPLC (X282) tR 4.30 min (100 %) ELSD tR 4.38 min (100 %) (Method 2); Rf
0.82 (10% MeOH/CH2Cl2, KMn04).
[3-hydroxy-4-(methoxycarbonyl)phenoxy]acetic acid (4.38)
O
4.33 (0.500 g, 1.77 mmol) was treated with a cocktail of TFA/CH2C12/TIS/H20
(47.5:47.5:2.5:2.5) (10 mL) and stirred for 1 h at rt. The cleavage cocktail was
removed in vacuo and the resulting residue was re-dissolved in 30% acetonitrile/70%
H20 (10 mL) and freeze-dried to yield a fluffy white lyophilisate (0.356 g, 1.58
mmol, 89%). 'H-NMR (500 MHz, CD3OD): 5H 7.78 (d, J = 9 Hz, 1H, o-CH), 6.53
(dd, J = 2.5 Hz, 9 Hz, 1H, m-CH), 6.45 (d, J = 2.5 Hz, 1 H, m-CH), 4.71 (s, 2H,
0C772C(0)0), 3.91 (s, 3H, C(0)0CH3); 13C-NMR (125 MHz, CD3OD): 8C 171.9
(C(0)OCH3), 171.6 (COH), 165.4 (C(O)OH), 164.8 (CH2OC), 132.6 (o-CH), 108.5
(m-CH), 107.3 (CC(0)OCH3), 102.7 (m-CH), 65.8 (CH2), 52.6 (C(0)OCH3); m/z
(ES~): 225.0 (M-H)~; HRMS (ES+) for C10H„O6 (M+H)+: calcd 227.0550, found




Using a procedure by Visintin et al.,222 a mixture of 2-(aminoethoxy)ethanol (5.00 g,
47.5 mmol), potassium carbonate (16.4 g, 119 mmol) and benzyl bromide (11.3 mL,
95 mmol) in acetonitrile (250 mL) was stirred at 50 °C for 20 h. The solid was
filtered and the solvent was evaporated from the filtrate in vacuo. The residue was
dissolved in HC1 (0.1 M) and washed with EtOAc (2 x 50 mL). The aqueous layer
was then made basic with NaOH (1 M) and extracted with CH2C12 (4 x 50 mL). The
solvent was dried (MgSQ4) and removed in vacuo, to give the product, which was
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used in the next reaction without further purification (11.53 g, 40.4 mmol, 85%). 1H-
NMR (250 MHz, CDC13): 5r 7.40-7.20 (m, 10H, Fh-fl), 3.70-3.60 (m, 6H, PhCH2
and NCH2), 3.57 (t, J = 7.5 Hz, 2H, NCH2C//20), 3.46 (t, 7 = 7.5 Hz, 2H,
OC//2CH2OH), 2.69 (t, 7=10 Hz, 2H, OCH2Ctf2OH); 13C-NMR (63 MHz, CDC13):
8C 139.8 (Ph-C), 129.3 (Ph-CH), 128.7 (Ph-CH), 127.4 (4-Ph-CH), 72.5
(OCH2CH2OH), 70.0 (NCH2CH20), 62.3 (OCH2CH2OH), 59.4 (PhCH2), 53.4




Using a procedure by Visintin et al.,222 4.40 (11.53 g, 40.5 mmol) was dissolved in
dry THF (90 mL) and cooled at 0 °C, then NaH (5.44 g, 162 mmol; 60% dispersion
in oil) was added in portions followed by a bromo acetic acid (8.46 g, 61 mmol). The
suspension was refluxed overnight under nitrogen. Water (3.5 mL) was added
carefully and then stirred for 5 minutes, then more water (100 mL) was added and
the aqueous layer washed with a mixture of hexane/Et20 1:1 (2 x 50 mL). The
aqueous solution was acidified to pH 2-3 with HC1 (1 M) and washed with Et20 (3 x
50 mL), then neutralised to pH 6/7 with NaOH (1 M). Solid sodium chloride was
added and the mixture was extracted with CH2C12 (5 x 75 mL). The solvent was
dried (MgS04) and removed in vacuo. The crude product was used in the next
reaction without further purification (11.17 g, 32.6 mmol, 80%). 1H-NMR (250
MHz, CDC13): 5h 7.44-7.10 (m, 10H), 3.88 (s, 2H), 3.68 (s, 4H), 3.61-3.34 (m, 4H);
13C-NMR (63 MHz, CDC13): 5c 137.53, 129.84, 128.78, 127.93, 71.39, 70.33, 69.69,
69.34, 59.14, 52.63; m/z (ES~): 342.1 (M-H)" (100%); RP-HPLC (ELSD): 3.02 min






Using a procedure by Visintin et al.,222 4.41 (11.17 g, 32.6 mmol) was dissolved in
MeOH (150 mL) and palladium (2.79 g, 10% on carbon) was added. The mixture
was stirred under a hydrogen atmosphere (760 mm Hg) at rt for 24 h. The catalyst
was removed by filtration through celite and the solvent removed in vacuo. The
residue was triturated with diethyl ether (100 mL) to give the title compound 4.42
(5.22 g, 32 mmol, 98%). *H-NMR (250 MHz, CD3OD): 6h 3.98 (s, 2H,
C//2C(0)OH), 3.89-3.72 (m, 6H, H2NCH2C/72 and OC//2CH2 and OCH2C//2), 3.22-
3.19 (m, 2H, NC//2CH20); 13C-NMR (63 MHz, CD3OD): 8C 173.66, 72.07, 71.69,




Using a procedure by Visintin et al. 222 crude [2-(2-Aminoethoxy)ethoxy]acetic acid
4.42 (5.10 g, 31.3 mmol) was suspended in H20 (50 mL) and K2C03 (8.65 g, 62.6
mmol) and stirred at rt for 10 minutes. V-(9-fluorenylmethoxycarbonyl) succinimide
(10.55 g, 31.3 mmol) was added to the mixture and stirred for 16 h. The reaction
mixture was then washed with diethyl ether (2 x 30 mL). The aqueous solution was
acidified to pH 1-2 with HC1, concentrated and extracted with CH2C12 (5 x 30 mL).
The solvent was dried (MgS04) and removed in vacuo. The obtained product was
crystallised from acetonitrile to give the title compound 4.43 (5.76 g, 15.0 mmol,
43%). 'H-NMR (250 MHz, CDC13): 5H 7.89 (d, J = 7.0 Hz, 2H), 7.79-7.68 (m, 2H),
7.55-7.39 (m, 4H), 4.50 (d, J = 7.5 Hz, 2H), 4.37-4.31 (m, 1H), 4.31 (s, 2H), 3.86-
3.84 (m, 2H), 3.79-3.77 (m, 2H), 3.73-3.69 (m, 2H), 3.59-3.50 (m, 2H); 13C-NMR
O
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(90 MHz, CDCI3): 5C 173.2 (Q, 156.5 (Q, 143.8 (C), 141.1 (Q, 127.5 (CH), 126.9
(CH), 125.0 (CH), 119.8 (CH), 71.0 (CH2), 70.1 (CH2), 69.9 (CH2), 68.3 (CH2), 66.6
(CH2), 47.0 (CH), 40.6 (CH2); m/z (ES+): 386.0 (M+H)+, 408.0 (M+Na)+; RP-HPLC
(ELSD): 4.28 min (100 %) (Method 2).
Methyl 4-(2-[(2,5-dioxopyrrolidin-l-yl)oxy]-2-oxoethoxy)-2-hydroxybenzoate
(4.44)
4.34 (0.150 g, 0.663 mmol) and AMiydroxysuccinimide (0.115 g, 0.995 mmol) were
dissolved in CH3CN (7 mL), followed by addition of EDC.HC1 (0.153 g, 0.995
mmol). The mixture was stirred for 24 hours at room temperature. The solvent was
evaporated in vacuo and the residue was dissolved in EtOAc (30 mL), which was
then washed with sat. NaHC03 (3x15 mL), 10% citric acid (3x15 mL), brine (2 x
15 mL), dried (MgSCL) and evaporated in vacuo to yield an off-white solid (0.187 g,
0.579 mmol, 87%). *H-NMR (250 MHz, (CD3)2SO): 5H 10.50 (s, 1H, OH), 7.87-
7.66 (m, 1H, o-CH), 6.70-6.52 (m, 2H, 2 x m-CH), 5.35 (s, 2H, 0CH2C(0)0), 3.80
(s, 3H, C(0)0CHi), 2.76 (s, 4H, 2CH2); 13C-NMR (63 MHz, (CD3)2SO): 5C 170.3
(C(0)OCH3), 169.5 (C(O)ON), 165.4 (NC(O)), 163.0 (COH), 162.7 (Ar-OCH2),
131.9 (o-CH), 108.0 (m-CH), 106.9 ( 164.0 (C(0)0C(CH3)3), 131.8 (o-CH), 108.0
(m-CH), 106.9 (CC(0)OCH3), 102.4 (m-CH), 63.2 (CH2), (C(CH3)3), 52.7







4.27 (83 mg, 0.272 mmol) was dissolved in EtOH (10 mL) followed by the
introduction of 10% Pd/C (15 mg) and a KE balloon. The reaction was stirred for 24 h
at rt, after which the Pd was removed by filtration over celite, and the MeOH was
removed in vacuo. The crude residue was re-dissolved in DMF (1.5 mL) and treated
with 4.43 (100 mg, 0.259 mmol) and HBTU (134 mg, 0.354 mmol) in DMF (1 mL),
followed by addition of DIPEA (0.180 mL, 1.03 mmol) and stirred overnight at rt.
The DMF was evaporated in vacuo and the residue re-dissolved in EtOAc (10 mL)
and washed with H2O (2 x 10 mL) and brine (10 mL). The EtOAc was then dried
over MgSCL and removed in vacuo. The resulting residue was purified by silica gel
chromatography eluted with 1-10 % MeOH/CPECL to yield colourless oil (116 mg,
0.173 mmol, 67%). *H-NMR (250 MHz, CDCI3): 5H 7.60 (d, J = 7.5 Hz, 2H, Fmoc-
H-24), 7.45 (d, J = 7.5 Hz, 2H, Fmoc-tf-27), 7.24-7.10 (m, 4H, Fmoc-//), 4.21 (d, J
= 7.5 Hz, 2H, C//2-20), 4.10-4.08 (m, 3H, NC(0)C//20 and H-21), 3.54-3.44 (m, 4H,
OC//2CH2O and OCH2C//20), 3.26-3.05 (m, 6H, 0(0)CCH2CH2C//2N and
OC//2CH2NH and OCH2C//2NH), 2.09-2.02 (m, 4H, 0(0)CC//2CH2CH2N), l.OS-
l.OS (m, 4H, 0(0)CCH2C//2CH2N), 6.70-6.52 (m, 2H, 2 x m-CH), 5.35 (s, 2H,
0C//2C(0)0), 3.80 (s, 3H, C(0)0CH3), 1.29 (s, 9H (Ctf3)3C0(0)C), 1-27 (s, 9H,
(Ctf3)3C0(0)C); 13C-NMR (63 MHz, CDC13): 8C 172.6 (C-3), 172.1 (C-9), 155.4
(C-18), 148.7 (C-23), 127.2 (C-25), 126.2 (C-26), 124.1 (C-27), 120.0 (C-24), 79.2
(C-l), 72.6 (C-15), 69.7 (C-13), 67.9 (C-12), 66.4 (C-10), 47.1 (C-21), 46.4 (C-6),
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37.9 (C-16), 33.1 (C-4), 27.7 (C-8), 23.6 (C-5); m/z (ES+): 669.3 (M+H)+; HRMS
(ES+) for C37H53N2O9 (M+H)+: calcd 669.3746, found 669.3749; RP-HPLC (ELSD)







4.45 (115 mg, 0.172 mmol) was treated with 20% piperidine in DMF for 40 min at rt,
after which the solvent removed in vacuo. The crude residue was re-dissolved in
DMF (1.4 mL) along with 4.38 (37 mg, 0.163 mmol) and HBTU (85 mg, 0.224
mmol) followed by addition of DIPEA (0.113 mL, 0.648 mmol). The reaction
mixture was stirred for 2 hours at rt, after which the solvent was removed in vacuo.
The residue was re-dissolved in EtOAc (5 mL), which was washed with H20 (2x5
mL) and brine (5 mL), dried over MgS04 and the solvent removed in vacuo before
being purified by silica gel chromatography eluted with 1-10 % MeOH/CH2Cl2 to
give the title compound 4.47 (92 mg, 0.141 mmol, 86%). 'H-NMR (250 MHz,
CDCI3): 8h 11.80 (s, 1H, OH-25), 8.50 (s, 1H, N//-17), 7.98-7.91 (m, 1H, H-23),
6.73-6.62 (m, 2H, T/-26 and T/-29), 4.72-4.63 (m, 4H, 10-CH2 and 19-CH2), 4.12 (s,
3H, 29-C//3), 4.02-3.80 (m, 4H, 12-CH2 and 13-CH2), 3.69 (t, J = 5.5 Hz, 2H, 16-
CH2), 3.57-3.20 (m, 6H, 15-CH2 and 2 x 6-CH2), 2.47-2.41 (m, 4H, 2 x 4-CH2), 2.02-
1.91 (m, 4H, 2 x 5-CH2), 1.65 and 1.64 (2 x s, 2 x 9H, 2 x (8-CH3)3); 13C-NMR (63
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MHz, CDCI3): 5C 172.6 (C-18), 172.3 (C-3), 170.6 (C-9), 163.7 (C-27), 163.1 (C-
21), 161.3 (C-25), 132.1 (C-23), 107.7 (C-29), 107.0 (C-24), 102.4 (C-26), 81.2 (C-
1), 70.4 (C-15), 69.5 (C-19), 68.0 (C-13), 67.5 (C-12), 65.0 (C-10), 52.5 (C-29), 47.3
(C-6), 46.7 (C-6), 41.0 (C-16), 32.8 (C-4), 32.1 (C-4), 28.4 (C-8), 26.9 (C-5), 25.5
(C-5); m/z (ES+): 655.2 (M+H)+ (100%), 677.2 (M+Na)+; HRMS (ES+) for
C32H5iN2Oi2 (M+H)+: calcd 655.3437, found 655.3437; RP-HPLC (ELSD) fR 4.58
min (100 %) (Method 2); Rf 0.38 (5% MeOH/CH2Cl2, KMn04).
12-(3-carboxypropyl)-l-(4-hydroxy-3-(methoxycarbonyI)phenoxy)-2,ll-dioxo-
6,9-dioxa-3,12-diazahexadecan-16-oic acid (4.48)
4.47 (45 mg, 68.7 pmol) was treated with a cocktail of TFA/CH2C12/TIS/H20
(47.5:47.5:2.5:2.5) (1 mL) and stirred for 1 h at rt. The cleavage cocktail was
removed in vacuo and the resulting residue was re-dissolved in 30% acetonitrile/70%
H20 (10 mL) and freeze-dried prior to purification by Prep-HPLC to yield a white
lyophilisate (11.6 mg, 21.2 pmol, 31%). ^-NMR (250 MHz, CD3OD): 5H 7.70 (d, J
= 7.5 Hz, 1H, o-CH), 6.51-6.42 (m, 2H, m-CH), 4.49 (s, 2H, NHC(0)C//20-Ar),
4.18 (s, 2H, NC(0)C//2), 3.83 (s, 3H, C(0)OCH3), 3.56-3.26 (m, 12H, 0CH2CN20
and 0C//2CH20 and OC//2CH2NH and OCH2C//2NH and H0(0)CCH2CH2C//2N),
2.24-2.17 (m, 4H, HO(0)CC//2), 1.79-1.71 (m, 4H, H0(0)CCH2Ctf2CH2N); 13C-
NMR (90 MHz, CD3OD): 5C 174.9 (C(O)OH), 174.5 (NC(0)CH20-Ar), 169.7
(NC(0)CH20), 168.6 (C(0)OCH3), 163.1 (COH), 130.8 (o-CH), 106.7 (CH30(0)C-
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At), 105.6 (m-CH), 101.1 (m-CH), 69.8 (OCH2CH2NH), 69.3 (NHC(0)CH20-Ar),
68.5 (0CH2CH20), 68.4 (0CH2CH20), 66.2 (NC(0)CH20), 50.8 (C(0)0CH3), 45.3
(H0(0)CCH2CH2CH2N), 44.2 (H0(0)CCH2CH2CH2N), 38.2 (OCH2CH2NH), 30.2
(H0(0)CCH2CH2CH2N), 29.6 (H0(0)CCH2CH2CH2N), 22.9
(H0(0)CCH2CH2CH2N), 21.9 (H0(0)CCH2CH2CH2N); m/z (ES ): 541.2 (M-H)'
(100%); HRMS (ES+) for C24H35N20,2 (M+H)+: calcd 543.2185, found 543.2185;
RP-HPLC (X2S2) tR 3.56 min (100 %) ELSD tR 3.64 min (100 %) (Method 2).
5.6.2 Binding and elution studies
Catechol modified peptide (4.9) - Binding
In a typical experiment, boronic acid modified CPG 4.3 was placed into a Supelco
Filtration Tube and washed in MeOH (3x), H20 (3x) and 100 mM PBS (pH 7.6) with
5 mM TCEP (3x). 0.6 mM peptide 4.9 solution was prepared in 100 mM PBS (pH
7.6) with 5 mM TCEP and mixed with varying equivalents (relative to peptide) of
boronic acid modified CPG 4.3 for either 1 min (10 and 20 eq) or 10 min (2, 4, 6, 10
and 20 eq). Peptide solution was removed from the boronic acid modified CPG 4.3
by vacuum filtration and eluate (100 pL) was injected onto an analytical HPLC
running Method 2 (General methods) with detection at 282 nm. The area under the
HPLC chromatogram peak was integrated using Agilent Chemstation software. All
experiments were carried out in triplicate.
Catechol modified peptide (4.9) - Elution
Boronic acid modified CPG 4.3 (6.3 pmol, 30 mg, theoretical loading = 0.21
mmol/g) was placed into a Supelco Filtration Tube and washed in MeOH (3x), H20
(3x) followed by addition of peptide 4.9 (5 mM) in 5% DIPEA in DMF with 20 mM
TCEP with mixing for 10 min. Peptide solution was removed by vacuum filtration
and the resin was washed with MeOH (2 x 0.5 mL), 5% DIPEA in DMF with 20 mM
TCEP (2 x 0.5 mL) and Et20 (3x1 mL) followed by drying of the resin in a vacuum
oven at 40 °C for 1 h. Loaded resin (2 mg) was treated with 1% TFA/H20 (1 mL) for
various lengths of time (<10 s and 1, 5, 10 and 15 min) before applying vacuum
filtration to the resin. Eluates were analysed by injecting onto an analytical HPLC
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running Method 2 (General methods) with detection at 282 nm. The area under the
HPLC chromatogram peak was integrated using Agilent Chemstation software. All
experiments were carried out in triplicate.
Hydroxamic acid modified peptide (4.25) - Binding
Binding of peptide 4.25 to boronic acid modified CPG 4.3 was carried out in a
similar manner to binding of peptide 4.9 except that 0.6 mM peptide 4.25 solution
was made in 100 mM PBS (pH 8.4). 1-6 eq of boronic acid CPG 4.3 were mixed
with peptide 4.25 solution for 30 min. In another study either 4, 10 or 20 eq of
boronic acid CPG 4.3 were mixed with peptide 4.25 solution for the following times:
0.5, 1, 2, 4, 10 and 30 min.
Hydroxamic acid modified peptide (4.25) - Elution
Saturation of CPG 4.3 with peptide 4.25 and elution was achieved using the same
method as with peptide 4.9 except the binding buffer used was 100 mM PBS (pH
8.4).
5.6.3 Tagging and enrichment studies
In a typical tagging experiment, peptide (1 mg/mL) in 50% CH3CN/50% 100 mM
TEAA pH 8.0 buffer was labelled with NHS-ester tag (3 eq) with mixing for 2 h
(TCEP (20 mM) was used when tagging with 4.1). Enrichment of tagged peptides
was carried out as in Section 5.6.2. Enriched tagged peptide mixtures were separated
online by nano-LC on a 25 min gradient (5-80% phase B, CH3CN + 0.5% acetic
acid), on-line separated on C18-packed picotip emitter (Proxeon) and analysed on an
LTQ-Orbitrap Classic (ThermoElectron, Germany) mass spectrometer.
5.6.4 NHSS cross-linker activation
In a typical NHSS activation reaction, diacid cross-linker (10 mg, leq) in dry DMF
(0.1 M) was added to polystyrene supported DCC (2.6 eq) along with NHSS (2.4 eq).
The resin mixture was stirred gently under nitrogen for 24 h, after which the resin
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was filtered and solvent removed in vacuo. The resulting NHSS ester was used
directly for protein cross-linking without further purification. Cross-linking was
confirmed by gel electrophoresis of cross-linked protein.
5.6.5 Cross-linking studies
Protein cross-linking studies were carried out at the Wellcome Trust Centre for Cell
Biology in the University of Edinburgh by Lau Sennels. In a typical (10 pL)
experiment, protein (0.8 pg/pL) in cross-linker buffer (10 mM HEPES pH 8.0, 200
mM potassium acetate) was mixed with NHS/NHSS activated cross-linker (in
protein/cross-linker ratios of 1:100-1:1000, final concentration = 1 mM) and
incubated on ice for 2 h. The reaction was stopped by addition of 2.5 M ammonium
bicarbonate (1 pL) for 45 min on ice. Gel electrophoresis of cross-linked proteins
was carried out using Invitrogen Pre-Cast 3-12% polyacrylamide gel using MES
running buffer and Coomassie blue stain. Bands from the SDS-PAGE gel
corresponding to cross-linked complexes were excised and the proteins
reduced/alkylated and digested using trypsin following standard protocols. Cross-
linked peptide mixtures were separated online by nano-LC on either 25 min or 95
min gradients (5-80% phase B, CH3CN + 0.5% acetic acid), on-line separated on
C18-packed picotip emitter (Proxeon) and analysed on an LTQ-Orbitrap Classic
(ThermoElectron, Germany) mass spectrometer. Raw data was acquired in cycles of
1 FT-MS (30000 resolution) and top 6 data-dependent IT-MS2 (7500 resolution),
singly-charged precursors excluded. Raw data was processed into peak lists using
MaxQuant (Cox and Mann, 2008) and searched against protein sequence databases
using in-house written software Xi. MS2 data was validated using the in-house
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